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1.1 Introduction
The demand for healthcare is rapidly increasing for reasons that include ageing 
populations, the availability of increasingly advanced and expensive new 
health technologies, and higher standards of living that raise the expectations 
of health and healthcare [1–3]. The growth rate of expenditures in healthcare 
tends to exceed that of the economy [4,5], which jeopardises the sustaina-
bility of publicly financed healthcare systems and risks the crowding out of 
other collective expenditures, for example, on public order and safety and on 
education [6]. As healthcare resources are limited, the resulting pressure on 
the available budgets renders priority setting in the allocation of healthcare 
resources inevitable. The need for priority setting is widely recognised and 
explicitly addressing priority setting is necessary for an optimal allocation of 
healthcare resources. Nevertheless, the debate and controversy that often 
follow (in particular, negative) resource-allocation decisions illustrate that 
healthcare priority setting is still politically and societally sensitive [1,2,7].
Publicly financed healthcare systems have two important objectives [1,8]. 
The first objective is to generate as much (health) value as possible from 
the healthcare budget, and hence to allocate the available resources in an 
efficient manner. The second objective is to distribute health and healthcare 
fairly, and hence to allocate the available resources in an equitable manner. 
Although it has been argued that an optimal allocation of healthcare resources 
involves setting priorities that contribute to meeting both objectives [1,8], 
important questions remain about which equity considerations should be con-
sidered, what (relative) weight these considerations should receive, and how 
they should be incorporated in resource-allocation decisions. 
This thesis aims to contribute to a better understanding of societal concerns 
for equity in healthcare priority setting, in particular for priority setting based 
on disease severity and the age of patients. The background to this thesis is 
described in sections 1.2 to 1.5 and the research questions it addresses are 
outlined in section 1.6. Note that this thesis has a strong focus on healthcare 
priority setting in the Netherlands. Nonetheless, its findings also have rele-
vance for other countries that seek to integrate societal concerns for equity 
with concerns for efficiency into the decision-making process.
1.2 Economic evaluations of new health technologies
Economic evaluations of new health technologies are increasingly used to 
inform decision makers on how to allocate the available healthcare resour-
ces in an efficient manner. In economic evaluations, health gains from health 
technologies are often expressed in terms of quality-adjusted life-years 
(QALYs). QALYs capture treatment-related gains in both quality of life and 
life expectancy and combine these gains into a single outcome measure [9]. 
The quality-of-life component of the QALY is measured on an interval scale, 
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on which the utility associated with the health state ‘dead’ is by convention 
anchored at 0 and the utility associated with the health state ‘full health’ at 1 
[9]. Health states that are perceived as being worse than ‘dead’ are associa-
ted with disutility (i.e. quality of life <0). Figure 1.1 illustrates that one QALY 
can represent one year in full health or, for example, two years in a less good 
health state with a quality of life of 0.5. 
In economic evaluations, QALY gains and the relevant costs associated with 
generating these gains are compared between the new health technology 
and a reference case (e.g. current standard of care) [9]. The outcome of 
this comparison is the incremental cost-effectiveness ratio (ICER) of the new 
health technology, which is used to inform resource-allocation decisions in 
healthcare [9].
Economic evaluations of new health technologies are commonly conducted 
from a broad societal perspective or a more narrow healthcare perspective 
[2,9]. In countries that apply a societal perspective (e.g. the Netherlands), the 
underlying objective is to maximise social welfare from the healthcare budget 
[2]. Therefore, the broader impacts of a resource-allocation decision (i.e. the 
benefits and costs that fall outside the healthcare system) are taken into 
account in the decision-making process [2]. In these countries, the decision 
rule can be written as [2,10]: 
vQ·∆Q - ∆ct > 0     (Eq. 1.1)
where vQ denotes the monetary value of a QALY (i.e. its consumption value), 
∆Q the incremental QALY gain, and ∆ct the incremental total costs that are 
associated with the QALY gain [2,10]. Note that ct is the sum of healthcare 
costs (ch) and broader consumption costs (cc) [2]. This equation can be rewrit-
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ten to demonstrate the decision rule that is commonly applied in economic 
evaluations:
∆ct/∆Q < vQ       (Eq. 1.2)
This equation demonstrates that the allocation of resources towards a new 
health technology can be considered welfare improving when the ICER of a 
new health technology (i.e. ∆ct/∆Q) is lower than the threshold value specified 
in terms of the societal willingness to pay for a QALY [2,10]. 
In countries that apply a healthcare perspective (e.g. England), the objec-
tive is to maximise population health from a (fixed) healthcare budget [2,10]. 
Therefore, only the impact of a resource-allocation decision on the healthcare 
system is taken into account in the decision-making process. In these coun-
tries, ct is replaced by ch and v is replaced by k in the decision rules, where 
k denotes the monetary value of a QALY specified in terms of the opportunity 
costs of resource-allocation decisions in healthcare [2,10–12]. 
The classic approach in economic evaluations is to adhere to the principle that 
a “QALY is a QALY is a QALY” [13], meaning that all QALY gains are valued 
equally regardless of by whom and in which context QALYs are gained [14]. 
However, adhering to this principle has become the subject of much debate 
as it relies on the assumption of distributive neutrality, whilst accumulating 
evidence suggests that the social value of a QALY may vary depending on 
equity considerations associated with characteristics of the patients (e.g. their 
age, lifestyle, and socioeconomic status), disease (e.g. its prevalence, seve-
rity, and outcome), and health technology under evaluation (e.g. the type and 
size of health gains it generates) [14–17]. In response to this debate, it has 
been advocated to incorporate equity considerations into the decision-making 
framework [14–16,18,19]. 
Many countries have incorporated equity considerations into the decision-ma-
king framework, albeit often in an ad hoc, implicit manner [20]. For example, 
by accepting a higher ICER in case a new health technology is indicated for 
severely ill patients or by requiring a lower co-payment from severely ill 
patients to improve their access to a new health technology [21,22]. However, 
to facilitate transparent and consistent decision-making [20], an increasing 
number of countries incorporates such considerations in an explicit manner 
by applying equity weights in economic evaluations [23–25]. One of the first 
countries to apply such weights was the Netherlands. 
1.3 Equity weighting in economic evaluations 
Equity weights can be attached to QALY gains or be reflected in the monetary 
threshold value (v or k) used in economic evaluations [1,14,16,26–29]. In the 
former case, the equity-adjusted ICER of a health technology is evaluated 
against a fixed monetary threshold value. In the latter case, the ICER of a 
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health technology is evaluated against a flexible, equity-adjusted monetary 
threshold value. The equity-adjusted decision rule can be written as [1,29]:
∆ct/∆Qi < vQi       (Eq. 1.3)
where the subscript i denotes the equity characteristic of the incremental 
QALY gain and vQi the monetary threshold value specified in terms of the 
societal willingness to pay for the equity-adjusted QALY [1,29]. Considering 
that the equity characteristic i has direct consequences for the distribution of 
health and healthcare, its normative justification and the empirical support for 
the underlying (combination of) equity consideration(s) are highly important. 
Furthermore, the equity-adjusted decision rule (Eq. 1.3) highlights the need 
to define a base case ‘equity scenario’ of which the weight and monetary value 
are known to enable differentiation between QALY gains [1,26,30]. This also 
raises questions about the implications of applying different weights or values 
for the allocation of healthcare resources.
The equity weights that are currently applied in economic evaluations are all 
based on some definition of disease severity that can be derived from the 
renowned severity and fair innings approaches [23–25,31–33]. These approa-
ches have the same normative standpoint that a higher weight should be 
attached to health gains in those who are worse off in terms of health in order 
to reduce health inequalities in society [31–33]. However, they have different 
standpoints with regard to whom are considered worse off. According to the 
severity approach, those with a lower amount of prospective health are worse 
off and, therefore, should be given a higher weight in resource-allocation deci-
sions [32]. However, according to the fair innings approach, those with a lower 
amount of lifetime (i.e. past and prospective) health are worse off and should 
be given a higher weight in such decisions [31,33]. Although both approaches 
are normatively justifiable and to some extent empirically supported, evi-
dence suggests that neither approach is fully aligned with societal concerns 
for equity weighting based on the disease severity of patients [1,34]. Indeed, 
evidence suggests that the public considers it important to take patients’ 
prospective as well as their lifetime health into account in resource-allocation 
decisions [1,15,34–36]. 
In an attempt to balance societal concerns for the severity and fair innings 
approaches, the intermediate approach ‘proportional shortfall’ was introdu-
ced and gradually implemented into the decision-making framework in the 
Netherlands [25,34,37]. 
1.4 Proportional shortfall
Proportional shortfall is calculated as the fraction of patients’ disease-related 
QALY loss, relative to their remaining QALY expectation in absence of the 
disease and is measured on a scale ranging from 0 “no QALY loss” to 1 “com-
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plete loss of remaining QALYs” (i.e. immediate death) [34]. According to this 
approach, those who lose a larger fraction of their remaining QALY expectation 
(i.e. those with a higher level of proportional shortfall) are worse off in terms of 
health and should, therefore, be given a higher weight in resource-allocation 
decisions [25,34]. In the Netherlands, this is operationalised by evaluating the 
ICER of a new health technology against a flexible, equity-adjusted monetary 
threshold value that is positively associated with the proportional shortfall 
level of the patients for whom the technology is indicated [25,38]. 
An important reason for implementing proportional shortfall in the Nether-
lands was that it mitigated discrimination against older patients implied by 
the fair innings approach and the use of ICERs for informing resource-allo-
cation decisions [25,37]. In theory, proportional shortfall indeed does not 
discriminate on the basis of age between patients [34]. For example, in the 
case of immediate death, patients aged 10 and 80 will both have a propor-
tional shortfall level of 1 and are, therefore, given the same (high) weight in 
resource-allocation decisions. However, in decision-making practice, propor-
tional shortfall may not just mitigate discrimination against older patients, but 
it may pave the way for discrimination in favour of older patients as they are, 
ceteris paribus, more likely to lose a larger fraction of their remaining QALY 
expectation than younger patients. For example, when patients aged 10 and 
80 both lose two of their remaining QALYs, patients aged 80 will have a rela-
tively higher level of proportional shortfall and, therefore, are given a higher 
weight than patients aged 10 in resource-allocation decisions. 
Equity weights based on proportional shortfall (or on any other definition of 
disease severity that can be derived from the severity and fair innings approa-
ches) do not explicitly distinguish between patients of different ages, nor aim 
to give weight to patients’ age in resource-allocation decisions. Nevertheless, 
the weights may be inextricably related to patients’ age, and hence their 
application in healthcare priority setting may have different consequences 
for patients of different ages. This raises the question to what extent this 
approach aligns with societal concerns for equity weighting based on disease 
severity and the age of patients. 
Proportional shortfall combines aspects of the severity and fair innings 
approaches and is, therefore, related to established conceptions of equity 
in healthcare priority setting. It should however be noted that there is still 
much debate about what equity approach is considered best for informing 
resource-allocation decisions in healthcare. Likewise, there are still questi-
ons about the empirical support in the general public for the use of specific 
approaches, such as proportional shortfall. The latter will be addressed in this 
thesis.
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1.5 Societal concerns for equity in healthcare priority setting
There are different ways to obtain insight into societal concerns for equity 
in healthcare priority setting and to incorporate related preferences into 
the decision-making framework. Insight into societal preferences is often 
obtained by using preference-elicitation methods (e.g. person trade-off and 
contingent-valuation tasks) in purposively designed questionnaires that are 
administered to large, representative samples of the general public [39–41]. 
The elicited preferences can, for example, be incorporated into the decisi-
on-making process by using them as an empirical base for equity weighting 
in economic evaluations. 
In order to increase the legitimacy and accountability of resource-alloca-
tion decisions as well as public support for potentially unpopular decisions, 
insight into societal preferences is increasingly obtained by using deliberative 
methods (e.g. citizens panels and juries), whether or not in combination with 
equity weighting in economic evaluations [40,42–45]. Deliberative methods 
facilitate a two-way flow of information between decision makers and (a small 
sample of) the public and serve to transform the viewpoints and preferences 
of both parties by acts of dialogue and negotiation [40,46,47]. As such, these 
methods can help to ensure that not only the outcomes of resource-allocation 
decisions are normatively justifiable and empirically supported, but that the 
decision-making process also meets these requirements [42,45].
Despite the increased use of deliberative methods in healthcare priority 
setting, their impact has rarely been assessed empirically [40]. Hence, ques-
tions remain about whether and how deliberative methods influence the 
viewpoints and preferences of participants and to what extent they (continue 
to) represent those of the general public [40,41,48]. Insight into the effect 
of deliberative methods is indispensable for making informed decisions on 
whether, how, and at what stage of the decision-process deliberative methods 
are best incorporated into the decision-making framework.
1.6 Objective and outline of this thesis
The overall objective of this thesis is to contribute to the improvement of the 
decision-making framework by providing further insight into societal concerns 
for equity in healthcare priority setting, in particular for priority setting based 
on disease severity and the age of patients. 
To meet the overall objective of this thesis, the following research questions 
are addressed: 
1. What is the normative justification and empirical support for equity  
weighting based on proportional shortfall in the Netherlands? 
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2. How much weight does the public attach to disease severity and the age 
of patients in healthcare priority setting?
3. What is the public willing to pay for quality-of-life gains in patients with 
different ages and levels of disease severity?
4. What is the public willing to pay for quality-of-life and life-expectancy 
gains in patients with different ages at the end of life?
5. How do different viewpoints on healthcare priority setting relate to con-
cerns for equity and efficiency in resource-allocation decisions? 
6. How does participating in a deliberative citizens panel influence the 
viewpoints of participants on healthcare priority setting?
Chapter 2 examines the normative justification and empirical support for 
equity weighting based on proportional shortfall in the Netherlands. A key 
finding in this chapter is that empirical support for equity weighting based on 
proportional shortfall may be inextricably related to the age of the patients 
for whom a new health technology is indicated. Chapters 3 to 5 build on this 
finding and examine how much weight the public attaches to disease severity 
and the age of patients in healthcare priority setting. Chapter 3 presents the 
results of a study in which person trade-off tasks were applied in an innova-
tive manner to obtain severity- and age-based equity weights. Chapters 4 
and 5 present the results of studies in which contingent-valuation tasks were 
applied to examine what the public is willing to pay for health gains in patients 
with different ages and levels of disease severity, the latter also operationa-
lised in an end-of-life context. Chapter 6 examines how different viewpoints 
on healthcare priority setting relate to concerns for equity and efficiency in 
healthcare priority setting. Chapter 7 examines how participating in a delibe-
rative citizens panel influences the viewpoints of participants on healthcare 
priority setting by extending previous applications of Q methodology.
Chapters 2 to 7 are based on articles published (or submitted for publication) 
in international peer-reviewed journals and can therefore be read indepen-
dently. It should be noted that this implies some inevitable overlap between 
these chapters.
Chapter 8 is the final chapter of this thesis. It discusses the main findings of 
this thesis, its strengths and limitations, and the implications for policy and 
future research.
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in the Netherlands
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moving forward: On the application of proportional shortfall in healthcare pri-
ority setting in the Netherlands. Health Policy. 2018;122(6):621-629.
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Abstract
The increasing demand for healthcare and the resulting pressure on available 
budgets render priority setting inevitable. If societies aim to improve health 
and distribute health(care) fairly, equity-efficiency trade-offs are necessary. 
In the Netherlands, proportional shortfall (PS) was introduced to quantify 
necessity of care, allowing a direct equity-efficiency trade-off. This study des-
cribes the history and application of PS in the Netherlands and examines the 
theoretical and empirical support for PS as well as its current role in health-
care decision making. We reviewed the international literature on PS from 
2001 onwards, along with publicly accessible meeting reports from the Dutch 
appraisal committee, Adviescommissie Pakket (ACP), from 2013 to 2016. Our 
results indicate that there is support for the decision model in which necessity 
is quantified and incremental cost-effectiveness ratios are evaluated against 
associated monetary reference values. The model enables a uniform frame-
work for priority setting across all healthcare sectors. Although consensus 
about the application of PS has not yet been reached and alternative ways 
to quantify necessity were found in ACP reports, PS has increasingly been 
applied in decision making since 2015. However, empirical support for PS is 
limited and it may insufficiently reflect societal preferences regarding age and 
reducing lifetime-health inequalities. Hence, further investigation into refining 
PS—or exploration of another approach—appears warranted for operationali-
sing the equity-efficiency trade-off. 
 Application of proportional shortfall in the Netherlands | 25
  2 
2.1 Introduction
The demand for healthcare is rapidly increasing for reasons that include 
ageing populations and the availability of increasingly advanced and expen-
sive (new) health technologies. As healthcare resources remain scarce, the 
resulting pressure on available budgets renders healthcare priority setting 
inevitable [1,2]. Although politically and societally sensitive, the need for pri-
oritisation is widely recognised and explicitly addressing priority setting has 
become indispensable for developing fairer methods for resource allocation in 
healthcare [3,4].
Economic evaluations of health technologies are often used to inform deci-
sion makers regarding how to allocate healthcare resources in an optimal 
way for society. However, the outcomes of economic evaluations only predict 
such decisions to a moderate extent [3,5,6]. One explanation for this dispa-
rity is that decision makers are not exclusively concerned with maximising 
health given available budgets, but also with distributing health(care) equi-
tably and fairly [3,5,7,8]. Hence, an optimal allocation of resources involves 
setting priorities that contribute to both efficiency and equity in the distribu-
tion of health(care) [9]. Recognising that these are both important objectives 
of healthcare systems, it has been advocated that societal concerns for equity 
be explicitly and transparently incorporated into the decision-making frame-
work [10–12]. 
In economic evaluations, the value of a health technology is commonly 
expressed in terms of an incremental cost per quality-adjusted life-year 
(QALY) ratio (ICER) that is evaluated against some monetary threshold value 
per QALY gained [3,13–15]. When the ICER is below this threshold, a health 
technology is considered cost-effective and eligible for reimbursement [16]. 
The classic approach in the economic-evaluation framework is to value QALY 
gains equally, i.e. to adhere to the principle that a ”QALY is a QALY is a QALY”, 
regardless of beneficiary and health technology characteristics [17]. However, 
this approach has been highly debated as it relies on the assumption of dis-
tributive neutrality [3]. In response to this debate, two general approaches 
have been suggested for operationalising the equity-efficiency trade-off [3,5]. 
One of these approaches applies equity weights to QALY gains and evaluates 
the adjusted ICER against a fixed monetary threshold value, and the other 
evaluates an unadjusted ICER against a flexible monetary threshold value 
[3,5,16]. Ideally, the operationalisation of the equity-efficiency trade-off is 
both normatively justifiable and empirically supported. However, this proves 
to be neither easy nor straightforward [3,18]. 
In relation to the operationalisation of the equity-efficiency trade-off, the 
severity of illness (SOI) and fair innings (FI) equity approaches have attrac-
ted much attention internationally. According to the normative theories about 
distributive justice that underlie these approaches, priority should be given to 
26 | Chapter 2
those who are worse off in terms of health [11,19,20]. However, the approa-
ches are based on different normative arguments with regard to whom is 
considered worse off, and hence differ with regard to how they are operatio-
nalised [3,19]. A common operationalisation of SOI aims to equalise absolute 
health benefits in terms of current and prospective health, while FI aims to 
do so in terms of lifetime health [3,10,11,19]. As such, FI also considers past 
health [11,19]. Although both SOI and FI are to some extent normatively 
justifiable and empirically supported, neither of these approaches appears 
to satisfactorily reflect societal preferences for equity [3,5,7]. Nonetheless, 
different countries have either implicitly or explicitly developed normative 
principles or guidelines that include (aspects of) SOI or FI for informing alloca-
tion decisions in healthcare [3,5,7]. For example, in the United Kingdom (UK), 
the National Institute for Health and Care Excellence (NICE) formalised the 
SOI approach by launching guidelines for prioritising end-of-life care [21,22], 
and in Norway, the SOI approach is currently formalised in terms of absolute 
shortfall [23,24]. In an attempt to balance societal concerns regarding SOI 
and FI [5], proportional shortfall (PS) was introduced in the Netherlands as an 
equity approach that combines aspects of SOI and FI [3,5]. Although consen-
sus about the application of PS has not yet been reached [25], the approach 
received considerable support from politicians and policy makers and was 
incorporated into the assessment phase of healthcare priority setting in the 
Netherlands [1,3]. As such, the Netherlands is one of the first countries to 
explicate the equity criterion in this context [3,5]. 
This study describes the history and application of PS in the Netherlands and 
examines the theoretical and empirical support for PS as well as its current 
role in healthcare decision making in the Netherlands by reviewing the inter-
national PS literature and publicly accessible meeting reports from the Dutch 
appraisal committee, the Adviescommissie Pakket (ACP). Although this study 
primarily focuses on healthcare priority setting in the Netherlands, the results 
of the study may also be useful for other countries seeking to operationalise 
the equity-efficiency trade-off for informing allocation decisions in healthcare. 
2.2 A brief history of healthcare priority setting in the Netherlands
The report “Choices in health care” that was presented by the Dunning Com-
mittee in 1991 was a landmark publication on healthcare priority setting in the 
Netherlands [26]. In this report, four criteria for priority setting were formu-
lated: necessity, effectiveness and efficiency of care, and patients’ individual 
responsibility for (paying for) care. In this report, the Dunning Committee 
used the metaphor of a funnel to describe a criteria-based decision model for 
evaluating the composition of the publicly funded health-insurance package. 
Based on this hierarchical model, technologies that (would subsequently) pass 
all criteria were to be included in the basic benefits package. The report was 
pivotal for the discussion on priority setting, and in the following years, the 
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criteria were put into practice [2,6,27]. The Dutch National Health Care Insti-
tute (ZIN) later reformulated these criteria as necessity of care, effectiveness, 
cost-effectiveness, and necessity of insurance, respectively, and supplemen-
ted these with a feasibility criterion [1,28]].
Although none of the criteria were defined and operationalised without dispute, 
this proved to be particularly difficult for the necessity of care criterion [2,29]. 
The Dunning Committee defined necessity of care as care that is necessary 
for the prevention of premature death and/or for patients who—due to some 
disease or condition—cannot function normally in society [2,26]. The latter 
part of this definition was regarded as problematic, as it was unclear how to 
interpret and quantify ‘normal’ functioning. Moreover, the term ‘necessity’ 
implied an absolute rather than a relative cut-off point for decision making, 
which was amplified by the Dunning Committee’s use of a funnel metaphor 
[2,26]. If a technology failed to pass ‘the sieve of necessity’, the techno-
logy would not be incorporated into the public health-insurance package, 
and assessment of its (cost-) effectiveness and need for insurance would be 
superfluous [2]. However, as the degree to which health technologies are 
necessary varies, it was suggested that this criterion be regarded as neither 
absolute nor isolated from the other criteria [2,30,31].
In 2001, Stolk et al. [2] proposed a decision model in which necessity of care 
was defined as ‘burden of illness’ (BOI) and operationalised as a relative cri-
terion by attaching a higher necessity score to health technologies that target 
diseases with a higher BOI level. Stolk et al. [2] described BOI as the average 
disease-related loss in quality and length of life of patients, relative to the 
situation in which the disease had been absent and quantified BOI in terms of 
QALYs on a 0−1 scale. Furthermore, they proposed connecting the necessity 
of care and (cost-) effectiveness criteria by attaching a higher societal willing-
ness to pay (WTP) per QALY gained to a higher level of BOI. Specifically, the 
authors suggested dividing the continuous 0−1 BOI scale into seven categories 
and evaluating the ICER of (new) health technologies against seven associated 
monetary threshold values per QALY gained. The proposed cost-effective-
ness threshold values per QALY gained ranged from approximately €4,500 to 
€45,000 [32]. Deciding on the exact cut-off points for the BOI categories, the 
cost-effectiveness threshold range, and the shape of their reciprocal relati-
onship were regarded as matters of political and societal concern. 
The proposed model received broad support as it contributed to the deve-
lopment of a transparent and coherent decision model for healthcare priority 
setting in the Netherlands by explicitly connecting the criteria formulated by 
the Dunning Committee and enabling a uniform and systematic quantifica-
tion of BOI across patient groups and disease areas [2,3,27–29]. Between 
2002 and 2005, BOI was further formalised as proportional shortfall (PS) and 
defined as a principle that is based on the normative standpoint that priority 
in healthcare should be given to those who, due to some disease and if left 
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untreated, lose the largest proportion of their QALY expectancy in absence of 
the disease [5,32,33]. PS is measured on a scale from 0 (no QALY loss) to 1 
(complete loss of remaining QALY, i.e. immediate death), by applying: 
PS =   
Disease-related QALY loss                             (Eq. 2.1)
             
Remaining QALY expectation in absence of the disease 
For example, a disease that results in the loss of 30 out of 60 remaining QALYs 
has a PS level of 0.5 (30/60), and a disease that results in the loss of 60 out of 
80 remaining QALYs has a PS level of 0.75 (60/80). The remaining QALY expec-
tation in absence of the disease can be calculated from age- and sex-specific 
mortality data [2,5]. Equation 1 can be rewritten as: 
PS = 1 -                
Expected QALYs without treatment           (Eq. 2.2)
               Remaining QALY expectation in absence of the disease  
 
Applying Equation 2.2 to the previous example, the PS level of 0.5 is calcu-
lated as 1 - (30/60), and the PS level of 0.75 is calculated as 1 - (20/80). PS 
can also be calculated by using the number of expected QALYs ‘with current 
treatment’ rather than ‘without treatment’ in the equations [34]. This may be 
a more logical calculation of PS as it arguably uses a more relevant compara-
tor and hence agrees with the economic-evaluation methodology. However, it 
should be noted that calculating PS relative to the current treatment will likely 
lead to a different, specifically lower, PS level for the same beneficiaries and 
(new) health technologies. Consequently, the outcome of a reimbursement 
decision that is informed by a PS level that is calculated relative to the current 
treatment may be different for the same beneficiaries and (new) health tech-
nologies than when the decision is informed by a PS level that is calculated 
relative to having no treatment. The debate on the preferred comparator is 
likely to continue in the coming period. 
While consensus concerning the definition and operationalisation of BOI gra-
dually increased, its exact categories and the associated cost-effectiveness 
threshold range remained a subject of discussion for some time. In 2006, the 
Council for Public Health and Society (RVZ) suggested a continuous, upward-
sloping curve with a maximum reimbursement of €80,000/QALY [29]. This 
figure was substantiated by the World Health Organisation (WHO) rule of 
thumb that less than three times the GDP per capita per disability-adjusted 
life-year (DALY) averted indicated good value for money for a health techno-
logy [35], by the finding that most reimbursed health technologies in the UK 
had an ICER of approximately €79,000/QALY [36], and by estimations of the 
value of a statistical life [37,38]. Although the figure of €80,000/QALY may 
have been set somewhat arbitrarily, it was considered “reasonable” [29,39]. 
Moreover, even though €80,000/QALY was not officially adopted as the thres-
hold value at that time, it was influential and provided the basis for ZIN to 
set three BOI categories with a maximum reimbursement of €80,000/QALY 
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for the highest BOI category in 2015 [25]. Table 2.1 presents these three 
BOI categories and the associated monetary reference values and shows that 
a higher WTP per QALY gained, i.e. a higher necessity score, is attached to 
health technologies that target diseases with a higher BOI level [2,25]. For 
example, the ICER of a health technology that targets a disease with a PS 
level of 0.5 is evaluated against a reference value of €50,000/QALY, while the 
ICER of a health technology that targets a disease with a PS level of 0.75 is 
evaluated against a reference value of €80,000/QALY. A health technology 
that targets a disease with a PS level below 0.1 is, in principle, not considered 
for reimbursement. Hence, this category is not included in the table [25,29]. 
Whether it is feasible, in practice, to not reimburse a health technology that 
targets a disease with a low PS level remains doubtful [40]. For example, 
episodic illnesses like migraine may not lead to a high average PS, but do 
represent substantial shortfall during the episode. 
Given the maximum reimbursement of €80,000/QALY for the highest BOI 
category and the intention to associate increasing levels of BOI with incre-
asing monetary reference values, ZIN set the two lower thresholds at €20,000 
and €50,000 per QALY. Together these may be seen as forming a logical set of 
values, given the endpoint of €80,000/QALY in relation to the highest BOI. In 
relation to the other two values, ZIN also referred to the threshold value that 
is applied to national immunisation and preventive care programmes in the 
Netherlands (€20,000/QALY threshold) and to a Dutch study on the societal 
WTP per QALY gained ‘in others’ (€50,000/QALY) [25,35]. ZIN advised reas-
sessing the reference values every five to ten years [25] and to not use them 
as strict cut-off values, but rather as references for the Dutch government 
when conducting price negotiations with pharmaceutical companies and for 
the ACP when recommending incorporation of health technologies into the 
public health-insurance package. 
The model, in which BOI is quantified and the ICERs of health technologies 
are evaluated against associated reference values, enables a transparent and 
coherent decision-making framework. Given that this model is increasingly 
applied in the Netherlands, the question arises whether there actually is suffi-
cient support for the operationalisation of BOI in terms of PS to explicate the 
equity criterion. In the next two sections we will discuss the theoretical and 
empirical support for using PS to inform priority setting in healthcare. In the 
subsequent section we will review the current role of PS in healthcare decision 
making in the Netherlands.
Table 2.1 Maximum reference values (in €) per QALY gained [25]
Burden of illness Maximum reference value per QALY gained
0.10 – 0.40 € 20,000
0.41 – 0.70 € 50,000
0.71 – 1.00 € 80,000
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2.3 Is there theoretical support for proportional shortfall? 
In order to optimally allocate healthcare resources for society, it has been 
advocated that societal concerns regarding equity be incorporated in the 
decision-making framework [10–12]. However, what society considers to be 
equitable and fair for priority setting is a normative question that different 
people in different contexts may answer differently. Hence, when operationa-
lising the equity-efficiency trade-off, an additional trade-off between different 
societal concerns regarding equity must be made. Consequently, increasing 
equality in the distribution of health(care) by applying one equity approach 
may lead to increasing inequality in the context of applying another [3,41]. 
It has also been argued that, when operationalising the equity–efficiency 
trade-off, different operationalisations are bound to face corresponding dif-
ficulties [3,16]. For example, in the context of curative healthcare, questions 
may arise concerning the handling of episodic diseases and the quantifica-
tion of related health benefits [3,16]. In the context of preventive healthcare, 
questions may arise concerning the group of beneficiaries and the timeframe 
that is regarded as relevant for estimating health benefits [3,16,18]. For 
example, should PS be calculated for all treated persons or only those for 
whom the illness was prevented? And should PS be calculated from the time 
of the preventive treatment or from the time the prevented illness would 
otherwise have occurred? Such choices can have a profound effect on the 
outcomes of PS calculations [42]. Other questions may, for example, arise 
concerning the use of age- and sex-specific mortality data as a reference 
point or threshold for calculating PS [20,43,44]. The use of such different 
reference points for different (age and sex) groups implies that there is not 
one age or health expectancy that would serve as a normative reference level 
for all groups. Hence, this could be regarded as including some inequ(al)ities 
in the calculation of PS [20]. These issues illustrate that not only is the choice 
of an equity approach normative, but additional normative choices must be 
made when applying the chosen equity approach in practice [3]. Inevitably, 
these choices have a large impact on PS calculations and therefore may have 
distributional consequences [3,18]. Although some initial choices were made 
when operationalising PS in the Netherlands [1,2,26], it should be noted that 
the discussion about how best to solve these issues is ongoing (both in the 
context of healthcare priority setting in the Netherlands and internationally). 
SOI and FI are two renowned equity approaches that are based on different 
normative arguments regarding whom is considered worse off in terms of 
health [3,19]. As described earlier, SOI commonly aims to equalise health 
benefits in terms of current and prospective health, and FI aims to do so in 
terms of lifetime health [3,10,11,19]. As such, FI is consistent with the notion 
that, all else equal, younger people should be prioritised over older people as 
they have not yet enjoyed a fair share of lifetime health [5,11]. It should be 
noted that the role of age is merely indirect in the FI approach as it is applied 
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as a proxy for lifetime health [20,43,44]. Indeed, in the FI approach, age itself 
is not regarded as a morally relevant argument for priority setting [44]. 
PS does not originate from a unique theory about distributive justice but was 
developed as an equity approach that combines aspects of SOI and FI by pri-
oritising those who are worse off in terms of a lower amount of prospective 
and lifetime health [3,5]. While SOI and FI aim to equalise absolute health 
benefits, PS aims to equalise relative benefits between persons with respect 
to their potential for health [5,33]. It has been argued that PS balances socie-
tal concerns regarding SOI and FI and treats the two approaches as equally 
important [5]. However, PS is calculated as the fraction of disease-related 
QALY loss relative to the remaining QALY expectation in absence of the disease 
rather than to the lifetime-QALY expectation from birth. Various authors have 
discussed the relative nature of PS and the theoretical and empirical relevance 
of using a lifetime perspective for informing allocation decisions in healthcare 
[20,23,45–47]. Here, we would like to point out that PS may be viewed as 
placing more emphasis on relative prospective-health loss, i.e. the SOI com-
ponent of PS, than on relative lifetime-health loss, i.e. the FI component of 
PS. This is illustrated by the fact that PS does not, by definition, discriminate 
between people with different levels of ‘enjoyed’ lifetime health as healthcare 
beneficiaries of all ages could potentially experience the same level of PS. For 
example, in the case of immediate death, healthcare beneficiaries who are 10 
and 80 years old are given the same weight in the distribution of healthcare, 
as both will have a PS level of 1. However, when the same beneficiaries lose 
two of their remaining QALYs, more weight will be given to the 80-year olds, as 
their PS level will be higher than that of the 10 year olds. Indeed, in allocation 
decisions, PS may more frequently give a higher weight to older patients than 
the FI approach would. Stolk et al. [5] argued that the FI approach “discrimi-
nates against the elderly more strongly than policy makers seem to prefer” 
and that PS could mitigate the ageism that is implied by the FI approach. 
It was, therefore, hypothesised that PS might be better aligned with distri-
butional preferences of health policy makers. Should this hypothesis not be 
supported by empirical evidence, the authors suggested to add age weights 
and adjust PS for age-related preferences. 
A strength of PS, which it shares with the SOI and FI approaches, lies in its 
quantification of health losses in terms of QALYs. This enables the application 
of PS across disease areas and patient populations. However, this strength 
comes with a limitation as treatment benefits beyond health and health-rela-
ted quality of life (QOL) that may not be captured by the QALY are increasingly 
recognised as being relevant [48]. Therefore, the current application of PS, 
i.e. its quantification in terms of QALYs, may be regarded as appropriate for 
informing decisions concerning curative and preventive treatments but less 
so for decisions concerning treatments that focus on broader benefits, for 
example related to wellbeing [49]. If the aim is to generate social welfare from 
the public health-insurance package, the application of an equity approach 
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that is uniformly applicable and hence that models information concerning 
health, QOL, and broader wellbeing could be preferable for informing deci-
sions concerning all healthcare sectors. We stress that this limitation should 
not be attributed to PS (or to FI or SOI) as a principle but rather to the way 
in which PS is currently quantified and applied in decision-making practice. In 
fact, PS does enable a uniform decision model for priority setting across all 
healthcare sectors, as the QALY in the PS equation can be replaced with—or 
complemented by—any other (generic) outcome measure of choice. 
2.4 Is there empirical support for proportional shortfall? 
We examined empirical support for PS by reviewing the international litera-
ture on PS in the context of healthcare priority setting. We used the search 
terms “proportional shortfall”, “preference”, “elicitation”, “priority setting”, 
and “health” or “healthcare” in Google Scholar. The search was performed 
on October 16, 2017 and supplemented with a hand search. We restricted 
the search to articles written in English or Dutch, published between 2001, 
i.e. the year in which PS was introduced in the Netherlands, and 2017, and of 
which the full text was available. Articles were selected for review if the aim 
of the study was to elicit preferences for PS relative to either preferences for 
no equity weighting or for weighting on the basis of another equity approach, 
such as SOI and/or FI. Our search resulted in 205 studies, in seven of which 
preferences for PS were elicited. Table 2.2 presents an overview of these 
seven studies and their results. 
Stolk et al. [33] compared support for SOI, FI, and PS by asking respondents 
to assign a priority rank to the treatment of ten health conditions. Stolk et 
al. found strong evidence for PS being consistent with social preferences for 
healthcare priority setting. Although preferences for PS dominated preferen-
ces for SOI, stronger support was found for FI. The authors obtained these 
results using a small convenience sample in the Netherlands that consisted 
of health policy makers, researchers, and students. Consequently, the results 
may be prone to bias, e.g. due to respondents sharing common opinions. 
Olsen [50] examined support for PS in a sample that was representative of 
the general adult population in Norway in terms of age and sex. Olsen applied 
a pairwise-choice task and asked respondents to prioritise patients based on 
their age, remaining lifetime health without treatment, and increase in remai-
ning lifetime health with treatment. Olsen found strong support for the FI 
approach; however, he found no support for PS. 
Brazier et al. [51] examined support for BOI operationalised in terms of PS in 
a sample that was representative of the general population in the UK in terms 
of age and sex by performing a web-based discrete choice experiment (DCE). 
Their main results did not support PS. However, when respondents who see-
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mingly misunderstood the DCE task were excluded, some support for PS was 
found. 
Rowen et al. [54] used the data from Brazier et al. [51] to examine support 
for PS by applying the number of expected QALYs ‘with current treatment’ 
rather than ‘without treatment’ in the PS equation. Rowen et al. concluded 
that, although the results were not robust against different versions of the 
DCE survey, there was some modest support for BOI operationalised in terms 
of PS relative to the current treatment. 
Van de Wetering et al. [52] examined support for PS in a sample that was 
representative of the general adult population in the Netherlands in terms of 
age, sex, and education level by conducting a web-based DCE. They found 
substantial preference heterogeneity and some counterintuitive results, as 
respondents were less likely to prioritise patients with higher levels of PS. 
Bobinac et al. [53] examined societal WTP for QALY gains in patients with 
different levels of PS in a sample that was representative of the general adult 
population in the Netherlands in terms of age, sex, and education level by 
conducting a web-based survey. They found occasional support for PS as a 
predictor of the WTP for QALY gains. Some support for PS was found when 
QALY gains were relatively small. However, the level of support decreased 
when QALY gains increased in size. In addition, support for PS was generally 
dominated by concerns for the (younger) age of patients.
Table 2.2 Empirical evidence on support for proportional shortfall (2001−2017)
Study Year Country Designa N Sample Support 
for PSb
Stolk et al. [33] 2005 NL Ranking exercise 65 Convenience ++





Brazier et al. [51] 2013 UK DCE 3,669 General public
(age and sex)
--/-
Van de Wetering et al. [52] 2015 NL DCE 1,205 General public
(age, sex, and 
education level)
--
Bobinac et al. [53] 2015 NL WTP 1,320 General public
(age, sex, and 
education level)
-
Rowen et al. [54]d 2016 UK DCE 3,669 General public
(age and sex)
+
Richardson et al. [55]c 2017 AU CSPC 606 General public
(age)
+
AU, Australia; CSPC, constant sum paired comparison; DCE, discrete choice experiment; NL, the Netherlands; 
NO, Norway; PS, proportional shortfall; UK, United Kingdom; WTP, willingness to pay; a Mode of administration: 
web-based survey in all studies; b Level of support for PS indicated by -- = no, - = limited, + = modest, ++ = strong; 
b Olsen [50] and Richardson et al. [55] examined support for PS in the context of preferences for length of life; d 
Rowen et al. [54] examined support for PS relative to the current treatment.
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Richardson et al. [55] examined support for PS in a sample that was close to 
being representative of the general adult population in Australia in terms of 
age. They applied constant-sum paired comparison tasks and asked respon-
dents to prioritise patients based on their gain in life years due to treatment, 
age, years to death without treatment, and age at death with and without tre-
atment. Their study found some support for PS; however, found that concerns 
for PS were dominated by concerns for the (individual) SOI and FI approaches. 
Richardson et al. further found that PS insufficiently reflects respondents’ 
age-related preferences.
Although each of these studies examined societal support by eliciting prefe-
rences for PS, it is important to note that the studies differ with respect to the 
samples, methods, additionally included variables, and/or equity approaches. 
In addition, Olsen [50] and Richardson et al. [55] examined preferences for 
equity in the context of length of life, and hence did not present PS in terms of 
proportional QALY shortfall. Consequently, a direct comparison of the results 
presented in Table 2.2 is not possible. 
2.5 What is the role of proportional shortfall in healthcare decision 
making? 
The necessity (of care and of insurance), effectiveness, cost-effectiveness, 
and feasibility criteria are addressed and quantified in the assessment phase 
of healthcare decision making in the Netherlands and subsequently assessed 
on social and ethical grounds in the appraisal phase. If the operationalisation 
of BOI in terms of PS is considered suboptimal for explicating the equity cri-
terion, it seems reasonable to expect that this would be explicitly discussed 
during meetings of the ACP appraisal committee. 
To examine the current role of PS in the appraisal phase of healthcare decision 
making in the Netherlands, we conducted a review of publicly accessible ACP 
meeting reports that were published between 1 January 2013 and 31 Decem-
ber 2016. The reports include agendas, minutes, and documents, including 
decision reports and draft ZIN reports that were discussed by the ACP. Table 
2.3 presents the terms (and their domains) addressing healthcare priority 
setting that we used for searching the reports (in the Dutch language, but 
translated here for clarity). Reports that did not allow a digital search, inclu-
ding ACP reports that were published before 1 January 2013 were excluded 
from the review, as were search terms that occurred in the names of health 
organisations and government ministries. Draft versions of minutes were 
included only if final minutes were not published. 
Between 2013 and 2016, 179 ACP reports were published of which two were 
excluded for not allowing a digital search. Table 2.4 presents the frequency 
with which the search terms were identified in the remaining 177 reports. The 
necessity of care and of insurance, effectiveness, cost-effectiveness (inclu-
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ding the search term efficiency), and feasibility criteria were identified 1,680, 
495, 8,700, 4,423, and 236 times, respectively. The effectiveness criterion 
was most frequently found, followed by the cost-effectiveness and necessity 
of care criteria. The necessity of insurance and feasibility criteria were iden-
tified less frequently.
PS was identified 14 times in a total of six reports, four of which discussed the 
operationalisation of BOI in terms of PS. In a report from 2013, ZIN described 
the definition and calculation of PS. In this report, ZIN stated that “PS was 
developed at a time when ageism was an important issue in the allocation of 
healthcare resources” and that “therefore BOI is calculated in proportion to 
life expectation, which ensures that PS does not distinguish between younger 
and older people”. However, ZIN also stated that “recently, there are incre-
asing indications that people do discriminate between age groups” and that 
people “value health gains in younger people more than in older people”, 
which “argues against PS and the rule of rescue, and in favour of FI”. In the 
accompanying minutes, an ACP member stated that “the passage about BOI is 
still not in agreement with what was discussed in previous meetings” and that 
s/he “understand[s] that applying the capability approach is out of reach”, 
but that s/he “would like to see the denominator removed from the presented 
definition of PS”. In a report from 2015, ZIN stated that “because we have not 
Table 2.3 Search terms used for reviewing ACP meeting reports
Domain Search term










Treatment benefits Therapeutic outcome; therapeutic value





Patient characteristics Age 
Socio-economic status; SES 
Lifestyle
Culpability; individual responsibility
Reference values Reference value(s)
(Monetary) threshold
ACP, Adviescommissie Pakket (the healthcare appraisal committee in the Netherlands)
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yet reached consensus about the quantification of BOI, we will temporarily 
[…] quantify BOI in terms of DALYs”. In this report, ZIN additionally stated 
that “priority will be given to solving this issue” and that “a report on the 
quantification of BOI will be issued this summer”. In a later report from 2015, 
ZIN stated that “the next coming months will be used to see how to better 
align the equity criterion PS with current social preferences”. According to the 
accompanying minutes, these statements by ZIN were not discussed by ACP 
members. 
The reference of one of the ACP members to Sen’s capability approach [41] 
may indicate a preference for quantifying health benefits in terms of broader 
wellbeing, as for example is done by applying the ICECAP measure [56]. Wel-
lbeing, including the terms capability and life satisfaction, was identified 93 
times in 29 reports from 2013 onwards, among which the capability approach 
was identified 15 times in five reports (not in table). In these reports, the 
capability approach was discussed as an alternative to quantifying health 
benefits in terms of QALYs. In a report from 2013, ZIN stated that “a recent 
discussion involves the question of whether the capability approach is better 
aligned with the social basis that underlies managing the public health-insu-
rance package” and that “applying this approach may be more appropriate 
for healthcare sectors where ‘health gains’ are not the primary objective, 
such as long-term care and mental healthcare”. The same report stated that 
“changing the desired outcome of healthcare does not answer the question of 
when care is more necessary for one person than for another” and that “the 
capabilities approach can also be applied to calculate lifetime capabilities (fair 
innings), prospective capabilities, or the relative loss of capabilities (propor-
tional shortfall)”, and so “applying the capability approach will not solve the 
issue of prioritisation in healthcare”. 
The ACP member’s request to remove the denominator from the PS equation 
may indicate a preference for operationalising the equity criterion in terms 
of absolute shortfall (AS) rather than proportional shortfall, and this may in 
turn indicate a preference regarding FI, age, and reducing lifetime-health 
inequalities [24,50]. AS was not identified in any of the ACP reports and the 
FI approach was identified 11 times in four reports. In contrast, the SOI 
approach was identified 0 times. However, concerns for SOI that were expres-
sed through concerns for prospective-health loss, the rule of rescue, and for 
the severity of (symptoms of) a disease or condition were identified 3 times 
in 1 report, 5 times in 3 reports, and 2614 in 92 reports, respectively (not in 
table). Age was identified 895 times in 79 reports. Regarding age and other 
patient characteristics, age was identified 16.6 and 2.3 times more frequently 
than SES and lifestyle (including the search terms culpability and individual 
responsibility), respectively. 
Although the operationalisation of BOI in terms of PS was occasionally dis-
cussed in some reports, and in one report from 2014 an ACP member stated 
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that “BOI cannot be quantified in numeric terms in this specific situation”, the 
application of BOI itself was not discussed. BOI was identified 672 times in 
68 reports, and from 2015 onwards, increasingly related to the correspon-
ding reference values (see Table 4.1), which were identified 328 times in 26 
reports. In 2013, BOI was most frequently expressed in qualitative terms, 
e.g. in terms of “low” or “high” BOI, and only sometimes in numeric terms, 
by disability weights used for calculating DALYs. From 2014 onwards, BOI was 
less frequently expressed in qualitative terms and was mostly quantified by 
disability weights or the number of DALYs lost, which at times were presented 
alongside the mean life expectancy of patients with and without the disease. 
In three reports, BOI was addressed as a relative measure; however, the 
presented disability weights or DALYs lost were not applied as such. From 
2015 onwards, BOI was most frequently quantified in terms of PS, in a total of 
seven reports. In four of these reports, PS calculations were presented along-
side disability weights, number of DALYs lost, mean life expectancy, or years 
of life lost calculations. 
Based on these results, it appears that the application of BOI was not publicly 
discussed by ACP members between 2013 and 2016. The operationalisation of 
BOI in terms of PS, and the role of PS in healthcare decision making, was infre-
quently discussed. While BOI was most frequently expressed qualitatively in 
2013, it was increasingly quantified in later years, usually in terms of disability 
weights or the number of DALYs lost. From 2015 onwards, ICERs were incre-
asingly related to the monetary reference values per QALY gained that were 
set by ZIN that year [25] and BOI was most frequently quantified in terms of 
PS. In this context, it needs noting that there was a change in ACP members 
in 2015 and this may have contributed to the increased application of PS from 
then on. In the reports, PS calculations were frequently presented alongside 
disability weights, number of DALY lost, life expectancy, and years of life loss 
calculations. This variety may reflect that there is no consensus (yet) about 
the application of PS in healthcare decision making in the Netherlands.
2.6 Discussion
The importance of operationalising the equity-efficiency trade-off for infor-
ming priority setting in healthcare is increasingly recognised. This study 
described the history and application of PS in the Netherlands, examined the 
theoretical and empirical support for PS as an operationalisation of the equi-
ty-efficiency trade-off, and looked into the current role of PS in healthcare 
decision making.
Overall, our results indicate general support for the decision model in which 
BOI is quantified and the ICERs of health technologies are evaluated against 
the reference values per QALY gained set by ZIN. This model connects the 
criteria for healthcare decision making that were previously formulated by the 
Dunning Committee and enables a uniform decision model for priority setting 
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across all healthcare sectors. Consequently, the model has received broad 
support in research and policy circles and has been incorporated into the 
healthcare decision-making framework in the Netherlands. 
Although the model is increasingly applied in decision-making practice, the 
results of our literature review suggest that theoretical support for PS is 
moderate at best. In applying PS, a trade-off between the SOI and FI approa-
ches is made and, consequently, societal preferences for either of the two 
equity approaches may be insufficiently reflected when allocating resources in 
healthcare. However, this may be regarded as a general limitation that comes 
with applying any equity approach in practice, as improving equality in the 
distribution of health(care) by applying one equity approach may inevitably be 
associated with increasing inequality in the context of applying another [3]. 
A limitation that is not restricted, but may be more specific to applying PS, is 
that it mitigates ageism between patient groups, as beneficiaries of all ages 
can experience the same level of PS. The results of our study suggest that this 
may inadequately reflect societal preferences relating to age and reducing 
lifetime-health inequalities between patient groups. Although the results of 
our literature review suggest that empirical support for PS is limited, it should 
be noted that that empirical evidence regarding PS so far is scarce and incon-
clusive, so that a rejection of the PS approach can also not be concluded. The 
societal concern regarding age that is currently insufficiently reflected by PS 
could be incorporated by adjusting PS for age. However, there is no empirical 
evidence (to date) to support the hypothesis that this would better align with 
societal preferences and hence future research on this topic will be necessary. 
The results of our review of publicly accessible ACP reports suggest that the 
ACP did not publicly discuss the definition and operationalisation of neces-
sity of care in terms of BOI between 2013 and 2016. In fact, BOI became 
increasingly quantified, and ICERs were increasingly evaluated against the 
reference values per QALY gained set by ZIN in 2015. The operationalisation 
of BOI in terms of PS was publicly discussed by the ACP, although only on rare 
occasions. This may indicate that the ACP supports the operationalisation of 
BOI in terms of PS. However, the variety of BOI quantifications in ACP reports 
demonstrates that consensus about the operationalisation and quantification 
of BOI has not yet been reached. 
Relatively few studies have examined the theoretical and empirical support 
for PS and, to our knowledge, no other study has examined the current role of 
PS in healthcare decision making in the Netherlands. Although this limits our 
ability to compare our results with those of others, we would like to compare 
the results of our empirical literature review to the results of a study con-
ducted by Nord and Johansen [57] and the public consultation of NICE on the 
valued-based assessment of health technologies [58–60]. Nord and Johansen 
[57] examined support for PS, relative to preferences for no other equity 
approach, by conducting an empirical literature review that built on an earlier 
review by Shah [61] and included 20 preference studies that were conducted 
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in nine different countries between 1991 and 2011. Under the assumption of 
a stable health condition and no loss in length of life for patients, Nord and 
Johansen found strong support for PS, although the strength of the support 
varied greatly between the included studies. Regarding the inclusion criteria 
for our literature review, five of the studies that Nord and Johansen included 
were conducted after the introduction of PS in the Netherlands. Of these five 
studies, two quantified health benefits in terms of QOL and three in terms of 
QALYs. However, none of the three latter studies elicited preferences for PS 
and, as such, were not included in our literature review. Although the results 
of our review seem to be discordant with Nord and Johansen’s results, and it 
is worth mentioning that in two of the five aforementioned studies the public 
was found to be less likely to prioritise patients with higher levels of SOI 
[45,62], a direct comparison of results is not possible for reasons that are 
previously described. 
NICE conducted a public consultation in the UK in 2014 on the topic of 
value-based assessment of health technologies [58–60]. NICE asked the 
public, including patients, economists, academics, and members of the phar-
maceutical industry ten related questions. One of the questions concerned 
the extent to which the public regarded PS as an appropriate approach for 
quantifying BOI [58]. NICE received responses from 121 individuals and orga-
nisations, but no general agreement emerged [59]. In summary, the public 
regarded PS as a measure that is feasible and suitable for calculating BOI 
in terms of health and QOL impact in cases where a disease affects older 
patients. However, as in the ACP, there were concerns about PS not being a 
suitable measure for capturing broader aspects of BOI that are not included in 
the QALY. In addition, there were concerns about PS assigning a lower weight 
to the BOI of younger patients than to older patients due to differences in 
the PS denominator, i.e. the remaining QALY expectation in absence of the 
disease. More generally, there were concerns about the strong reliance on the 
QALY in health technology assessment and in the calculation of BOI, resulting 
in a possible double counting of benefits when setting priorities in healthcare 
[59]. Because of the lack of agreement that emerged from the public consul-
tation, NICE decided to not change their current health-technology appraisal 
and end-of-life guidelines [60].
Some limitations of our study must be mentioned. A first limitation concerns 
the lack of a systematic review of the studies that we used to examine the 
theoretical and empirical support for PS. However, as the number of studies 
examining PS is limited, we believe that our review was comprehensive and that 
our results were not influenced by the lack of a systematic search. A second 
limitation concerns the use of publicly accessible ACP reports to examine the 
current role of PS in healthcare decision making in the Netherlands. In addi-
tion to public meetings, the ACP held closed meetings between 2013 and 
2016, and the role of PS may have been discussed more frequently in these. 
However, the reports of these closed meetings are not publicly accessible and 
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therefore could not be included in our review of ACP reports. Although the 
role of PS may have been discussed more frequently during closed meetings, 
and the inclusion of closed meeting reports might have changed the review 
results, it seems reasonable to expect that any discussion of PS in a closed 
meeting would have been reflected in a public meeting where the decision 
making actually took place. A final limitation concerns the risk of double coun-
ting search terms due to a possible overlap in ACP meeting reports. This risk 
was reduced by excluding concept versions of minutes unless a final version 
was not available; however, this distinction could not always be made for 
meeting documents. For example, documents concerning the reimburse-
ment of a specific treatment may have been discussed at more than one ACP 
meeting. As a result, a higher relative importance may have been assigned 
to some of the search terms. However, as the main objective of our review 
of ACP reports was to examine the role of PS in healthcare decision making, 
and PS was infrequently identified, we believe that the influence of possible 
double counting on conclusions drawn from the review is limited. Concerning 
the frequency with which the search terms were identified in the ACP meeting 
reports, we would like to additionally point out that these frequencies should 
be considered in the broader context of priority setting in the Netherlands. 
This broader context determines the agenda and the priorities that are set 
in ACP meetings and hence influences the frequency with which the search 
terms were identified. Apart from these limitations, we consider it a strength 
of our study that we have examined support for PS at three different levels, 
i.e. at a theoretical, empirical, and decision-making level. To our knowledge, 
this is the first study to examine support for PS in such an extensive manner. 
Ideally, the operationalisation of the equity-efficiency trade-off are normati-
vely justifiable and empirically supported. The various normative choices that 
need to be made in this context indicate that a trade-off or a compromise 
between different societal concerns regarding equity and fairness needs to 
be made. Consequently, the ‘perfect’ explication of the equity criterion may 
not exist, and PS, like any other explication, will have its strengths and limi-
tations. The results of our study indicate that the decision model in which 
increasing levels of BOI are quantified and ICERs are related to the associated 
monetary reference values per QALY gained is supported and increasingly 
applied in decision-making practice. The operationalisation of BOI in terms of 
PS enables a uniform decision model for priority setting across all healthcare 
sectors that can be applied by replacing or complementing the QALY in the PS 
equation with a broader, wellbeing-related, generic outcome measure such as 
the ICECAP [56]. The results of our study also indicate that PS insufficiently 
reflects societal preferences regarding age and reducing lifetime-health ine-
qualities between patient groups. Future research is needed to develop and 
examine alternative versions of PS, such as a version of PS that is adjus-
ted for wellbeing- and age-related preferences. These could be compared to 
the current operationalisation of PS, also in terms of alignment with general 
public preferences. There are different possibilities for combining PS and age 
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in a preference-elicitation study. For example, it may be interesting to elicit 
preferences for a PS version in which the denominator of the PS equation 
consists of patients’ lifetime-QALY expectation. It may also be interesting to 
elicit preferences for combinations of PS and lifetime health (or age). For this, 
a matrix combining different age and PS classes could be used. To increase 
comparability between studies, we recommend using a more standardised 
approach to eliciting equity weights. Related to this, we would like to mention 
that the variety of the ways in which BOI is quantified in ACP reports may, 
understandably, reflect the present lack of consensus about the application 
of PS. However, this variety is in itself undesirable as it hampers the transpa-
rency and comparability of BOI quantifications for different beneficiaries and, 
subsequently, of the relevant cost-effectiveness threshold of (new) health 
technologies in the Netherlands. ZIN is expected to publish a report on the 
standardisation of the BOI quantification later this year to solve this issue.
2.7 Conclusions
The results of this study suggest that there is support for the decision model 
in which BOI is quantified and ICERs are evaluated against increasing mone-
tary reference values. Although consensus regarding the application of PS has 
not yet been reached, BOI is increasingly quantified in terms of PS in decisi-
on-making practice. As any (generic) outcome measure can be included in the 
PS equation, PS enables a uniform decision model for priority setting across 
all healthcare sectors. Empirical support for PS appears to be limited, as PS 
may insufficiently reflect societal preferences regarding age and reducing life-
time-health inequalities. Hence, further investigation into the refinement of 
PS—or exploration of another approach—appears warranted for operationali-
sing the equity-efficiency trade-off in healthcare priority setting. 
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Chapter 3 
Equity weights for priority 
setting in healthcare: 
Severity, age, or both?
Based on: Reckers-Droog VT, van Exel NJA, Brouwer WBF. Equity weights 
for priority setting in healthcare: Severity, age, or both? Value in Health. 
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Abstract 
Priority setting in healthcare can be guided by both ‘efficiency’ and ‘equity’ 
principles. The latter principle is often explicated in terms of disease severity 
and, for example, defined as absolute or proportional shortfall. These seve-
rity operationalisations do not explicitly consider patients’ age even though 
age may be inextricably related to severity and an equity-relevant characte-
ristic. This study examines the relative strength of societal preferences for 
severity and age for informing allocation decisions in healthcare. We elicited 
preferences for severity and age in a representative sample of the public in 
the Netherlands (n=1,025) by applying choice- and person-trade-off (PTO) 
tasks in a design in which severity levels and ages varied both separately and 
simultaneously between patient groups. We calculated PTO ratios and, additi-
onally, applied OLS regression models to aid interpretation of the ratios when 
severity and age both varied. Respondents attached a higher weight (median 
of ratios: 2.46-3.50) to reimbursing treatment for relatively more severely 
ill and younger patients when preferences for both were elicited separately. 
When preferences were elicited simultaneously, respondents attached a 
higher weight (median of ratios: 1.98 and 2.42) to reimbursing treatment for 
relatively younger patients, irrespective of patients’ severity levels. Ratios 
varied depending on severity level and age, and were generally higher when 
the difference in severity and age was larger between groups. Our results 
suggest that severity operationalisations and equity weights based on seve-
rity alone may not align with societal preferences. Adjusting decision-making 
frameworks to reflect age-related societal preferences should be considered.
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3.1 Introduction
The increasing demand for healthcare and the resulting pressure on scarce 
resources render healthcare priority setting inevitable. Allocation decisions 
can be guided by both efficiency and equity principles, and hence be informed 
by the cost-effectiveness of health technologies and equity considerations 
associated with, for example, patient and disease characteristics [1–6]. Alt-
hough it has been advocated to explicitly and transparently incorporate these 
principles into the decision-making framework [7–9], there is little agree-
ment on how equity considerations should be defined and how the trade-off 
between efficiency and equity, or between equity considerations, should be 
operationalised [3,4]. This may partly explain why, so far, only a few countries 
integrated equity considerations and weights into formal decision-making 
frameworks [3]. Examples of countries that have done so are Norway and the 
Netherlands [10,11]. Text box 3.1 includes a brief overview of the equity con-
siderations and decision-making frameworks applied in these two countries.
Text box 3.1 Equity considerations and decision-making frameworks in Norway 
and the Netherlands
In Norway, equity considerations are explicated in terms of disease severity and 
defined as absolute shortfall (AS). AS is operationalised as the disease-related loss 
of remaining QALYs without the new technology, compared to the QALY expecta-
tion in absence of the disease [10,12,13]. The Magnussen Committee suggested 
to divide AS into six severity classes and evaluate the ICERs of health technolo-
gies that target diseases with an AS of 0-3.9, 4-7.9, 8-11.9, 12-15.9, 16-19.9 and 
>20 QALYs against thresholds of NOK 275,000/QALY, NOK 385,000/QALY, NOK 
495,000/QALY, NOK 605,000/QALY, NOK 715,000/QALY, and NOK 825,000/QALY 
(approximately €28,800 - €87,000), respectively [14,15]. Although the Norwegian 
government did not formally adopt the suggested AS classes and thresholds, they 
are informally used to inform allocation decisions in healthcare [10]. In the Nether-
lands, equity considerations are also explicated in terms of severity, and severity 
is defined in terms of proportional shortfall (PS). PS is operationalised as the 
fraction of disease-related QALY loss without the new technology, relative to the 
remaining QALY expectation in absence of the disease and measured on a scale 
from 0 (no QALY loss) to 1 (complete loss of remaining QALYs) [11,16,17]. PS is 
divided into four severity classes. Health technologies that target diseases with 
a PS level of <0.10 are, in principle, not reimbursed [11,16]. The ICERs of health 
technologies that target diseases with PS levels of 0.10-0.40, 0.41-0.70, and 0.71-
1.00 are evaluated against reference values of €20,000/QALY, €50,000/QALY, and 
€80,000/QALY, respectively [11,16,18–20]. Since 2018, the Dutch National Health 
Care Institute (ZIN) supplements information on PS with information on patients’ 
AS and prospective health (PH) to be transparent about the possible consequences 
of applying PS for different age groups [11]. PH is a severity operationalisation that 
considers patients expected health and death and prioritises those with the worst 
prognosis without the new technology [21]. PH is calculated as the remaining QALY 
expectation from the onset of disease in case of no treatment [21]. 
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The decision-making frameworks applied in Norway and the Netherlands both 
account for societal preferences relating to the disease severity of patients. 
However, neither explicitly accounts for age-related societal preferences. This 
may be (partially) explained by the fact that, politically, age usually is not 
regarded as a relevant or even acceptable decision criterion [22–24]. It should, 
however, be noted that—in decision-making practice—severity is not indepen-
dent from age and not explicitly accounting for age in allocation decisions 
can still result in a prioritisation that favours certain age groups over others 
[25]. For example, in Norway, younger patients are, ceteris paribus, more 
likely to lose a larger absolute amount of their remaining quality-adjusted 
life-years (QALYs), and hence may indirectly be prioritised over older patients. 
Moreover, for older patients it becomes increasingly difficult, if not impossible, 
to fall into the highest severity class. For example, 65-year old patients may, 
on average, have no more than 15 QALYs left to lose. In the Netherlands, PS 
was implemented with the intention to avoid ageism in allocation decisions by 
enabling patients of all ages to lose the same relative amount of their remai-
ning QALYs [11,18]. However, older patients are, ceteris paribus, more likely 
to lose a larger fraction of their remaining QALYs, and hence may indirectly be 
prioritised over younger patients [13]. 
Although equity weights based on AS and PS may be inextricably related to 
patients’ age, neither explicitly distinguishes between age groups nor aims 
to weight age in allocation decisions. Hence, prioritising between age groups 
with AS or PS levels that are equal or fall into the same severity class is 
not possible within current decision-making frameworks. Empirical evidence, 
however, suggests that the public considers information on severity and 
age important and generally prefers prioritising younger over older patients 
[26–34]. At the same time, evidence regarding the direct trade-off between 
preferences for severity and age and the relative weight these should receive 
in allocation decisions is limited [17,35]. The aim of this study is, therefore, 
to contribute to the existing literature on this topic by examining the relative 
strength of societal preferences for severity and age. To meet this aim, we 
applied the person-trade-off (PTO) approach in a design in which severity 
levels and ages varied both separately and simultaneously between patient 
groups. We compare preferences for severity and age in relation to AS, PS, 
and prospective health (PH), as these severity operationalisations are cur-
rently applied in Norway and the Netherlands. The results may be of interest 
to all countries seeking to understand equity considerations associated with 
severity and age, and operationalise these considerations in the context of 
healthcare priority setting. 
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3.2 Methods
3.2.1 Sample and data collection
A questionnaire was designed and, subsequently, distributed online in October 
2018. Respondents (n=1,025) were quota sampled to represent the public in 
the Netherlands in terms of age (18-70 years), sex, and education level (see 
Table 3.1). Prior to collecting the data, we pilot tested the comprehensiveness 
of the questionnaire and clarity of the applied concepts and choice- and PTO 
tasks in two consecutive samples (n=120 and 1,023). 
Before respondents completed the questionnaire, we explained that healthcare 
resources are scarce and policy makers inevitably have to choose between 
competing health technologies and patient groups for reimbursement. We 
asked respondents to advise policy makers faced with the choice of reimbur-
sing a health technology for one of two patient groups (labelled A and B) on 
how best to allocate the available budget. We explained that there were no 
differences between the patient groups other than those explicated and that 
the treatment type and costs were the same for both groups. We limited the 
duration of the disease and treatment-related health gain to one year to stan-
dardise the health gains from treatment in different age groups. This avoided 
the influence of other considerations, including preferences for lifetime health 
and health maximisation. Based on this temporary loss in health-related 
quality of life (QOL) and no loss in length of life, we calculated patients’ AS, 
PS, and PH (not shown to respondents) and compared preferences for severity 
and age in relation to these severity operationalisations.
Table 3.1 Sample characteristics (n=1,014)a
% Mean (SD)









Health status (0-100 VAS) 75.4 (17.7)
Completion time of PTO tasks (in min) 7.7 (5.1)
PTO, person trade-off; VAS, visual analogue scale; a Respondents who completed the PTO tasks in less than 115 
seconds (n=11) are excluded from this table; b Low = lower vocational and primary school; Medium = middle voca-
tional and secondary school; High = higher vocational and academic education.
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3.2.2 Questionnaire
The questionnaire consisted of three parts. In part one, we introduced three 
central concepts in text and graphs to respondents: (i) QOL, operationalised 
in points on a visual analogue scale (VAS) that ranged from 0 ‘the worst health 
you can imagine’ to 100 ‘the best health you can imagine’ [36]; (ii) severity, 
operationalised in terms of disease-related QOL loss; and (iii) treatment-rela-
ted QOL gain. To familiarise respondents with these concepts and the applied 
tasks, we asked them to rate their current health on the VAS and complete 
one example choice- and one PTO task. We further asked them to assess 
the clarity of the concepts and example tasks on a seven-point Likert scale 
ranging from 1 ‘very unclear’ to 7 ‘very clear’. 
In part two, respondents stated their preferences for severity and age by 
completing a total of six randomly assigned choice- and associated PTO tasks 
in three similarly structured modules. In the choice tasks, respondents stated 
their preference for reimbursing treatment for either patient group A or B, or 
their indifference between the groups, based on the contingency that both 
groups consisted of 100 patients. In the associated PTO tasks, we set the res-
pondents’ group of preference (or in case of indifference a randomly selected 
group) as a reference group consisting of 100 patients. We asked respondents 
to indicate in four iterative steps of how many patients (between 100 and 
1,000,000) the other group should consist in order to be indifferent between 
the two groups. Figure 3.1 presents a graphical representation of the PTO 
process, including the iterative steps taken to elicit respondents’ preferences 
and the intervals between the steps. A detailed description of the applied PTO 
approach and examples of the choice- and PTO tasks are included in Appendix 
3.1.
Fig. 3.1 Graphical representation of the iterative PTO processa
a In step four, respondents indicated the number of patients within the indicated range. For respondents with a 
consistent preference for one of the patient groups, this range was restricted to a maximum of 1,000,000 patients. 
Step 1 Step 2 Step 3 Step 4
B B(X)=125 B B(X)=100-125
B B(X)=150 A B(X)=125-150
A B(X)=175 B B(X)=150-175
A B(X)=175-200
B B(X)=200
B B(X)=225 B B(X)=200-225
A B(X)=250 A B(X)=225-250
A B(X)=300 B B(X)=250-300
A B(X)=300-1,000,000
Suppose patient group A consists of 100 patients and group B of X patients.
For which patient group (A of B), do you think, should treatment be reimbursed?
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We started each module with introducing the patient groups and explaining 
that the groups would have lived in full health (a score of 100 on the VAS) 
until the age of 80 if they had not fallen ill at the age of X (with X=10, 40, or 
70). We then explained that the disease affected patients’ QOL, but not their 
life expectancy. Due to the disease, their QOL decreased from 100 to Y (with 
Y=20, 50, or 80) on the VAS for the duration of one year after which it resto-
red to the initial level. If patients would receive treatment, their QOL would 
increase with 20 points during that year. In module 1, respondents completed 
two choice- and associated PTO tasks based on a ‘small’ and ‘large’ difference 
in severity between the patient groups (i.e. 30 points, from 100 down to 20 
vs. 50 or 50 vs. 80, and 60 points, from 100 down to 20 vs. 80, respectively), 
while patients’ ages were kept constant. In module 2, respondents completed 
two choice- and associated PTO tasks based on a ‘small’ and ‘large’ difference 
in age between the groups (i.e. 30 years, age 10 vs. 40 or 40 vs. 70, and 60 
years, age 10 vs. 70, respectively), while patients’ severity levels were kept 
constant. In module 3, respondents completed two choice- and associated 
PTO tasks based on a ‘small’ and ‘large’ difference in both severity and age 
between the groups (i.e. 30 points/years and 60 points/years, respectively).
Table 3.2 presents the applied attributes and levels, and Table 3.3 in the 
Results section includes the applied choice sets and associated AS, PS, and PH 
levels. We reduced the possible risk of order effects by presenting modules 1 
and 2, the choice sets, and patient groups in random order to respondents. In 
part three of the questionnaire, we asked respondents about their socio-de-
mographic characteristics. 
Table 3.2 Overview of attributes and levels
Attributes Levels
Severitya (in points on VAS) 20; 50; 80
Age (in years) 10; 40; 70 
QOL after treatmentb (in points on VAS) 40; 70; 100
Treatment-related QOL gain (in points on VAS) 20
Life expectancy (in years) 80
QOL, health-related quality of life, VAS, visual analogue scale (range 0-100); a Severity is operationalised in terms 
of disease-related QOL loss; b QOL after treatment is calculated as: 100 – disease-related QOL loss + treatment-re-
lated QOL gain. 
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3.2.3 Statistical analyses and hypotheses
We examined preferences for severity and age by calculating the percen-
tage of total with a preference for reimbursing treatment for patient group 
A, group B, or neither of the groups, and the mean- and median-based PTO 
ratios. A PTO ratio of 1 indicates that respondents, on average, attach an 
equal weight to reimbursing treatment for groups A and B, and a ratio of >1 
(<1) that they attach a higher (lower) weight to reimbursing treatment for 
group A. We present the unpooled (i.e. per choice set) and pooled (i.e. per 
‘small’ and ‘large’ difference) mean- and median-based PTO ratios, including 
our calculation methods, in Table 3.4. We focus the discussion of the results 
on the ratio of medians (ROMs) and median of ratios (MORs) to account for 
outliers. 
To aid interpretation of the PTO ratios in module 3, we applied Ordinary Least 
Squares (OLS) regression models in which we assumed utility equivalence 
between reimbursing treatment for the patient groups. We regressed the dif-
ference in patient numbers (multiplied by patients’ treatment-related QOL 
gain) on the differences in severity level (∆Severity) and age (∆Age) between 
the groups and calculated the marginal rate of substitution (MRS) (95% CI) 
between ∆Severity and ∆Age by bootstrapping (5,000 repetitions) the ratio 
of the coefficients. We present the OLS results both including and excluding 
respondents with outlying preferences (-1.96> z-score >1.96) in Table 3.5. 
We focus the discussion of the results on the latter to account for outlying 
preferences. Note that, for calculating the preferences (in %) and PTO ratios, 
we restructured the patient-group order to ‘A vs. B’ for all respondents. For 
the regression models, we used the order in which the groups were presented 
to respondents (‘A vs. B’ or ‘B vs. A’). Although this was necessary for con-
ducting the different analyses, the difference in data structure and applied 
methods hampers a direct comparison between the PTO ratios and the ratios 
obtained from the OLS regressions. 
We determined a minimum completion time of 115 seconds for the PTO tasks 
based on the distribution of the time respondents needed for completing the 
tasks in the pilot and a timed test of the tasks by three independent resear-
chers. We excluded respondents who completed the tasks more quickly from 
the analyses as we expected these speeders to have completed the tasks too 
quickly to properly read, understand, and complete them. We performed sen-
sitivity analyses to test the robustness of our results by alternately repeating 
the analyses excluding respondents who reported a low score (i.e. 1-3 level) 
for the clarity of the example PTO task and preferred reimbursing treatment 
for neither of the patient groups. We identified only 11 speeders, and hence 
did not perform sensitivity analyses on this subgroup.
Before conducting the analyses, we formulated the following hypotheses:
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Hypothesis 1: Respondents prefer—and attach a higher weight to—reim-
bursing treatment for the relatively more severely ill patient group, when 
patients’ ages are equal (module 1);
Hypothesis 2: Respondents prefer—and attach a higher weight to—reim-
bursing treatment for the relatively younger patient group, when patients’ 
severity levels are equal (module 2). 
As evidence regarding the direct trade-off between severity and age is limited 
[17,35], we formulated no hypothesis, yet explored preferences when patients’ 
severity level and age varied simultaneously (module 3). 
We conducted the analyses using Stata 15.1 (Stata Corp LP, College station, 
Texas).
3.3 Results
Respondents assessed the clarity of the concepts in text at mean (SD) 5.9 
(1.0) and in graphs at 5.7 (1.2), and of the example choice task at 5.5 (1.3) and 
PTO task at 5.0 (1.7) on the seven-point Likert scale. Of the respondents, 177 
(17.3%) reported a low score for the clarity of the example PTO task. 
Table 3.3 presents the percentages of respondents with a preference for reim-
bursing treatment for group A, group B, or neither of the groups. Table 3.4 
presents the PTO ratios.
In module 1, most respondents (range 47.4-58.9% across choice sets; Table 
3.3) preferred and, on average, attached a higher weight to reimbursing tre-
atment for the relatively more severely ill patient group at all ages. These 
results provide evidence in support of hypothesis 1. The strength of respon-
dents’ preferences varied across severity levels, ages, and the size of the 
difference in severity between the groups. When the difference in severity 
was ‘small’ (choice sets 1 to 6; Table 3.4), the MOR was 2.51, indicating that 
respondents, on average, valued reimbursing treatment for one more seve-
rely ill patient equally to that for 2.51 less severely ill patients. The ROMs 
were relatively higher when the two patient groups were lower on the severity 
scale. The ROMs appeared to increase with age when patient groups were 
lower on the severity scale (i.e. choice sets 2, 4 and 6; Table 3.4). When the 
difference in severity was ‘large’ (choice sets 7 to 9; Table 3.4), the MOR was 
2.75 and the ROM was somewhat higher in the youngest age group. 
In module 2, most respondents (range 44.4-63.3% across choice sets; Table 
3.3) preferred and, on average, attached a higher weight to reimbursing tre-
atment for the relatively younger patient group at each severity level. These 
results provide evidence in support of hypothesis 2. The strength of preferen-
ces again varied across ages, severity levels, and the size of the difference in 
age between the groups. When the difference in age was ‘small’ (choice sets 
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1 to 6; Table 3.4), the MOR was 2.46, indicating that respondents, on average, 
valued reimbursing treatment for one younger patient equally to that for 2.46 
older patients. The ROMs were relatively higher when it concerned compari-
sons between the higher age groups (i.e. choice sets 2, 4 and 6; Table 3.4). 
The ROMs did not show a clear relation with severity levels. When the diffe-
rence was ‘large’ (choice sets 7 to 9; Table 3.4), the MOR was 3.50 and the 
ROM was slightly higher for the highest severity level.
In module 3, most respondents (range 38.5-74.0% across choice sets; Table 
3.3) preferred reimbursing treatment for the relatively younger patient group 
and respondents, on average, attached a higher weight to reimbursing tre-
atment for younger patients, irrespective of patients’ severity levels (choice 
sets 1, 3, 5 and 7 have ROMs >1, whereas choice sets 2, 4, and 8 have ROMs 
<1). In module 3, the MORs were somewhat lower than in modules 1 and 2. 
When the difference in severity and age was ‘small’ (choice sets 1 to 8; Table 
3.4), the MOR was 1.98 and when this was ‘large’ (choice sets 9 to 10; Table 
3.4), the MOR was 2.42. 
Table 3.5 presents the OLS results. The ∆Severity coefficient indicates that, 
ceteris paribus, respondents attached a higher weight to reimbursing treat-
ment for relatively more severely ill patients. The implied ratios are 2.48 and 
1.97 per point increase in ∆Severity, given a ‘small’ and ‘large’ difference in 
severity between the groups in models 1 and 2, respectively. The ∆Age coef-
ficient indicates that, ceteris paribus, respondents attached a higher weight to 
reimbursing treatment for relatively younger patients. The implied ratios are 
1.49 and 1.73 per year increase in ∆Age, given a ‘small’ and ‘large’ difference 
in age between the groups in models 1 and 2, respectively. The MRS (95% CI) 
between ∆Severity and ∆Age were -1.23 (-4.02; 1.56) and -0.66 (-1.01; -0.31) 
for models 1 and 2. This indicates that ∆Age was considered relatively more 
important when the differences between the patient groups were ‘large’. The 
sensitivity analyses showed consisted results. 
Our results suggest that AS, PS, and PH are all consistent with societal pre-
ferences when severity levels differ between patient groups and their ages 
are equal. However, none of these severity operationalisations is fully consis-
tent with societal preferences when severity levels are equal and ages differ 
between patient groups. When severity levels and ages both vary, our results 
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suggest that AS may be most consistent with societal preferences (in 6/10 
choice sets), followed by PS (in 2/10 choice sets) and PH (in 1/10 choice sets).
3.4 Discussion
In this study, we examined the relative strength of societal preferences for 
severity and age in the context of healthcare priority setting. Our main fin-
dings are that respondents, on average, preferred—and attached a higher 
weight to—reimbursing treatment for relatively more severely ill and younger 
patients, when preferences for severity and age were elicited separately. 
When preferences were elicited simultaneously, respondents, on average, 
preferred—and attached a higher weight to—reimbursing treatment for relati-
vely younger patients, irrespective of patients’ severity levels. We found that 
the relationship between preferences for severity and age is nonlinear and 
dependent on severity levels, ages, and the size of the difference in severity 
and/or age between the patient groups. Moreover, we found that preferences 
were generally stronger when the difference between the groups was larger. 
It should be noted that these findings need to be considered in relation to 
Table 3.5 Regression resultsa
Model 1b
DV: Including outliers Excluding outliers
∆nrPatients*QOLgain β (SE) 95% CI β (SE) 95% CI
∆Severity 5245.40** (1662.67) 1982.73, 8508.07 1193.73*** (324.82) 556.33, 1831.14




DV: Including outliers Excluding outliers
∆nrPatients*QOLgain β (SE) 95% CI β (SE) 95% CI
∆Severity 2215.53** (791.01) 663.32, 3767.73 985.00*** (272.28) 450.69, 1519.31
∆Age -2051.20** (791.01) -3603.41, -498.99 -1490.30*** (272.28) -2024.61, -956.00
R2 0.01 0.04
n 1,014 1,006
DV, dependent variable; SE, standard error; QOL gain, treatment-related gain in quality of life (20 points on 
visual analogue scale); ∆Age, difference in age (in years) between patient group A and B; ∆nrPatients*QOLgain, 
difference in the number of patients between patient group B and A, each multiplied by the treatment-related gain 
in QOL; ∆Severity, difference in severity (in points QOL loss) between patient group A and B; DV, dependent vari-
able; a Respondents who completed the PTO tasks in less than 115 seconds (n=11) are excluded from this anal-
ysis. The results are presented in- and excluding respondents with outlying (-1.96> z-score >1.96) preferences; 
b Model 1 presents the results for a difference of 30 points in QOL loss and 30 years in age between the patient 
groups; c Model 2 presents the results for a difference of 60 points in QOL loss and 60 years in age between the 
patient groups; ∙ p<0.10; * p<0.05; ** p<0.01; *** p<0.001.
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the applied design and that preferences for severity and age may differ when 
elicited on full (or equally wide) severity and age scales, or when elicited in 
relation to prolonged health improvements or improved life expectancy. It 
should also be noted that a considerable minority of respondents stated a 
preference for reimbursing treatment for neither of the patient groups or 
for the relatively less severely ill and/or older patient group. This preference 
heterogeneity is consistent with the results of previous studies [4].
Our results suggest that AS, PS, and PH are all consistent with societal pre-
ferences when severity levels differ between patient groups and their ages 
are equal, yet none is fully consistent with societal preferences when severity 
levels are equal and ages differ between patient groups. When severity levels 
and ages both vary, our results suggest that AS may be most consistent 
with societal preferences, followed by PS and PH. These latter results are 
consistent with those of Stolk et al. [35], who compared support for AS, PS, 
and PH by applying a ranking exercise in a small convenience sample (n=65). 
Our results are also consistent with those of other studies that empirically 
investigated equity weights and emphasise the relevance of both patients’ 
severity and age in allocation decisions [24,26–35]. For example, our results 
are consistent with those of Dolan and Tsuchiya [27] who found that preferen-
ces for age were stronger than those for severity when preferences for both 
were elicited simultaneously. They already suggested that these preferences, 
therefore, should not be considered in isolation of each other. Our results are 
inconsistent with some studies that found the social value of QALYs to be rela-
tively independent of patients’ age [37–39]. Although these differences may 
result from differences in applied preference-elicitation methods, they may 
also result from preference heterogeneity over time and between countries. 
The main strengths of this study lie in the extensively pilot-tested questi-
onnaire and innovative application of the PTO approach in a design in which 
we varied severity levels and ages separately and simultaneously between 
patient groups. Other methods, e.g. discrete choice experiments, could have 
been applied here; however, we chose to apply the PTO approach as this 
enabled us to keep the tasks relatively simple for respondents and to better 
understand the elicited preferences at the level of an individual respondent. 
Other strengths lie in the reduction of the possible risk of order effects by pre-
senting two modules, the choice sets, and patient groups in random order and 
in the avoidance of other considerations by limiting the duration of the disease 
and QOL gain to one year. We are aware that this comes with the limitation 
that our results cannot be generalised to severity and age-related preferen-
ces in relation to QALY gains. Some further limitations need to be discussed. 
A first limitation is common to all preference-elicitation studies and concerns 
the sensitivity of the results to the way in which the questions were framed 
[4,27,40]. For example, severity and age were the only attributes that varied 
and this may have influenced the relative strength of preferences for these 
attributes. Preferences for severity and age may differ when elicited in com-
64 | Chapter 3
bination with other attributes [41]. To some extent, this was already observed 
when age and severity were varied simultaneously rather than separately. A 
second limitation concerns the instruction to assume that there were no other 
differences between the groups than those explicated. Nonetheless, prefe-
rences may have been influenced by omitted variables [41,42]. For example, 
respondents may have considered aspects like spill-over effects on family or 
informal carers, and productivity losses [29,32]. They may also have consi-
dered the acceptability of a less than perfect health state at an older age, the 
degree of health inequality between the groups, and the risk or uncertainty 
associated with severity levels and treatment gains [43–46]. A third limita-
tion concerns a possible upwards bias of the PTO ratios caused by censoring 
the number of patients between 100 and 1,000,000 in the PTO tasks [47]. 
However, the influence of censoring may be counterbalanced by including 
respondents with no preference for either of the groups in the analysis as 
the robustness checks indicated that the obtained ratios were in fact pulled 
downwards by this. A final limitation concerns the low R-squared values of the 
regression models. These low values indicate that the models do not explain 
much of the data variability. However, the implied ratios associated with an 
increase of 30 points and 30 years increase in the difference in severity and 
age between the patient groups resemble the mean-based PTO ratios in Table 
3.4 and the OLS results aided the interpretation of the PTO ratios in module 
3 as intended. 
Our results are consistent with those of previous studies, suggesting that 
the outcomes of allocation decisions informed by AS may be better aligned 
with societal preferences than those informed by PS or PH [20,26–30,35]. 
However, our results also suggest that none of these severity operationalisa-
tions may be sufficiently adequate for guiding decisions that concern patients 
of different ages. At least, not when aiming to align the outcomes of these 
decisions with societal preferences. If so, current AS, PS, and PH applica-
tions may all need to be ‘age weighted’ when ages differ between patient 
groups, irrespective of differences in their severity level. This may be even 
more necessary for those severity operationalisations that do not indirectly 
favour younger over older patients, like AS does. Whether or not age weights 
are normatively acceptable and societal preferences are to be reflected in 
allocation decisions are pressing questions in this context, but fall outside the 
scope of the current paper. 
Further research is warranted to examine the relative strength of preferences 
for severity and age when severity is operationalised on a QALY scale, thus 
incorporating both length and quality of life attributes. Research may further 
be aimed at examining the relevant thresholds for QALYs gained in different 
age-adjusted severity classes. For this, a matrix-based design could poten-
tially be used to account for the nonlinear relationship between preferences 
for severity and age [16]. Finally, different preference-elicitation methods and 
inclusion of other attributes in the trade-off may lead to different findings. 
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Hence, further research is necessary to examine the most appropriate design 
for estimating severity and age weights for informing allocation decisions in 
healthcare. 
3.5 Conclusions
The results of this study indicate that the public prefers prioritising relati-
vely more severely ill patients when patients’ ages are equal and younger 
patients when their severity levels are equal. When patients’ severity levels 
and ages both vary, the public seems to prefer prioritising relatively younger 
patients, irrespective of patients’ severity levels. These results suggest that, 
when aiming to better reflect societal preferences in decision-making, current 
severity operationalisations and decision-making frameworks may need to be 
adjusted for age-related societal preferences. 
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Appendix 3.1: Person trade-off approach and task examples
Person trade-off approach
Respondents completed a total of six choice- and six associated person tra-
de-off (PTO) tasks across three similarly structured modules, thus completing 
two choice- and two PTO tasks in each module. Before completing the first 
choice task in a module, we assigned respondents to a choice set in which the 
attributes and levels represented a ‘small’ difference of 30 points in QOL loss 
and/or 30 years in age between the patient groups. Based on this difference 
and given the contingency that both groups consisted of 100 patients, we 
asked respondents to state a preference for reimbursing treatment for patient 
group A or B, or, in case of indifference for neither of the groups. We then pre-
sented the same choice set to respondents and explained that the groups now 
differed in size. We set respondents’ patient group of preference in the prece-
ding choice task (or, in case of no preference, a randomly selected group) as 
reference group and explained that this group again consisted of 100 patients. 
We then asked respondents to complete a PTO task in which they could state 
in three iterative steps (see Figure 3.1 for a graphical representation of the 
iterative PTO process, including the steps taken and the interval between the 
steps) of how many patients (between 100 and 1,000,000) the other group 
should consist in order for them to be indifferent. Subsequently, we assigned 
respondents to a second choice set in which the attributes and levels repre-
sented a ‘large’ difference of 60 points in QOL loss and/or 60 years between 
the patient groups, based on which we asked them to complete a second 
choice- and PTO task, similar in set up as the first. 
Choice task example 
The disease-related loss in quality of life can differ between patients. In the 
graph below, you see two patient groups that would have had a life expec-
tancy of 80 years in full health had they not become ill. Both patient groups 
have become ill at the age of 40. The disease lasts for one year and leads to 
a lower quality of life during this year.
Due to the disease, the quality of life of patients in group A decreases from 
100 to 50 and in group B from 100 to 80 on a scale from 0 (the worst health 
you can imagine) to 100 (the best health you can imagine). Treatment can 
reduce the effects of the disease. As a result, the quality of life in both groups 
during the year is 20 points higher than without treatment. In group A, the 
quality of life will increase from 50 to 70 and in group B from 80 to 100. After 
this year, all patients will regain their full health. 
There are no other differences between the two patient groups. The treat-
ments and costs are also the same.
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Imagine that the treatment of only one of the two patient groups can be reim-
bursed from the public health insurance package and that you could advise 
health policy makers on what would be the optimal way of allocating the 
healthcare budget. 
If both patient groups consist of 100 patients, for which patient group, do you 
think, should the treatment be reimbursed? 
In the example of the PTO task below, we assume that the respondent has 
stated a preference for patient group A in the preceding choice task, and 
hence the subsequent PTO task is set at 100 patients for patient group A.
PTO task example
The disease-related loss in quality of life can differ between patients. In the 
graph below, you see the same two patient groups that would have had a life 
expectancy of 80 years in full health had they not become ill. Both patient 
groups have become ill at the age of 40. The disease lasts for one year and 
leads to a lower quality of life during this year.
Due to the disease, the quality of life of patients in group A decreases from 
100 to 50 and in group B from 100 to 80 on a scale from 0 (the worst health 
you can imagine) to 100 (the best health you can imagine). Treatment can 
reduce the effects of the disease. As a result, the quality of life in both groups 
during the year is 20 points higher than without treatment. In group A, the 
Patient group A Patient group B No preference
Due to the disease, the quality of
life decreases from 100 to 50
Due to the disease, the quality of
life decreases from 100 to 80
Due to treatment, quality of life 
increases from 50 to 70 
for one year
Due to treatment, quality of life 
increases from 80 to 100 
for one year
Patients are now 40 years old Patients are now 40 years old
Patients’ life expectancy is 
80 years
Patients’ life expectancy is 
80 years
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quality of life will increase from 50 to 70 and in group B from 80 to 100. After 
this year, all patients will regain their full health. 
There are no other differences between the two patient groups. The treat-
ments and costs are also the same.
Imagine that the treatment of only one of the two patient groups can be reim-
bursed from the public health insurance package and that you could advise 
health policy makers on what would be the optimal way of allocating the 
healthcare budget. 
You have stated a preference for reimbursing treatment for patient group A 
if both groups consisted of 100 patients. Now, suppose that the two patient 
groups differ with regard to the number of patients in each group. 
In the four steps below, we assume that the respondent stated a preference 
for reimbursing treatment for patient group A in the choice task, for patient 
group A in step one, for patient group B in step two, and again for patient 
group B in step three of the PTO process. 
Patient group A Patient group B
Due to the disease, the quality of
life decreases from 100 to 50
Due to the disease, the quality of
life decreases from 100 to 80
Due to treatment, quality of life 
increases from 50 to 70 
for one year
Due to treatment, quality of life 
increases from 80 to 100 
for one year
Patients are now 40 years old Patients are now 40 years old
Patients’ life expectancy is 
80 years
Patients’ life expectancy is 
80 years
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Step one
Suppose that group A consists of 100 patients and group B of 200 patients. 
For which patient group, do you think, the treatment should be reimbursed? 
■  Patient group A 
□ Patient group B
Step two
Suppose that group A consists of 100 patients and group B of 250 patients. 
For which patient group, do you think, the treatment should be reimbursed? 
□ Patient group A
■ Patient group B
Step three
Suppose that group A consists of 100 patients and group B of 225 patients. 
For which patient group, do you think, the treatment should be reimbursed? 
□ Patient group A
■ Patient group B
Step four
You have stated a preference for reimbursing the treatment for patient group 
A if group A consists of 100 patients and group B of 200 patients, but your 
preference shifts to patient group B if group A consists of 100 patients and 
group B of 225 patients. 
Of how many patients should group B consist (more than 200 and less than 
225) in order for your preference for patient group A and B to be equally 
strong? 
Note: For respondents with a consistent preference for one of the patient 
groups, the range in step four was restricted to a maximum of 1,000,000 
patients. 
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Chapter 4 
Willingness to pay for 
health-related quality of  
life gains in relation to 
disease severity and 
the age of  patients
Based on: Reckers-Droog VT, van Exel NJA, Brouwer WBF. Willingness to pay 
for health-related quality of life gains in relation to disease severity and the 
age of patients. Forthcoming in Value in Health. 2021.
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Abstract
Decision-making frameworks that draw on economic evaluations increasingly 
use equity weights to facilitate a more equitable and fair allocation of health-
care resources. These weights can be attached to health gains or reflected 
in the monetary threshold against which the incremental cost-effectiveness 
ratios of (new) health technologies are evaluated. Currently applied weights 
are based on different definitions of disease severity and do not account for 
age-related preferences in society. However, age has been shown to be an 
important equity-relevant characteristic. This study examines the willingness 
to pay (WTP) for health-related quality of life (QOL) gains in relation to the 
disease severity and age of patients, and the outcome of the disease. We 
obtained WTP estimates by applying contingent-valuation tasks in a repre-
sentative sample of the public in the Netherlands (n=2,023). We applied 
random-effects Generalised Least Squares regression models to estimate 
the effect of patients’ disease severity and age, size of QOL gains, disease 
outcome (full recovery/death one year after falling ill), and respondent charac-
teristics on the WTP. Respondents’ WTP was higher for more severely ill and 
younger patients, and for larger sized QOL gains, but lower for patients who 
died. However, the relations were non-linear and context dependent. Respon-
dents with a lower age, who were male, had a higher household income, and 
a higher QOL stated a higher WTP for QOL gains. Our results suggest that—if 
the aim is to align resource-allocation decisions in healthcare with societal 
preferences—currently applied equity weights do not suffice.
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4.1 Introduction
An important objective of publicly financed healthcare systems is to maxi-
mise population health given a certain budget constraint [1]. To meet this 
objective, economic evaluations can be used to inform decision makers about 
whether reimbursing a (new) health technology can be considered good 
value for money. In economic evaluations, health gains are often expres-
sed in terms of quality-adjusted life-years (QALYs), comprising gains in both 
health-related quality of life (QOL) and life expectancy (LE) [2,3]. The incre-
mental cost-effectiveness ratio (ICER) of a technology is evaluated against a 
monetary threshold that represents the maximum societal willingness to pay 
(WTP) for a QALY or the opportunity costs of spending within the healthcare 
sector [4–6]. 
Traditionally, a “QALY is a QALY is a QALY” in economic evaluations [7], meaning 
that all health gains are valued equally. However, equity weights can be atta-
ched to health gains or reflected in the monetary threshold to facilitate a more 
equitable and fair allocation of healthcare resources [1,8–12]. In the former 
case, the equity-adjusted ICER of a technology is evaluated against a fixed 
monetary threshold and in the latter case, the (unadjusted) ICER of a tech-
nology is evaluated against a flexible, equity-adjusted monetary threshold 
[1,10]. These weights can be based on a range of equity considerations that, 
for example, are related to characteristics of the patients, disease, or techno-
logy [1,12–20]. To facilitate consistent and accountable decision making, it has 
been advocated to explicitly and transparently integrate such considerations 
into the decision-making framework [21–24]. Although many countries (e.g. 
France, Germany, Sweden, and Australia do this in an ad hoc, implicit manner 
[25–27], Norway, the Netherlands, and England do this in an explicit manner 
by applying equity weights [28–31]. Text box 4.1 includes a brief overview of 
how the weights are applied in these countries.
Societal preferences for equity weighting based on disease severity (defined 
broadly here to include absolute shortfall, proportional shortfall, and end-of-
life considerations associated with terminal illnesses as described in Text box 
4.1) are increasingly studied, also in relation to patients’ age. The available 
evidence suggests that the public considers age to be an important equity-re-
levant characteristic (often reflected by giving a higher weight to health gains 
in younger patients), possibly even more important than disease severity 
[1,5,11,40–43]. Nevertheless, the weights applied in Norway, the Netherlands, 
and—classifying terminally ill patients as severely ill [44]—England are all 
based on disease severity. These weights do not directly account for patients’ 
age nor aim to weight age in resource-allocation decisions, even though they 
may be inextricably related to patients’ age [11]. For example, the weights 
based on absolute shortfall in Norway may implicitly prioritise younger over 
older patients and, conversely, the weights based on proportional shortfall in 
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the Netherlands and end-of-life considerations in England may implicitly prio-
ritise older over younger patients [11,45–47]. 
The aim of this study was to examine the willingness to pay (WTP) for health 
gains in relation to the disease severity and age of patients and to examine 
whether the WTP was different between health gains in patients who fully 
recovered and patients who died (one year after falling ill). Based on the 
available evidence on societal preferences in this context, we hypothesised 
that WTP would be higher for more severely ill and younger patients, and for 
patients who can be considered terminally ill. We further hypothesised that 
the elicited WTP would be sensitive to scale and to household income, indica-
ting the theoretical validity of the elicited WTP [48]. 
We elicited the WTP for health gains in terms of an increase in monthly basic 
health-insurance premium in a representative sample of the general public in 
the Netherlands, as this relates directly to the payment vehicle used for collec-
tively funding healthcare in this country. Given the aim of our study, we focus 
on the relative rather than absolute WTP for health gains. The results of this 
study may inform decisions on the relative size of severity- and/or age-depen-
dent equity weights and on the range and shape of monetary thresholds used 
to evaluate the ICERs of health technologies. The results are considered to 
be of particular interest to the Netherlands, Norway, and England given their 
Text box 4.1 Application of equity weights in Norway, the Netherlands, and England
In Norway and the Netherlands, the (unadjusted) incremental cost-effectiveness 
ratio (ICER) of a health technology is evaluated against a monetary threshold 
that is weighted based on the disease severity of the targeted patient population 
[11,28,31]. In Norway, a flexible threshold in the range of NOK 275,000 to 825,000 
(~ €27,500 to €82,500) per quality-adjusted life-year (QALY) gained is (informally) 
applied, with a maximum weight of 3 attached for evaluating the ICER of a health 
technology that targets patients with the highest level of disease severity (i.e. an 
absolute shortfall of ≥20 QALYs) [31,37,38]. Absolute shortfall is calculated as the 
disease-related loss of remaining QALYs without the new health technology, com-
pared to the remaining QALY expectation in absence of the disease [31,39,40]. In 
the Netherlands, a flexible threshold in the range of €20,000 to €80,000 per QALY 
gained is applied, with a maximum weight of 4 attached for evaluating the ICER of 
a health technology that targets patients with the highest level of disease seve-
rity (i.e. a proportional shortfall of 0.71–1.00) [11,28,29]. Proportional shortfall is 
calculated as the proportion of absolute shortfall, relative to the remaining QALY 
expectation in absence of the disease and measured on a scale from 0 “no QALY 
loss” to 1 “complete QALY loss” [8,28].  Health technologies that target patients 
with the lowest level of disease severity (i.e. a proportional shortfall of <0.10) are 
generally not recommended for reimbursement [28,41,42]. In England, a weight 
in the range of 1.7 to 2.5 can be attached to QALYs that are gained by prolonging 
the lives of terminally ill patients (normally with a remaining life expectancy of 
≤24 months) by at least three months [43]. The resulting (equity-adjusted) ICER 
of a health technology is then evaluated against the common threshold range of 
£20,000 to £30,000 (~ €23,000 to €34,500) [43].
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current use of equity weights, but also to other countries that (intend to) inte-
grate equity and efficiency considerations into their formal decision-making 
framework. 
4.2 Methods
4.2.1 Sample and data collection
We designed a contingent-valuation (CV) study that was administered online 
by a professional research agency (Dynata). Respondents were quota sampled 
to be representative of the general public in the Netherlands in terms of age 
(18-75 years), sex, and education level and to obtain a broad range in house-
hold income. Before conducting the main study in August 2019, we conducted 
a pilot study in a small sample (n=100) to test the range of the payment scale 
and clarity of the tasks. The results of this study did not lead to modifications, 
and hence we merged the pilot and main data before conducting the analyses 
(total sample n=2,023).
Before respondents completed the questionnaire, we explained that health-
care resources are scarce and decision makers use information on societal 
preferences in order to allocate the available resources in an optimal manner 
for society. We asked respondents to complete the CV tasks from a social-
ly-inclusive-personal (SIP) perspective [49]. This implied that they had to take 
into consideration the possibility that they themselves, their family, friends, 
and/or acquaintances could be part of the hypothetical patient group as well 
as unknown others. As the SIP perspective represents a combination of the 
personal and social perspectives [49], applying it may be seen as yielding 
relevant WTP estimates for health gains in the context of a collectively funded 
healthcare system like that of the Netherlands [49,50]. Upon completion of 
the questionnaire, respondents received a fee of 50 eurocents that they could 
save in a personal account or donate to charity.
4.2.2 Questionnaire
The questionnaire consisted of four parts. In part one, we introduced respon-
dents to the following concepts using text and graphs: (i) QOL, operationalised 
on a visual analogue scale (VAS) ranging from 0 “dead” to 100 “full health”, 
(ii) disease severity, operationalised as disease-related QOL loss (in points 
from 100 on the VAS) in patients who fully recovered and as a combination 
of QOL and LE (in years) loss in patients who died one year after falling ill, 
and (iii) treatment-related QOL gain (in points on the VAS). We familiarised 
respondents with the concepts and tasks by asking them to assess their own 
QOL ‘today’ on the VAS and complete a practice task from an individual per-
spective [49]. After completing this task, we asked respondents to assess its 
level of clarity on a seven-point Likert scale ranging from 1 “very unclear” to 7 
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“very clear” and to indicate on what they would likely economise to cover the 
stated WTP to increase their awareness of the associated opportunity costs.
In part two, respondents completed two tasks from a SIP perspective for 
which they were randomly assigned to two out of 20 scenarios. Each scenario 
started with the introduction of a group of 10,000 patients aged 10, 20, 40, or 
70. We explained that the patients would have lived in full health (a score of 
100 on the VAS) until the age of 80 had they not fallen ill. Due to the disease, 
their QOL decreased from 100 to either 90, 70, 50, 30, or 10 on the VAS for 
the duration of one year. After this year, they would fully recover (i.e. a score 
of 100 on the VAS). The disease would not affect their LE. We explained that 
a treatment was available that would increase patients’ QOL with 10 points on 
the VAS during the year of illness and that the treatment type and costs were 
the same for all patients. The treatment could be made available to patients 
by increasing the monthly basic health-insurance premium for the duration 
of one year. This increase would apply to all adult inhabitants of the Nether-
lands. We elicited respondents’ WTP for the treatment-related QOL gains by 
applying the two-step procedure described in Text box 4.2. After respon-
Text box 4.2 Contingent-valuation procedure
Willingness to pay was elicited by applying a two-step contingent-valuation proce-
dure, consisting of a payment scale and a bounded open-ended question [51]. The 
payment scale ranged from a €0 to €24 increase in monthly basic health-insurance 
premium with unevenly distributed intervals between the value points (i.e. €0, 
€0.50, €1, €1.50, €2, €2.50, €3, €4, €5, €6, €7, €8, €10, €12, €14, €16, €18, €20, 
€22, €24, and “more”). Note that monthly payment of health-insurance premiums 
is mandatory for all adults (18+) in the Netherlands. By approximation, the number 
of adults was 13.7 million and the monthly premium €115.00 per person in 2019 
[52]. In step one, we asked respondents to inspect the payment scale from left to 
right and indicate the increase in monthly premium they were certainly willing to 
pay for the duration of one year. We then asked them to again inspect the payment 
scale from left to right and indicate the increase in monthly premium they would 
certainly not be willing to pay for the duration of one year. In step two, we asked 
respondents to indicate the maximum increase in monthly premium they would 
be willing to pay within the range obtained in step one. In both steps, we asked 
respondents to take their net monthly household income into account as a proxy 
for their ability to pay. We asked respondents who stated a WTP of €0 in step one 
to explain their main reason for having this preference by completing an open-
text field or checking one of six randomised answer options. Three answer options 
related to true zero valuations (i.e. “I cannot afford to pay more than €0”, “Trea-
ting these patients is not worth more than €0 to me”, and “I believe the treatment 
is worth more than €0, but I would rather spend my money on something else”) 
and three answer options related to protest zero valuations (i.e. “I am against 
an increase in monthly basic health-insurance premium”, “Patients should pay for 
the treatment themselves”, and “The value of health and healthcare cannot be 
expressed in monetary terms”). The open-text field answers were qualitatively 
assessed by the first two authors and subsequently classified as a true or protest 
zero valuation.
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dents completed the second task, we asked them to indicate how certain they 
were of actually paying the stated WTP in case the increase became effective 
immediately, on a seven-point Likert scale ranging from 1 “very uncertain” to 
7 “very certain”.
In part three, respondents completed one additional task from a SIP per-
spective for which they were randomly assigned to one out of 20 scenarios 
that were evenly distributed across five modules. In modules 1−4, the level of 
disease severity was 50, treatment-related QOL gain was 20 points (modules 
1 and 3) or 50 points (modules 2 and 4), and patients either fully recovered 
(modules 1 and 2) or died (modules 3 and 4) one year after falling ill. We used 
the data from modules 1 and 2, and from the scenarios in part 2 in which 
the level of disease severity was also 50 to examine whether respondents’ 
WTP was sensitive to scale [53]. We used the data from modules 1−4 to 
examine whether respondents’ WTP for similar sized QOL gains was diffe-
rent between gains in patients who fully recovered and patients who died. 
In module 5, we focused on a different question that is reported elsewhere. 
Appendix 4.1 includes a task example and Appendix 4.2 an overview of the 
scenario characteristics. 
In part four, we asked respondents about their socio-demographic 
characteristics.
4.2.3 Statistical analyses and hypotheses
Before conducting the analyses, we excluded protest zero valuations (see Text 
box 4.2), outliers, and speeders. We identified outliers based on the distribu-
tion of stated WTPs (z-score ≥1.64). We classified respondents who completed 
the three tasks in less than 90 seconds as speeders, based on a timed test of 
completing the tasks by three researchers not involved in this study. 
We calculated the raw mean (SD; 95% CI) WTP for QOL gains in all scenarios 
and the difference in raw mean (SE; 95% CI) WTP for similar sized QOL gains 
in patients who fully recovered and died one year after falling ill. We applied 
two-tailed Welch’s t-tests (Bonferroni corrected) to examine whether the 
latter was statistically significantly different from 0. Furthermore, we applied 
seven random-effects Generalised Least Squares models to estimate the 
effect of scenario and respondent characteristics on the WTP. Models 1 and 2 
were based on the data obtained in part 2 of the questionnaire and included 
the scenario characteristics disease severity and age of patients, and their 
interaction. Models 3 to 6 were based on the data obtained in part 2 and 3 of 
the questionnaire. Model 3 included the scenario characteristics disease seve-
rity, age of patients, size of QOL gains, and disease outcome (full recovery/
death, one year after falling ill). Model 4 also included the interaction between 
the disease severity and age of patients. Models 5 to 7 consecutively included 
the interactions between the disease severity and age of patients, size of QOL 
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gains and age of patients, and disease outcome and age of patients as well 
as the respondent characteristics age, age2, sex, children (yes/no), education 
level, household income (adjusted for household size using an elasticity scale 
of 0.5 to account for economies of scale [54]), and QOL. We assumed that 
respondents might have used their first WTP stated from a SIP perspective 
as a reference (anchor) in the subsequent tasks. After testing this assump-
tion, we decided to account for a time effect in all models (labelled ‘CV task’) 
[55]. A downwards adjustment of a previously stated WTP could also indicate 
a violation of the monotonicity principle that a larger sized QOL gain should, 
ceteris paribus, result in a higher WTP [56]. Therefore, we performed sen-
sitivity analyses to examine the robustness of our results by repeating the 
analyses excluding respondents who, ceteris paribus, stated a lower WTP for 
larger QOL gains. We also examined the robustness of our results by alterna-
tely repeating the analyses excluding respondents who reported a low clarity 
score (i.e. 1−3 level) for the practice task, reported a low certainty score (i.e. 
1−3 level) for actually paying the stated WTP, and completed the three tasks 
in less than 39 (instead of the predetermined 90) seconds based on the dis-
tribution of completion times (z-score ≤-1.64). Furthermore, we examined the 
effect of respondents’ proximity to the age of patients and of respondents’ 
stated WTP in the practice task on the WTP. 
Before conducting the analyses, we hypothesised that respondents’ WTP 
would be higher for QOL gains in more severely ill patients (i.e. patients with 
a higher level of disease severity and patients who died one year after falling 
ill) and for QOL gains in younger patients. Moreover, we hypothesised that 
respondents’ WTP would be sensitive to scale and to household income in 
the sense that the WTP would be higher for larger sized QOL gains and for 
respondents with a relatively higher household income. Evidence in support 
of the latter hypothesis would indicate the theoretical validity of the elicited 
WTP [48].
We conducted the analyses using Stata 16.1 (Stata Corp LP, College station, 
Texas).
4.3 Results  
Table 4.1 presents the descriptive statistics of the sample (n=1,317) that 
remained after excluding protest zero valuations (n=73), outliers (n=31), and 
speeders (n=602). Of the speeders, 50 also gave protest zero valuations and 
12 also stated an outlying WTP. The statistics indicate that the sample was 
representative of the general public in the Netherlands in terms of sex and 
education level, but somewhat older.
The remaining respondents assessed the mean (SD) clarity of the practice 
task at 5.9 (1.1) and certainty of actually paying the stated WTP at 5.4 (1.3) on 
the seven-point Likert scales. A total of 50 (3.8%) respondents reported a low 
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clarity score, 98 (8.3%) a low certainty score, and 37 (2.8%) stated, ceteris 
paribus, a lower WTP for a larger sized QOL gain.
Table 4.2 presents the raw mean (SD; 95% CI) WTP for QOL gains of 10 
points in patients who fully recovered one year after falling ill. On average, 
the WTP was €8.0 per month for the duration of one year. The results indicate 
that respondents’ WTP was generally higher for QOL gains in more severely 
ill patients (average WTP: €7.3 to €8.4) and younger patients (average WTP: 
€7.8 to €8.4); however, the relations were non-linear. We observed a relati-
vely low average WTP of €8.0 for QOL gains in patients with a severity level 
of 50 and a relatively high average WTP of €8.4 for QOL gains in patients with 
a severity level of 70. We also observed a relatively low average WTP of €7.9 
for QOL gains in patients aged 20. As the SDs were relatively large and the 
95% CIs largely overlapped, these results suggest strong preference hetero-
geneity and only partially support the hypotheses that respondents’ WTP is 
higher for more severely ill and younger patients.
Table 4.3 presents the raw mean (SD; 95% CI) WTP for QOL gains of 20 and 
50 points in patients with a severity level of 50 who fully recovered and who 
died one year after falling ill (for comparison presented with the WTP for 
QOL gains of 10 points in patients with severity level 50 who fully recovered, 
copied from Table 4.2). These results indicate that respondents’ WTP was 
generally higher for larger sized QOL gains and ‘hump shaped’ across ages, 
Table 4.1 Descriptive statistics
Sample (n=1,317)a General publicb
% Mean (SD) % Mean
Age (Years) 51.5 (15.9) 46.1











Household income (After tax)
  <€1,999
  €2,000 – €3,999







QOL (0-100 VAS) 81.3 (16.4)
Completion time of CV tasks (Minutes) 6.0 (27.7)
CV, contingent valuation; NS, Not Stated; QOL, health-related quality of life; VAS, visual analogue scale (rang-
ing from 0 “dead” to 100 “full health”); a Consistent protest zero valuations (n=73), outliers (n=31), speeders 
(n=540), and respondents who met more than one exclusion criterion (n=62) are excluded from the table; b Age 
is based on statistics for population aged 18-75 years, sex is based on statistics for the overall population, and 
education level is based on statistics for population aged 15-75 years. Population statistics for 2019, source: 
Statistics Netherlands (https://opendata.cbs.nl/statline); c Low = lower vocational and primary school, Medium = 
middle vocational and secondary school, High = higher vocational and academic education.
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with a peak at age 10, 20, or 40 depending on the size of the gain and whether 
patients fully recovered or died. Respondents’ WTP was higher for similar 
sized QOL gains in patients who fully recovered than in patients who died, 
except for gains of 20 points in patients aged 20 and 40. Most differences 
were not statistically significant, except for the lower mean (SE; 95% CI) WTP 
of €4.5 (1.8; -8.0, -1.0) for QOL gains of 50 points in patients aged 20 who died 
than in those who fully recovered (Bonferroni corrected, α/4). Although these 
results indicate that respondents’ WTP is higher for younger patients and 
larger sized QOL gains, they do not support the hypothesis that respondents’ 
WTP is higher for patients who die.
Tables 4.4 and 4.5 present the regression results. Note that models 1 and 2 
are based on the data obtained in part 2 and models 3 to 7 are based on the 
data obtained part 2 and 3 of the questionnaire. The results indicate that—
compared to severity level 10—a higher severity level was, ceteris paribus, 
associated with a higher WTP though it was relatively low for patients with 
severity level 90 (model 1: β 1.08) and it decreased at a marginal rate when 
data were aggregated (e.g. model 2: β 0.83 to 1.32). Compared to age 10, 
a higher age was, ceteris paribus, associated with a lower WTP (model 1: β 
-0.25 to β -0.84; model 3: β -0.09 to -1.09), but only the coefficient for age 70 
was statistically significant. The interaction between patients’ disease seve-
rity and age indicates in some scenarios that respondents’ WTP for QOL gains 
in patients with different levels of disease severity was dependent on their 
age. When patients had a severity level of 10, respondents’ WTP was, ceteris 
paribus, higher for patients aged 10 than for patients aged 20 (model 2: β 
-1.10; model 4: β -1.39; model 5: β -1.50) and for patients aged 40 (model 
2: β -1.22; model 4: β -1.34; model 5: β -1.45). However, WTP was relatively 
higher for patients aged 20 from severity level 50 onwards (model 2: β 1.14 
to 1.63; model 4: β 1.45 to 2.23; model 5: β 1.51 to 2.39) and for patients 
aged 40 from severity level 70 onwards (model 2: β 1.57; model 4: β 1.35 to 
1.92; model 5: β 1.58 to 2.19). The results further indicate that—compared to 
QOL gains of 10 points—QOL gains of 20 and 50 points were, ceteris paribus, 
associated with a higher WTP though at a decreasing marginal rate (models 
3 to 5: β 1.43 to 1.46 for 20 points and β 2.82 to 2.90 for 50 points) and—
compared to gains in patients who fully recovered—gains in patients who died 
one year after falling ill were, ceteris paribus, associated with a lower WTP 
(models 3 to 6: β -0.74 to -0.80). These results support the hypotheses that 
respondents’ WTP is higher for more severely ill patients and larger sized QOL 
gains. However, they only partially support the hypothesis that respondents’ 
WTP is higher for younger patients as this was dependent on patients’ level of 
disease severity in some scenarios.
The results presented in Table 4.5 provide further insight into the interacti-
ons between patients’ disease severity, the size of QOL gains, and disease 
outcome and age of patients (see Figure 4.1), and into the effect of respon-
dent characteristics on WTP. The results indicate that respondents’ WTP for 
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QOL gains of different sizes in patients with different disease outcomes was 
dependent on patients’ age. Compared to patients aged 10, respondents’ WTP 
was lower for patients aged 70 when the QOL gain was 10 points (model 6: 
β -0.90) and higher for patients aged 20 when the QOL gain was 20 points 
(model 6: β 1.35). Compared to patients aged 10, respondents’ WTP was lower 
for patients aged 70 when the patients fully recovered (model 7: β -0.99).
With regard to respondent characteristics, a higher age was associated with 
a lower WTP (models 4 to 6: β -0.34 to -0.35). Being male (models 5 to 7: β 
1.64), having children (models 5 to 7: β 0.99 to 1.02), having a higher (adju-
sted) household income (models 5 to 7: β 1.44 to 1.45), and a higher QOL 
(models 5 to 7: β 0.02) were also associated with a higher WTP. 
The results confirm the theoretical validity of the elicited WTP. The sensitivity 
analyses indicated that respondents’ stated WTP in the practice task had a 
marginal effect on the stated WTP in the subsequent tasks (models 1 to 7: β 
0.01) and that our results were robust.
4.4 Discussion
Our aim was to examine the WTP for QOL gains in relation to the disease 
severity and age of patients in a representative sample of the general public 
in the Netherlands. Furthermore, our aim was to examine whether the WTP 
was different between QOL gains in patients who fully recovered and patients 
who died one year after falling ill, and whether the WTP was sensitive to 
scale. Our main findings are that the WTP is generally higher for QOL gains 
in patients with a higher level of disease severity and younger age, and for 
larger sized gains, but is lower for gains in patients who die one year after 
falling ill. However, the relations were non-linear and context dependent. For 
example, the WTP was higher for QOL gains in patients aged 10 than for gains 
in patients aged 20 and 40 when patients had a severity level of 10, but the 
WTP was higher for patients aged 20 and 40 from severity levels 50 and 70 
onwards. The WTP for QOL gains in patients aged 70 was consistently lower 
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than for gains in younger patients. This may be explained by the fact that 
these patients already had their ‘fair share of life’ at onset of the disease or 
that less than ‘full health’ is more accepted at an older age [45,57–59].
We would like to make four remarks in relation to our findings. Firstly, we 
applied a SIP perspective for eliciting respondents’ WTP and, therefore, our 
findings can be driven by self-regarding as well as other-regarding prefe-
rences of respondents. Although we investigated the potential influence of 
observable self-regarding preferences (e.g. associated with having children 
and respondents’ proximity to the age of patients), we acknowledge that 
unobservable self-regarding preferences (e.g. associated with the probabi-
lity of respondents’ own need for treatment) may have impacted our results. 
Secondly, our findings need to be considered in relation to the applied design. 
The WTP for QOL gains may differ when elicited on full QOL and age scales, 
in combination with LE gains, or from a societal perspective that excludes 
respondents from the hypothetical patient group [49]. Thirdly, we observed 
considerable preference heterogeneity, which is consistent with the findings of 
other studies that examined societal preferences in this context [1,10,12,53]. 
Accounting for (some of) this heterogeneity in resource-allocation decisions 
may be possible and worth pursuing, especially when aiming to align the out-
comes of such decisions with societal preferences. However, our results and 
those of other related studies indicate that societal preferences are complex 
and, consequently, there will likely always be groups in society who do (not) 
agree with decisions made (based on average values). Finally, the (differences 
in) stated WTPs could be considered modest. However, they need to be con-
sidered in relation to the respondent instruction that the increase in monthly 
basic health-insurance premium would apply to all adult inhabitants of the 
Netherlands for the duration of one year. Hence, on an aggregated level the 
(differences in) WTP per QALY is substantial. The treatment generates 1000 
QALYs (i.e. 10.000 patients * 0.1 QALY), and hence on average WTP is ~1.3 
million euros (calculated as 8 euros * 12 months * 13.7 million premium 
payers / 1000 QALYs). Although this value is much higher than the mone-
tary thresholds currently applied in the Netherlands (see Text box 4.1) and 
likely influenced by the scenario characteristics (e.g. the number of patients 
and certainty of QOL gains), it should be noted that such high values are 
not uncommon in preference-elicitation studies [61] and, considering the 
high ICERs of some health technologies that are currently reimbursed in the 
Netherlands [62,63], also not in decision-making practice.
Our findings are consistent with those of other studies that find societal 
support for attaching a higher weight to health gains in more severely ill and 
younger patients [11,40,64–66] and to larger sized health gains [53], and 
with those of other studies that find no support for attaching a higher weight 
to gains in terminally ill patients [67–70]. The latter is consistent with studies 
that find that the public may attach a lower weight to health gains in patients 
with an undesirable ‘end point after treatment’ [e.g. 60–63]. Although there 
 Willingness to pay for QOL gains in relation to severity and age  | 93
  4 
may be a moral case for attaching a higher weight to health gains in terminally 
ill patients [75], our findings—like those of previous studies [67–70]—suggest 
that empirical support for applying a higher weight to these gains may be 
limited. This is recognised by the National Institute for Health and Care Excel-
lence (NICE) in England who recently proposed to replace their end-of-life 
criterion (see Text box 4.1) by considerations that relate more broadly to the 
disease severity of patients in order to better align their decision-making 
framework with societal preferences [75,76]. 
However, as these societal preferences are usually not elicited in monetary 
terms, we are limited in our ability to directly compare our results to those of 
others. However, we can compare our results to those of Bobinac et al. [5] as 
they applied the CV approach from a societal perspective in scenarios similar 
to ours. Both our studies found a higher WTP for health gains in younger 
patients and larger sized gains. However, in contrast to our findings, Bobinac 
et al. [5] found a lower WTP for health gains in patients with a higher level of 
disease severity and a higher WTP for gains in terminally ill patients. This may 
be explained by the different way in which they operationalised disease seve-
rity and the health gain in the specific scenarios, i.e. in terms of proportional 
shortfall and the prevention of immediate death [5]. 
The main strengths of this study lie in the use of a realistic payment vehicle, 
pilot-tested payment scale, and two-step CV procedure. Although we could 
have applied other methods (e.g. a discrete choice experiment) to elicit res-
pondents’ WTP, the CV method enabled us to approach respondents’ common 
decision context and examine their explicit WTP (instead of, for example, deri-
ving their WTP from the trade-off between scenario characteristics). Other 
strengths lie in the randomisation of scenarios, exclusion of speeders, res-
triction of the disease duration to one year, and standardisation of patients’ 
risk of falling ill and dying within a certain time frame (i.e. 100%, implying 
no uncertainty), the size of the patient group and QOL gains as well as the 
costs of treatment as this reduced the possible influence of an order effect, 
satisficing behaviour [77], cognitive biases associated with risk assessment 
[78], and of other considerations (e.g. related to health maximisation and 
the budget impact of reimbursing the new treatment) on our results. We 
appreciate that the latter strength comes with the limitation that our results 
cannot be generalised to other scenarios, for example, in which the number 
of patients is uncertain, patients are at risk of falling ill or of dying within 
a particular time frame (i.e. introducing uncertainty), or in which patients’ 
lives are (also) prolonged. Another strength that comes with a limitation is 
the exclusion of protest zero valuations. Although including these valuations 
would have confounded the estimated WTP, it should be noted that the classi-
fication into protest and true zero valuations is not always straightforward and 
inevitably has some impact on results [79]. Some other limitations need to 
be discussed as well. A first limitation concerns the possible influence of pay-
ment-scale characteristics on the WTP. We facilitated a more exact mapping 
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of respondents’ WTP on the payment scale by applying a scale with a reaso-
nable range and uneven intervals between the value points [80,81]. However, 
we cannot rule out the possibility that the scale influenced respondents’ WTP, 
particularly in case of unstable or not (yet) well-formed preferences [80]. We 
accounted for this by controlling for a time-effect and discussing the results 
in relative rather than absolute terms. A second limitation concerns the hypo-
thetical context in which we elicited respondents’ WTP [82]. Although the 
outlined context of a collectively funded healthcare system is realistic, we 
cannot rule out the possibility that their hypothetical nature increased the risk 
of an upward ‘hypothetical’ bias, in which case the stated WTP could be an 
overestimation of respondents’ true WTP s [83]. However, we also cannot rule 
out the possibility that their realistic nature increased the risk of a downward 
‘strategic’ bias, in which case free-rider behaviour of respondents may have 
offered a counterbalance [84]. A third limitation concerns the inclusion of QOL 
gains that (in some scenarios) fully restored patients’ QOL to 100 points as 
this means we cannot distinguish between the effect of the size of QOL gains 
from the effect of patients’ health being fully restored on respondents’ WTP 
[85]. A final limitation concerns the low R2 values of the regression models. 
We would like to note that our aim was not to predict WTP, and hence to 
explain as much data variance as possible. Rather, our aim was to assess 
whether WTP was influenced by scenario characteristics (i.e. associated with 
the disease severity and age of patients, the size of QOL gains, and outcome 
of the disease) and the models successfully aided in meeting that aim. Further 
research is warranted to obtain insight into other factors that may influence 
WTP for QOL gains. This fell outside the scope of the current study.
Our results are consistent with those of other studies suggesting that equity 
weights based on end-of-life considerations may not be consistent with socie-
tal preferences [69,86–89]. At least, not if the weight is attached to QOL gains 
in terminally ill patients as in the current study. Furthermore, our results 
are consistent with those of other studies suggesting that weights based 
on disease severity are consistent with societal preferences. However, our 
results suggest that the weights may decrease marginally with increasing 
disease severity, have a fairly narrow range across severity levels (possibly 
narrower than the threshold range of €20,000 to €80,000 currently applied 
in the Netherlands), and are dependent on patients’ age. Further research is 
necessary to examine the robustness of these results in relation to the preva-
lence of a disease and the related budget impact of a new technology.
As there is much variation between the results and designs of studies that 
examine the strength of societal preferences [60], there is still considerable 
uncertainty about the ‘exact’ weight. For example, a recent study estimated 
equity weights based on patients’ disease severity in the range of 2.5 to 2.8 
by using the person-trade-off approach [11]. Given the very limited evidence 
on the WTP for health gains in representative samples the of general public, 
further research is necessary to inform decisions about the appropriate size 
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and range of equity weights and, in relation to this, the range and shape of the 
monetary thresholds against which the ICERs of new health technologies are 
evaluated. This may, for example, concern research into the most appropriate 
design for eliciting the WTP for health gains from a societal or SIP perspective. 
4.5 Conclusions
Our results indicate that the WTP is higher for QOL gains in more severely ill 
and younger patients, and for larger sized QOL gains. It is lower for QOL gains 
in patients who die. However, the relations are non-linear and context depen-
dent. These results suggest that—if the aim is to align resource-allocation 
decisions in healthcare with societal preferences—currently applied equity 
weights do not suffice.
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Appendix 4.1: Contingent-valuation task example (scenario 5)
Imagine a group of 10,000 patients who all have the same disease and to 
which you, your family, friends, and/or acquaintances can also belong. The 
patients would have lived in full health until the age of 80 had they not fallen 
ill. 
The patients fall ill at the age of 10. The disease lasts for one year and leads 
to a lower quality of life during this year. Due to the disease, patients’ quality 
of life decreases from 100 to 70 on the scale from 0 (dead) to 100 (full health). 
A treatment is available that reduces the effects of the disease. The type 
and costs of the treatment are the same for all patients. Due to treatment, 
patients’ quality of life during the year of illness is 10 points higher than without 
the treatment. Patients’ quality of life will increase from 70 to 80 points. After 
this year, the patients fully recover and their quality of life returns to a score 
of 100. 
To be able to pay for this treatment, the monthly basic health-insurance 
premium will increase for the duration of one year for all adult (18+) inhabi-
tants of the Netherlands. Thus, this increase also applies to people who are 
not affected by the disease. After this year, the monthly premium will return 
to its current level. Without the increase in monthly premium, the patients will 
not be treated.
Please inspect the row with amounts below, from left to right, and state the 
highest basic health-insurance premium you are certainly willing to pay extra 
per month for the treatment that increases the 10-year-old patients’ quality of 
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Please be considerate of your net monthly household income when answering 
this question.
Please inspect the row with amounts below again, from left to right, and state 
the first basic health-insurance premium you are certainly not willing to pay 
extra per month for the treatment that increases the 10-year-old patients’ 
quality of life from 70 to 80 on the scale from 0 (dead) to 100 (full health).
Please be considerate of your net monthly household income when answering 
this question.
You have stated that you are certainly willing to pay €X extra basic health-in-
surance premium per month for the treatment that increases the 10-year-old 
patients’ quality of life from 70 to 80 on the scale from 0 (dead) to 100 (full 
health), but certainly not more than €Y.
You have stated that you are certainly willing to pay €X extra basic health-in-
surance premium per month for the treatment that increases the 10-year-old 
patients’ quality of life from 70 to 80 on the scale from 0 (dead) to 100 (full 
health), but certainly not more than €Y.
Within the range €X - €Y, what is the maximum amount you are willing to pay 
extra in monthly basic health-insurance premium for the treatment? Please 
be considerate of your net monthly household income when answering this 
question.
€0 €0.5 €1 €1.5 €2 €2.5 €3 €4 €5 €6 €7 €8 €10 €12 €14 €16 €18 €20 €22 €24 more
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
€0 €0.5 €1 €1.5 €2 €2.5 €3 €4 €5 €6 €7 €8 €10 €12 €14 €16 €18 €20 €22 €24 more
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
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Appendix 4.2: Scenario characteristics
Table 4.2.1 Overview of scenario characteristicsa
Scenario characteristics










2 1 10 10 10 100 Full recovery 80
2 20 10 10 100 Full recovery 80
3 40 10 10 100 Full recovery 80
4 70 10 10 100 Full recovery 80
5 10 30 10 80 Full recovery 80
6 20 30 10 80 Full recovery 80
7 40 30 10 80 Full recovery 80
8 70 30 10 80 Full recovery 80
9 10 50 10 60 Full recovery 80
10 20 50 10 60 Full recovery 80
11 40 50 10 60 Full recovery 80
12 70 50 10 60 Full recovery 80
13 10 70 10 40 Full recovery 80
14 20 70 10 40 Full recovery 80
15 40 70 10 40 Full recovery 80
16 70 70 10 40 Full recovery 80
17 10 90 10 20 Full recovery 80
18 20 90 10 20 Full recovery 80
19 40 90 10 20 Full recovery 80
20 70 90 10 20 Full recovery 80
3 1 21 10 50 20 70 Full recovery 80
22 20 50 20 70 Full recovery 80
23 40 50 20 70 Full recovery 80
24 70 50 20 70 Full recovery 80
2 25 10 50 50 100 Full recovery 80
26 20 50 50 100 Full recovery 80
27 40 50 50 100 Full recovery 80
28 70 50 50 100 Full recovery 80
3 29 10 50 20 70 Death 11
30 20 50 20 70 Death 21
31 40 50 20 70 Death 41
32 70 50 20 70 Death 71
4 33 10 50 50 100 Death 11
34 20 50 50 100 Death 21
35 40 50 50 100 Death 41
36 70 50 50 100 Death 71
QOL, health-related quality of life (measured in points on a visual analogue scale (VAS) ranging from 0 “death” to 
100 “full health”); a The number of patients is 10,000 in each scenario; b Severity is operationalised in terms of dis-
ease-related QOL loss and measured in points from 100 on the VAS; c Treatment-related QOL gain is measured in 
points on the VAS; d QOL after treatment is measured in points on the VAS and calculated as: 100 – disease-related 
QOL loss + treatment-related QOL gain; e Disease outcome is one year after falling ill (patients who fully recover 
return to having a QOL of 100 on the VAS).
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Abstract
Health gains are increasingly weighted in economic evaluations of new health 
technologies to guide resource-allocation decisions in healthcare. In England, 
for example, a higher weight is attached to quality-adjusted life-years (QALYs) 
gained from life-extending end-of-life (EOL) treatments. Societal preferen-
ces for QALY gains in EOL patients are increasingly examined. Although the 
available evidence suggests that gains in health-related quality of life (QOL) 
may be preferred to gains in life expectancy (LE), little is known about the 
influence of EOL patients’ age on these preferences. In this study, we examine 
the willingness to pay (WTP) for QOL and LE gains in EOL patients of diffe-
rent ages in a sample (n=803) of the general public in the Netherlands. We 
found that WTP was relatively higher for QOL and LE gains in younger EOL 
patients. We further found indications suggesting that WTP may be relatively 
higher for QOL gains at the EOL. However, relative preferences for QOL and 
LE gains appeared to be independent of the age of EOL patients. Our results 
may inform discussions on attaching differential weights to QOL and LE gains 
in EOL patients of different ages with the objective to better align resource-al-
location decisions with societal preferences. 
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5.1 Introduction
Health gains are increasingly weighted in economic evaluations of new health 
technologies to guide healthcare priority setting. Under strict conditions, the 
National Institute for Health and Care Excellence (NICE) in England, attaches a 
higher weight to quality-adjusted life-year (QALY) gains in patients at the end 
of life (EOL) [1]. The weight can be applied to QALYs gained from life-exten-
ding end-of-life treatments if, and only if, the following conditions are met: (i) 
the health technology under evaluation is indicated for patients with a short 
life expectancy, normally of less than 24 months, (ii) there is sufficient evi-
dence that the technology prolongs patients’ lives by at least three months, as 
compared to current treatment, and (iii) the technology is licensed or other-
wise indicated for small patient populations. The maximum weight that can 
be applied ranges between 1.7 and 2.5, so that the adjusted incremental 
cost-effectiveness ratio (ICER) of the technology can be evaluated against the 
normal threshold range of £20,000 to £30,000 per QALY gained [1]. Note that 
this equals a maximum threshold of £50,000 for an unadjusted ICER.
Since NICE introduced this ‘EOL premium’ in 2009 [1], societal preferen-
ces for health gains in EOL patients (as compared to non-EOL patients) are 
increasingly examined [2]. Possibly because the premium solely applies to 
life-extending EOL treatments [1], most of these studies examined societal 
preferences solely in relation to gains in life expectancy (LE) [2]. Only a few 
studies (also) examined these preferences in relation to gains in health-rela-
ted quality of life (QOL). The results of studies that examined preferences for 
both types of health gains seem to suggest that societal preferences for QOL 
gains may be stronger than for LE gains in EOL patients, thus calling into ques-
tion NICE’s EOL premium [e.g. 3,4]. The extent to which these preferences are 
influenced by the age of EOL patients remains largely unexplored [5]. 
Based on empirical evidence that societal preferences for health gains in 
younger patients may be relatively strong [6,7], it seems plausible to hypo-
thesise that societal preferences for QOL and LE gains in younger EOL patients 
would be stronger than for similar gains in older patients. Based on empirical 
evidence that societal preferences for health gains and losses may be depen-
dent on what is considered an acceptable health state at different ages [8,9], 
it also seems plausible to hypothesise that the relative preferences for QOL 
and LE gains would be different for EOL patients of different ages. As there 
is little evidence on the role of age in this context, we explore whether there 
is indeed any evidence of this by examining the relative strength of societal 
preferences for QOL and LE gains in EOL patients of different ages. 
We elicited preferences in terms of the willingness to pay (WTP) for the health 
gains and, given the aim of our study, focused on the relative rather than 
absolute height of the WTP. Our results may inform discussions in countries 
that consider attaching differential weights to QALYs gained from life-exten-
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ding EOL treatments, like England, or to QOL and LE gains in EOL patients of 
different ages with the objective to (better) align resource-allocation decisi-
ons with societal preferences. 
5.2 Methods
5.2.1 Sample and data collection
We collected data as part of a larger contingent-valuation (CV) study in August 
2019 [10]. Here, we report on the WTP elicited from 803 respondents who 
were quota sampled to be representative of the general public in the Nether-
lands by age (18-75 years), sex, and education level and to cover a broad 
range of household incomes.
We asked respondents to complete the tasks from a socially-inclusive-perso-
nal (SIP) perspective and take into consideration that they themselves, their 
family, friends, and/or acquaintances as well as unknown others could be part 
of the hypothetical patient group. This perspective represents a combina-
tion of the personal and social perspectives [11] and facilitated the use of an 
increase in monthly health-insurance premium as payment vehicle, which is 
how adult inhabitants of the Netherlands contribute to the collectively funded 
healthcare system.
5.2.2 Questionnaire
At the start of the questionnaire (see Figure 5.1), we introduced respondents 
to the following concepts: (i) QOL, operationalised in points on a visual ana-
logue scale (VAS) ranging from 0 “dead” to 100 “full health”, (ii) severity, 
operationalised in terms of disease-related QOL loss (in points from 100 on 
the VAS) and LE loss (in years from 80 life years), and (iii) treatment-related 
QOL and LE gains. We familiarised respondents with the concepts and tasks 
by asking them to assess their own QOL “today” on the VAS and complete 
one practice task from a personal perspective. Respondents then assessed 
the level of clarity of the practice task on a seven-point Likert scale ranging 
from 1 “very unclear” to 7 “very clear” and indicated on what expenses they 
would likely cut back to cover the stated WTP. We asked the latter to increase 
respondents’ awareness of the associated opportunity costs. 
We then asked respondents to complete three tasks from a SIP perspective. 
For the first two tasks, we randomly assigned respondents to two out of 20 
scenarios in which patients fully recovered one year after falling ill. For the 
third task, we randomly assigned respondents to one out of eight scenarios in 
which patients died one year after falling ill. These eight scenarios were evenly 
distributed across two modules and are the main focus of this study (see 
Appendix 5.1 and 5.2 for an overview of the characteristics and a description 
of the scenarios). Each of the scenarios described a group of 10,000 patients 
 
  5 
 Willingness to pay for gains in end of life patients of different ages | 109
who would have lived in full health (a score of 100 on the VAS) until the age of 
80 had they not fallen ill at age 10, 20, 40, or 70. Due to the disease, patients’ 
QOL decreased from 100 to 50 on the VAS for the duration of one year, after 
which they died. We explained that a treatment was available that improved 
patients’ health with 50 points.
In module 1, treatment increased patients’ QOL from 50 to 100 points on the 
VAS but did not affect their LE (this remained one year). In module 2, treat-
ment increased patients’ LE with one additional year but did not affect their 
QOL (this remained 50 on the VAS). We explained that the treatment could 
be made available to patients by increasing the monthly health-insurance 
premium for all adult inhabitants of the Netherlands for the duration of one 
year. We elicited respondents’ WTP for the health gains by applying a two-step 
CV procedure (see Appendix 5.2 for a description of the procedure and a task 
example). At the end of the questionnaire, we asked respondents about their 
socio-demographic characteristics.
Fig. 5.1 Questionnaire structurea 
CV, contingent-valuation; LE, life expectancy; QOL, health-related quality of life (measured in points on a visual 
analogue scale, ranging from 0 “dead” to 100 “full health”); a CV task 3 (i.e. modules 1 and 2) is the main focus 
of the current study and, therefore, presented in contrasting black (note that the questionnaire included three 
additional modules on which we report elsewhere [10]; Severity is operationalised in terms of disease-related QOL 
loss and measured in points from 100 on the VAS; Disease outcomes “Full recovery” and “Death” occur one year 
after falling ill. 
Introduction
CV task 1 & 2
Age: 10, 20, 40, or 70
Severity: 10, 30, 50, 70, or 90
Type of gain: QOL
Size of gain: 10 points
Disease outcome: Full recovery
CV task 3: Module 1 CV task 3: Module 2
Age: 10, 20, 40, or 70 Age: 10, 20, 40, or 70
Severity: 50 Severity: 50
Type of gain: QOL Type of gain: LE
Size of gain: 50 points Size of gain: 50 points
Disease outcome: Death Disease outcome: Death
Socio-demographic characteristics
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5.2.3 Statistical analyses
Before conducting the analyses, we classified WTPs of €0 as either a true or 
protest zero valuation (see Appendix 5.2 and 5.3 for the classification crite-
ria and distribution of true and protest zero valuations across scenarios). We 
excluded protest zero valuations, outlying WTPs (z-score ≥1.64, determined 
based on the distribution of raw WTPs), and speeders (minimum completion 
time of 90 seconds, determined based on a timed test by three researchers). 
We first analysed the data obtained from the third task. We calculated the 
mean (SD; 95% CI) and differences in mean (SE; 95% CI) WTP for QOL 
and LE gains in EOL patients of different ages (see Appendix 5.3 for median 
(IQR) WTPs). We applied two-tailed Welch’s t-tests (Bonferroni corrected) to 
examine whether WTP for QOL and LE gains was different at different ages. We 
bootstrapped (5000 repetitions) the differences in means to examine whether 
WTP for LE gains and QOL gains was relatively different between different 
ages. We further applied Ordinary Least Squares (OLS) models to examine 
the (interaction) effect of patients’ age and the type of health gain on WTP. 
We then analysed the data obtained from all three tasks to account for 
the panel structure of the data and allow for individual effects. We applied 
random-effects Generalised Least Squares (GLS) models to further examine 
the (interaction) effect of patients’ age, the type of health gain, and respon-
dent characteristics on WTP. We controlled for the scenario characteristics of 
the first two tasks, i.e. severity, age, size of the health gain, disease outcome 
(the latter two variables coded as 0 ”10 points/full recovery after one year” 
and 1 ”50 points/death after one year” to avoid perfect multicollinearity), and 
a time-effect (labelled “CV task”) in all GLS models. 
We performed sensitivity analyses to assess the robustness of our results by 
regressing log(WTP+1) on scenario and respondent characteristics and by 
examining the effect of respondents’ proximity to the age of patients (coded 
as |Age respondents – Age patients|) on WTP. We assessed the latter as 
respondents closer to the specified age of patients may have had strong(er) 
self-regarding preferences, and hence a higher WTP in some scenarios. We 
further assessed robustness by examining the effect of the WTP stated in the 
practice task and by repeating the analyses excluding respondents with a low 
clarity score (i.e. 1−3 level) for the practice task and relaxing the minimum 
completion time to 39 seconds (z-score ≤-1.64, based on the distribution of 
completion times). 
We conducted the analyses using Stata 16.1 (Stata Corp LP, College station, 
Texas).
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5.3 Results
Table 5.1 presents the descriptive statistics of the sample (n=495) that 
remained after excluding protest zero valuations (n=86), outliers (n=25), and 
speeders (n=197). 
Table 5.1 Sample characteristics (n=495)a
% Mean (SD)









Household income (After tax)
  <€1,999
  €2,000 – €3,999







QOL (0-100 VAS) 80.5 (16.9)
Completion time of CV tasks (Minutes) 5.1 (8.4)
CV, contingent-valuation; NA, Not Applicable; NS, Not Stated; QOL, health-related quality of life (measured in 
points on a visual analogue scale, ranging from 0 “dead” to 100 “full health”); a Respondents who gave protest 
zero valuations (n=86) or stated an outlying raw WTP (n=25) in the third CV task as well as respondents who 
completed the three CV tasks in less than 90 seconds (n=197) are excluded from this table. Of the respondents 
who completed the tasks too quickly, 10 also stated an outlying WTP; b Low = lower vocational and primary 
school, Medium = middle vocational and secondary school, High = higher vocational and academic education.
Table 5.2 presents the mean (SD; 95% CI) WTP for QOL and LE gains in 
EOL patients of different ages and the difference in means (SE; 95% CI). On 
average, WTP was €8.7 per month for the duration of one year for QOL gains 
and €7.9 for LE gains. WTP was higher for QOL and LE gains in younger than 
in older EOL patients, except for a relatively low WTP for QOL gains in EOL 
patients aged 20. The results indicate that WTP for QOL and LE gains were 
similar in EOL patients aged 10, but higher for LE than for QOL gains in EOL 
patients aged 20. WTP was higher for QOL than for LE gains for EOL patients 
aged 40 and 70. The observed differences were not statistically significantly 
different from 0 at different ages, nor between different ages (p>0.10).
Table 5.3 presents the OLS regression results. These results indicate that com-
pared to EOL patients aged 10, a higher age was, ceteris paribus, associated 
with a lower WTP for health gains (model 1: β -1.48 to -2.60). The difference 
in WTP for QOL and LE gains was not statistically significant, neither was the 
interaction between patients’ age and the type of health gain.
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Table 5.2 Mean (SD; 95% CI) WTP for QOL and LE gains in end-of-life patients of different ages (n=495)a 
QOL gainb LE gainc Difference 
(QOL gain – LE gain)
Age n Mean (SD) 95% CI n Mean (SD) 95% CI ΔMean (SE) 95% CI
10 71 9.8 (6.7) 8.2, 11.4 51 9.8 (9.5) 7.1, 12.5 0.0 (1.5) -3.1, 2.9
20 64 7.8 (6.2) 6.3, 9.4 62 8.7 (6.9) 7.0, 10.5 -0.9 (1.2) -3.2, 1.4
40 61 8.9 (8.1) 6.8, 10.9 62 7.2 (6.0) 5.7, 8.7 1.7 (1.3) -0.8, 4.2
70 60 8.0 (6.7) 6.2, 9.8 64 6.3 (6.4) 4.7, 7.9 1.7 (1.2) -0.7, 4.0
n 256 239
Average 8.7 (7.0) 7.8, 9.5 7.9 (7.3) 7.0, 8.8 0.8 (0.6) -0.5, 2.0
LE, life expectancy; QOL, health-related quality of life (measured in points on a visual analogue scale (VAS), rang-
ing from 0 “dead” to 100 “full health”); WTP, willingness to pay (in € per month for the duration of one year); a 
Respondents with protest zero valuations, outlying WTPs (Module 1: ≥€32.80; Module 2: ≥€46.75), and those who 
completed the tasks in less than 90 seconds are excluded from this table; b Module 1: Treatment-related QOL gain 
is 50 points, and hence patients’ QOL is restored to 100 points on the VAS for the duration of one year, after which 
they will die; c Module 2: Treatment-related LE gain is 1 year, and hence patients’ will live one additional year with a 
QOL of 50 points on the VAS, after which they die. 
Table 5.3 OLS regression results
Model 1 Model 2
DV: WTP β (SE) 95% CI β (SE) 95% CI




















LE gain (QOL gain = reference) -0.62 (0.64) -1.87, 0.64 -0.02 (1.30) -2.57, 2.53
Age*LE gain (Age 10; QOL gain = reference)
  20*LE gain
  40*LE gain









Constant 10.06*** (0.69) 8.70, 11.43 9.81*** (0.84) 8.16, 11.46
R2 0.02 0.03
n 495
DV, dependent variable; * p<0.10, ** p<0.05, *** p<0.01.
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Table 5.4 on the next page presents the GLS regression results. These results 
confirm that compared to patients aged 10, a higher age was, ceteris paribus, 
associated with a lower WTP for health gains (model 3 to 5: β -0.56 to -1.00). 
Note that the difference in WTP for health gains in patients aged 20, 40, and 
70 became smaller when controlling for the scenario characteristics of CV 
tasks 1 and 2, and for respondent characteristics. Compared to QOL gains, LE 
gains were, ceteris paribus, associated with a lower WTP. However, this esti-
mate was only statistically significant when modelled as a main effect (model 
3: β -1.28), not when modelled as a conditional effect (models 4 and 5: β -1.39 
and -1.22). The interaction between patients’ age and the type of health gain 
indicates that the WTP for QOL and LE gains was independent of patients’ 
age. The results further indicate that WTP generally increased with increased 
severity (models 3 to 5: β 0.40 to 1.76) and was higher for a health gain of 50 
points in patients who died than for a health gain of 10 points in patients who 
fully recovered one year after falling ill (models 3 to 5: β 1.99 to 2.08). Note 
that it was not possible to distinguish between the effect of the size of the 
health gain and patients’ disease outcome on WTP. A higher respondent age 
was further associated with a lower WTP (model 5: β -0.28), whereas having 
children (model 5: β 1.65) and a higher household income (model 5: β 1.78) 
were associated with a higher WTP. The sensitivity analyses indicated that the 
WTP stated in the practice task (see Appendix 5.4, model 5B: β 0.01, p<0.001) 
had a marginal effect on WTP and that our results were robust.
5.4 Discussion
This study was one of the first to examine societal preferences for QOL and LE 
gains in EOL patients of different ages. We found that WTP is relatively higher 
for QOL and LE gains in younger patients, which might be explained by prefe-
rences relating to lifetime health [8]. We further found indications of a higher 
WTP for QOL gains than for LE gains at the EOL; however, relative preferences 
for QOL and LE gains appeared to be independent of the age of EOL patients. 
Reckers-Droog et al. [10] discuss the main strengths and limitations of our 
design. Here, we want to highlight that we applied a SIP perspective for eli-
citing WTP, and hence cannot clearly distinguish between (unobservable) 
self-regarding and other-regarding preferences. Nonetheless, this perspective 
likely aligns most with actual decisions regarding higher payments to a col-
lectively funded healthcare system like that of the Netherlands. We also want 
to highlight that we elicited preferences under certainty (in terms of QALYs 
gained) in hypothetical scenarios, in which we standardised the healthy-life 
expectancy and total health gain of the patient groups. This aimed to increase 
the clarity of the tasks and reduce the possible influence of other considerati-
ons (e.g. associated with health maximisation). Nonetheless, this came at the 
expense of realism and generalisability, and may have influenced our results. 
For example, WTP may have been different if the scenarios described patients 
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at risk of falling ill or if treatment improved patients’ health with a specific 
probability. In addition, two limitations that are specific to the current study 
deserve emphasis. First, the QOL gains of 50 points in module 1 fully resto-
red patients’ QOL to 100 points in their last year of life, which means that we 
cannot distinguish between the effect of QOL gains and patients’ health being 
fully restored on WTP. Second, we did not separate the effect of patients’ age 
in the first two tasks (where patients gained 10 points and fully recovered) 
from the effect of their age in the third task (where patients gained 50 points 
and died) in the GLS models. However, this enabled us to assess the effect 
of patients’ age on WTP without introducing multicollinearity. Note that the 
direction and relative strength of the age coefficients correspond between the 
OLS and GLS models, indicating that our conclusions regarding age-related 
preferences in society may be robust and independent of the size of health 
gains and disease outcome of patients.
With this study, we aimed to contribute to the limited evidence on societal 
preferences for QOL and LE gains in EOL patients of different ages. Our fin-
dings confirm previous findings that societal preferences for health gains in 
younger patients are relatively strong and extent these findings to the EOL 
context. They also confirm previous findings that dispute NICE’s application 
of a premium solely for LE gains, rather than for QOL gains or a combination 
of both, at the EOL. As such, they may inform discussions in countries that 
consider attaching differential weights to QOL and LE gains in EOL patients 
of different ages, aiming to better align resource-allocation decisions with 
societal preferences.
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Appendix 5.1: Scenario characteristics
Table 5.1.1 Overview of scenario characteristicsa
Scenario characteristics
Module Scenario Age 
(at disease onset)






1 10 10 10 100 Full recovery 80
2 20 10 10 100 Full recovery 80
3 40 10 10 100 Full recovery 80
4 70 10 10 100 Full recovery 80
5 10 30 10 80 Full recovery 80
6 20 30 10 80 Full recovery 80
7 40 30 10 80 Full recovery 80
8 70 30 10 80 Full recovery 80
9 10 50 10 60 Full recovery 80
10 20 50 10 60 Full recovery 80
11 40 50 10 60 Full recovery 80
12 70 50 10 60 Full recovery 80
13 10 70 10 40 Full recovery 80
14 20 70 10 40 Full recovery 80
15 40 70 10 40 Full recovery 80
16 70 70 10 40 Full recovery 80
17 10 90 10 20 Full recovery 80
18 20 90 10 20 Full recovery 80
19 40 90 10 20 Full recovery 80
20 70 90 10 20 Full recovery 80
1 21 10 50 50 100 Death 11
22 20 50 50 100 Death 21
23 40 50 50 100 Death 41
24 70 50 50 100 Death 71
2 25 10 50 50 50 Death 12
26 20 50 50 50 Death 22
27 40 50 50 50 Death 42
28 70 50 50 50 Death 72
QOL, health-related quality of life (measured in points on a visual analogue scale (VAS) ranging from 0 “death” to 
100 “full health”); a The number of patients is 10,000 in each scenario; b Severity is operationalised in terms of dis-
ease-related QOL loss and measured in points from 100 on the VAS; c Treatment-related QOL gain is measured in 
points on the VAS; d QOL after treatment is measured in points on the VAS and calculated as: 100 – disease-related 
QOL loss + treatment-related QOL gain; e Disease outcome is one year after falling ill (patients who fully recover 
return to having a QOL of 100 on the VAS).
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Appendix 5.2: Applied perspectives and contingent-valuation 
procedure
Applied perspectives
1. Practice task: individual perspective
At the start of the scenario, respondents were asked to imagine that their 
quality-of-life (QOL) was 100 on a visual analogue scale (VAS) ranging from 0 
“dead” to 100 “full health” and that—due to some disease—their QOL decre-
ased to 40 on the VAS. The disease would last for one year and after this year 
they would return to full health (a score of 100 on the VAS). During this year, 
respondents’ QOL could be improved from 40 to 80 points on the VAS by 
taking a medicine that would not have any negative side effects. This medi-
cine would not be covered by their health-insurance and would have to be paid 
out of pocket on a monthly basis. We elicited respondents’ willingness to pay 
(WTP) for the treatment-related QOL gain by applying the two-step procedure 
described below.
2. Task 1 and 2: socially-inclusive-personal perspective
For task 1 and 2, respondents were randomly assigned to two out of 20 
scenarios. Each scenario started with the introduction of a group of 10,000 
patients aged 10, 20, 40, or 70. We explained that the patients would have 
lived in full health (a score of 100 on the VAS) until the age of 80 had they 
not fallen ill. Due to the disease, their QOL decreased from 100 to either 90, 
70, 50, 30, or 10 on the VAS for the duration of one year. After this year, they 
would fully recover (i.e. return to a score of 100 on the VAS). The disease 
would not affect patients’ life expectancy (LE). We explained that a treatment 
was available that would increase patients’ QOL with 10 points on the VAS 
during the year of illness and that the treatment type and costs were the 
same for all patients. The treatment could be made available to patients by 
increasing the monthly basic health-insurance premium for the duration of 
one year. This increase would apply to all adult inhabitants of the Netherlands. 
We elicited respondents’ WTP for the treatment-related QOL gains by applying 
the two-step procedure described below.
3. Task 3: socially-inclusive-personal perspective
For task 3, respondents were randomly assigned to one out of eight scena-
rios that were evenly distributed across two modules. Each scenario started 
with the introduction of a group of 10,000 patients aged 10, 20, 40, or 70. 
We explained that the patients would have lived in full health (a score of 100 
on the VAS) until the age of 80 had they not fallen ill. Due to the disease, 
patients’ QoL decreased from 100 to 50 on the VAS for the duration of one 
120 | Chapter 5
year, after which the patients would die. We explained that a treatment was 
available that improved patients’ health by 50 points and that the treatment 
type and costs were the same for all patients. In module 1, the treatment 
increased patients’ QoL from 50 to 100 on the VAS, while it did not affect 
their LE (this remained one year). In module 2, the treatment did not affect 
patients’ QoL (this remained 50), but it increased their LE with one additional 
year. The treatment could be made available to patients by increasing the 
monthly basic health-insurance premium for the duration of one year. This 
increase would apply to all adult inhabitants of the Netherlands. We elicited 
respondents’ WTP for the treatment-related QOL gains by applying the two-
step procedure described below.
Contingent-valuation procedure
We elicited the willingness to pay (WTP) for the health gains by applying a two-
step contingent-valuation procedure. In step one, we presented a payment 
scale that ranged from a €0 to €24 increase in monthly health-insurance 
premium with unevenly distributed intervals between the value points (i.e. €0, 
€0.50, €1, €1.50, €2, €2.50, €3, €4, €5, €6, €7, €8, €10, €12, €14, €16, €18, 
€20, €22, €24, and “more”). We asked respondents to inspect the payment 
scale from left to right and indicate the increase in monthly premium they 
were certainly willing to pay for the duration of one year. We then asked them 
to again inspect the payment scale from left to right and indicate the increase 
in monthly premium they would certainly not be willing to pay for the duration 
of one year. We asked respondents who stated a WTP of €0 to explain their 
main reason for having this preference by completing an open-text field or by 
checking one of six randomised answer options that either related to a true 
zero valuation or a protest zero valuation. The open-text field answers were 
qualitatively assessed by the first two authors and subsequently classified 
as either true or protest zero valuation. The answer options relating to true 
zero valuations were “I cannot afford to pay more than €0”, “Treating these 
patients is not worth more than €0 to me”, and “I believe the treatment is 
worth more than €0, but I would rather spend my money on something else”. 
The answer options relating to protest zero valuations were “I am against an 
increase in monthly health-insurance premium”, “Patients should pay for the 
treatment themselves”, and “The value of health and healthcare cannot be 
expressed in monetary terms”. In step two, we asked respondents to indi-
cate the maximum increase in monthly health-insurance premium they would 
be willing to pay within the payment range obtained in step one. In both 
steps, we asked respondents to take their net monthly household income (as 
a proxy for their ability to pay) and the contingency that the stated WTP would 
be mandatory for all adult inhabitants of the Netherlands into account. Note 
that, by approximation, the number of adults is 13.7 million and the monthly 
health-insurance premium is €115.00 per person in 2019 [13].
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Example of a contingent-valuation task (Module 1, scenario 23)
Imagine a group of 10,000 patients who all have the same disease and to 
which you, your family, friends, and acquaintances can also belong. The 
patients would have lived in full health (a score of 100) until the age of 80 had 
they not fallen ill. 
The patients fall ill at the age of 40. Due to the disease, patients’ quality of 
life decreases from 100 to 50 for the duration of one year. After this year the 
patients will die. 
A treatment is available that reduces the effects of the disease. The treatment 
and the costs of treatment are the same for all patients. Due to treatment, 
patients’ quality of life will be 50 points higher during their last year of life than 
without the treatment. Hence, patients’ quality of life will increase from 50 to 
100 points. After this year, the patients will die. 
To be able to pay for this treatment, the monthly health-insurance premium 
will increase for the duration of one year for all adult (18+) inhabitants of the 
Netherlands. Thus, this increase also applies to people who are not affected 
by the disease. After this year, the monthly premium will return to its current 
level. Without the increase in monthly premium, the patients will not receive 
the treatment.
Please inspect the row with euro amounts below, from left to right, and indi-
cate the highest health-insurance premium you are certainly willing to pay 
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quality of life from 50 to 100 on the scale from 0 (dead) to 100 (full health) 
during their last year of life.
Please be considerate of your net monthly household income when answering 
this question.
€0 €0.5 €1 €1.5 €2 €2.5 €3 €4 €5 €6 €7 €8 €10 €12 €14 €16 €18 €20 €22 €24 more
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Please inspect the row with euro amounts below again, from left to right, and 
indicate the first health-insurance premium you are certainly not willing to pay 
extra per month for the treatment that increases the 40-year-old patients’ 
quality of life from 50 to 100 on the scale from 0 (dead) to 100 (full health) 
during their last year of life.
Please be considerate of your net monthly household income when answering 
this question.
€0 €0.5 €1 €1.5 €2 €2.5 €3 €4 €5 €6 €7 €8 €10 €12 €14 €16 €18 €20 €22 €24 more
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
You have indicated that you are certainly willing to pay €X extra health-insu-
rance premium per month for the treatment that increases the 40-year-old 
patients’ quality of life from 50 to 100 on the scale from 0 (dead) to 100 (full 
health) during their last year of life., but certainly not more than €Y.
Within the range €X - €Y, what is the maximum amount you are willing to pay 
extra in monthly health-insurance premium for this treatment? Please be con-
siderate of your net monthly household income when answering this question.
 
 
  5 
 Willingness to pay for gains in end of life patients of different ages | 123
Appendix 5.3: Zero valuations and median willingness to pay
Table 5.3.1 Distribution of true and protest zero valuations across scenariosa
QOL gainb LE gainc
Scenariod True zero (n) Protest zero (n) Scenariod True zero (n) Protest zero (n)
21 1 11 25 7 15
22 7 9 26 4 9
23 5 13 27 7 12
24 1 7 28 8 10
n 14 40 n 26 46
LE, life expectancy; QOL, health-related quality of life (measured on a visual analogue scale (VAS), ranging from 0 
“dead” to 100 “full health”); a See Appendix B for the classification criteria. b Treatment-related QOL gain is 50 points, 
and hence patients’ QOL is restored to 100 points on the VAS for the duration of one year, after which the patients 
die. c Treatment-related LE gain is 1 year, and hence patients’ will live one additional year (i.e. two years from onset 
of the disease) with a QOL of 50 points on the VAS, after which they will die.  d See Appendix 5.1 for an overview 
of scenario characteristics.
Table 5.3.2 Median (IQR) WTP for QOL and LE gains in end-of-life patients of different ages (n = 520)a 
QOL gainb LE gainc Difference 
(QOL gain – LE gain)
Age n Median (IQR) n Median (IQR) ΔMedian (IQR)
10 74 10.0 (4.0 – 15.0) 55 9.0 (3.0 – 20.0) 1.0 (1.0 – -5.0)
20 67 7.0 (2.5 – 14.0) 65 8.0 (2.8 – 14.0) -1.0 (-0.3 – 0.0)
40 63 6.0 (2.5 – 15.0) 65 6.0 (2.5 – 12.0) 0.0 (0.0 – 3.0)
70 66 7.3 (2.5 – 15.0) 65 4.0 (2.0 – 10.0) 3.3 (0.5 – 5.0)
n 270 250
Average 7.5 (3.0 – 15.0) 6.5 (2.5 – 12.0) 1.0 (0.5 – 3.0)
IQR, interquartile range; LE, life expectancy; QOL, health-related quality of life (measured in points on a visual 
analogue scale (VAS), ranging from 0 “dead” to 100 “full health”); WTP, willingness to pay (in € per month for the 
duration of one year); a Respondents with protest zero valuations (n=86) and those who completed the tasks in 
less than 90 seconds (n=197) are excluded from this table. In the scenarios, the groups consist of 10,000 patients 
with a severity level of 50 points on the VAS; b Treatment-related QOL gain is 50 points, and hence patients’ QOL is 
restored to 100 points on the VAS for the duration of one year, after which the patients die; c Treatment-related LE 
gain is 1 year, and hence patients’ will live one additional year (i.e. two years from onset of the disease) with a QOL 
of 50 points on the VAS, after which they will die.
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societal views and preferences concerning healthcare priority setting. PloS 
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Abstract
Policymakers increasingly need to prioritise between competing health tech-
nologies or patient populations. When aiming to align allocation decisions with 
societal preferences, knowledge and operationalisation of such preferences is 
indispensable. This study examines the distribution of three views on health-
care priority setting in the Netherlands, labelled “Equal right to healthcare”, 
“Limits to healthcare”, and “Effective and efficient healthcare”, and their rela-
tionship with preferences in willingness to trade-off (WTT) exercises. A survey 
including four reimbursement scenarios was conducted in a representative 
sample of the adult population in the Netherlands (n=261). Respondents were 
matched to one of the three views based on agreement with 14 statements 
on principles for resource allocation. We tested for WTT differences between 
respondents with different views and applied logit regression models for exa-
mining the relationship between preferences and background characteristics, 
including views. Nearly 65% of respondents held the view “Equal right to 
healthcare”, followed by “Limits to healthcare” (22.5%), and “Effective and 
efficient healthcare” (7.1%). Most respondents (75.9%) expressed WTT in at 
least one scenario and preferred gains in quality of life over life expectancy, 
maximising gains over limiting inequality, treating children over elderly, and 
those with adversity over those with an unhealthy lifestyle. Various back-
ground characteristics, including the views, were associated with respondents’ 
preferences. Most respondents held an egalitarian view on priority setting, yet 
the majority was willing to prioritise regardless of their view. Societal views 
and preferences concerning healthcare priority setting are related. However, 
respondents’ views influence preferences differently in different reimburse-
ment scenarios. As societal views and preferences are heterogeneous and 
may conflict, aligning allocation decisions with societal preferences remains 
challenging and any decision may be expected to receive opposition from 
some group in society.
 Societal views and preferences concerning healthcare priority setting | 129
  6 
6.1 Introduction
Healthcare resources are scarce and policymakers in publicly funded health-
care systems are increasingly confronted with the need to prioritise between 
competing health technologies or patient populations for reimbursement 
[1,2]. An important objective of a healthcare system is to generate as much 
health as possible, given the budget constraint [3]. To achieve this objective, 
economic evaluations of (new) health technologies are applied to guide policy-
makers in making decisions concerning the allocation of healthcare resources 
[4,5]. In health-economic evaluations, the value of a health technology is 
commonly expressed in terms of quality-adjusted life-years (QALYs) and eva-
luated against some monetary threshold value per QALY gained [1,6]. 
Regardless of whether the decision rule for economic evaluations implies the 
maximisation of health under a fixed budget or the maximisation of welfare for 
society, traditionally, health technologies with lower incremental cost-effec-
tiveness ratios (ICERs) than some relevant threshold are eligible for funding 
[3,4,7]. Often, both the weight attached to QALY gains and the applied thres-
holds are constant in such evaluations. This assumes that a “QALY is a QALY 
is a QALY”, regardless of beneficiary characteristics and the context in which 
QALYs are gained [8]. However, the practice of valuing all QALY gains equally, 
and hence regardless of these aspects, has become a matter of debate as evi-
dence is accumulating that this may insufficiently reflect societal preferences 
[1,4,6,9–12]. Indeed, the public also considers an equitable or fair allocation 
of health and healthcare important in the allocation of healthcare resources 
[4,10,13,14] and societal preferences concerning healthcare priority setting 
are related to the (i) characteristics of healthcare beneficiaries, e.g. a patient’s 
age, potential to benefit from treatment, remaining life-years, social role, and 
lifestyle, (ii) characteristics of the disease, e.g. the rarity of a disease and the 
burden of illness associated with a disease prior to treatment, and (iii) charac-
teristics of interventions, e.g. the size, type, duration, and costs of health 
gains [1,4,10,15–18]. Although health economists tend to agree that such 
preferences should play a role in decisions concerning resource allocation 
in healthcare [4], they are generally not included in health-economic evalu-
ations (even though notable exceptions like in the Netherlands exist [19]). 
The discrepancy between prioritisation based on health-economic evaluations 
and societal preferences for distributing health and healthcare is considered 
one of the reasons for the modest impact of health-economic evaluations on 
the outcome of allocation decisions [20–22]. To bridge this gap, knowledge 
and operationalisation of an equity-dependent decision rule appears to be 
indispensable.
Empirical evidence suggests that, although some members of the public appear 
unwilling to prioritise in healthcare, the majority accepts priority setting as 
being necessary [4,18,23]. However, little is known about the criteria that 
should be used according to the public and about the weight these should 
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receive in allocation decisions [17,18,24–27]. Commonly, studies examine 
societal preferences for priority setting on an aggregate or mean level [28]. 
Less common are studies that examine the heterogeneity of societal pre-
ferences or the relationship between underlying rationales and preferences 
[17,18,25–27]. In a previous study, Wouters et al. [17] used Q methodology to 
identify three societal viewpoints regarding healthcare priority setting among 
members of the public in the Netherlands: “Equal right to healthcare”, “Limits 
to healthcare”, and “Effective and efficient healthcare”. Brief descriptions 
of these viewpoints can be found in Text box 6.1. In the current study, we 
examine the distribution of the three views in the general adult population and 
the relationship between these views and preferences concerning healthcare 
priority setting in four willingness to trade-off (WTT) exercises to inform pri-
ority-setting decisions in healthcare.
Text box 6.1 Societal viewpoints on healthcare priority setting in the Netherlands
The view “Equal right to healthcare” comprises an egalitarian view on health and 
healthcare. People with this view consider access to healthcare a basic human right. 
Everyone is equal, hence has an equal right to healthcare. According to people with 
this view, prioritisation should solely be based on the need for care and prioritisa-
tion based on patient, disease, and intervention characteristics, such as the effect 
of treatment, is opposed. What is considered to be “the right care” is a matter 
of personal concern for patients and, according to people with this view, patients 
should be supported in their treatment choices regardless of the costs. 
The view “Limits to healthcare” comprises a view with a strong concern for pro-
viding “the right care” for patients. People with this view consider health-related 
quality of life to be an important outcome of treatment. According to people with 
this view, providing the right care may imply refraining from (life prolonging) treat-
ment. People with this view do not consider cost-effectiveness to be an important 
criterion for priority setting, although they do consider it important to make good 
use of money. Hence, providing treatments that generate minimal benefits should 
be avoided. Priority setting based on patient characteristics is rejected, with an 
exception made for lifestyle. According to people with this view, patients who are 
culpable of their own disease should receive lower priority and prevention should 
receive higher priority in allocation decisions. 
The view “Effective and efficient healthcare” comprises a utilitarian view on health 
and healthcare. People with this view consider it important to generate as much 
health for society as possible given the budget constraint, and consider a patient’s 
capacity to benefit from treatment important when setting priorities. Although 
people with this view focus on the cost-effectiveness of treatments, they do believe 
it is not possible to “put a [fixed] price on life”. The value of health benefits depends 
on circumstances and patient characteristics, such as age and culpability, and hence 
these should be taken into account in priority setting. 
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6.2 Methods 
6.2.1 Sample and data collection
A professional internet survey company in the Netherlands distributed the 
questionnaire in October and November 2015, to a random sample that was 
stratified in terms of age, sex, and education level in order for it to be repre-
sentative of the general adult population in the Netherlands regarding those 
characteristics. According to the Medical Research Involving Human Subjects 
Act, no ethical approval was required for this study. Prior to participating 
in the study, respondents were informed about the objectives of the study 
and how anonymity of respondents was guaranteed. They were informed that 
participation in the study was voluntary and could be stopped at any time, in 
which case the data they had provided would be discarded. Respondents could 
only enter the study after giving written consent for the use of their data for 
the purpose of the study.
Before answering questions about distributive preferences, respondents were 
explained that healthcare resources are scarce and that health policymakers 
inevitably have to make difficult choices between competing health techno-
logies or patient populations for reimbursement. It was explained that the 
consequence of reimbursing one (type of) technology for one patient group 
implied not being able to reimburse another. Subsequently, respondents were 
asked to advise health policymakers on what would be the optimal allocation 
of available healthcare resources in four reimbursement scenarios.
In the next subsection, the questionnaire, including the statements and reim-
bursement scenarios, that was used for matchings respondents to a view 
and for eliciting their preferences is described. Subsequently, the reimburse-
ment scenarios, scenario characteristics, and accompanying WTT exercises 
are discussed in more detail. In the final subsection of the Methods section, 
the analyses and hypotheses are described that were used for examining the 
distribution of the views and the relationship between respondents’ views and 
preferences concerning healthcare priority setting.
6.2.2 Questionnaire
The questionnaire consisted of three parts. In part one, respondents were 
asked about demographic and background characteristics. In part two, res-
pondents were asked to express their level of agreement on a seven-point 
Likert scale (ranging from completely disagree to completely agree) with 14 
statements on principles for resource allocation that were extracted from 
Wouters et al. [17] and presented to respondents in random order. Table 6.1 
presents these statements including respondents’ mean (SD) level of agree-
ment with each of the statements. To match respondents to one of the three 
views on healthcare priority setting, four statements were selected for each 
of the views and two additional statements were selected to untie, in case 
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a respondent scored similarly on more than one view. The statements were 
selected based on the criteria that a statement should be characterising and 
distinguishing for one of the three views, which means that the statement 
should have a high factor score in that view and/or that this score should be 
statistically significantly different from factor scores of the other two views 
[17,29,30]. The assumption underlying the matching of respondents to one 
of the views was that respondents who expressed a relatively high level of 
agreement with statements that are characteristic and/or distinguishing for a 
specific view have a view that is similar to that view. 
In part three of the questionnaire, respondents were presented four reim-
bursement scenarios. The scenarios were based on the study by Wouters et 
al. [17] and designed in such a way that differences in preferences between 
respondents with different views could manifest themselves. Each of the 
scenarios included two options, labelled A and B, that differentiated two com-
peting treatments, based on the type of health gain, or patient groups, based 
on patients’ potential to benefit from treatment, age, or lifestyle. Respon-
dents were asked to advise health policymakers on reimbursement, by first 
choosing between the two treatments or patient groups and subsequently, 
depending on the scenario, indicating the relative size of the health gain or 
patient group that would make them indifferent between the two options. 
Respondents were allowed to opt out in case they had no preference for one of 
the options. When a respondent chose to opt out, they were asked to explain 
their choice by checking one of two provided answer options that indicated 
equality between the treatments or patient groups, e.g. ‘both treatments are 
equally effective’ or ‘both treatments are equally ineffective’, or by completing 
an open text field. As an example, scenario one is included in the supporting 
information.
6.2.3 Reimbursement scenarios
The reimbursement scenarios were similarly structured but differed in terms 
of treatment and patient characteristics. In scenario 1, respondents were 
asked to choose between two treatments based on their preference for health 
gains in terms of 3 points in health-related quality of life (QOL) or 3 months 
in life expectancy (LE), while both patient groups currently had a remaining 
LE of 3 months with a QOL of 3 points. The QOL scale ranged from 0 to 10, 
with 0 representing ‘the worst imaginable health state’ and 10 representing 
‘the best imaginable health state’. When a respondent preferred treatment A 
with a gain in QOL, they were asked at which point they would be indifferent 
between a gain in QOL between 0 and 3 points and a gain of 3 months in LE for 
treatment B (and vice versa if respondents preferred the LE gain). In scenario 
2, respondents were asked to choose between two patient groups based on 
patients’ potential to benefit from treatment. Respondents stated their pre-
ference for maximising health gains or limiting health inequality between the 
patient groups, by choosing between a 3 point gain in QOL in patient group A 
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or a 1 point gain in QOL in patient group B, while both groups currently had a 
QOL of 5 (on a scale from 0 to 10). When a respondent preferred the health 
maximising option, they were asked at which point they would be indifferent 
between a gain in QOL between 0 and 3 points and a gain of 1 point in QOL 
for the other patient group (or how large the difference should be, up to 5 
points, to switch to patient group A, if they had a preference for patient group 
B). In scenario 3, respondents were asked to prioritise a 12 month increase 
in LE by choosing between two patient groups based on their preference for 
treating children (<18 years) or elderly (>70 years). When a respondent chose 
to treat the group of children, they were asked at how many months between 
0 and 12 months gain in LE they would be indifferent between treatment of 
the two age groups (and vice versa if respondents preferred to treat the group 
of elderly). In scenario 4, respondents were asked to choose between two 
patient groups based on their preference for reducing the risk from 1:1,000 
to 1:10,000 of a life-threatening illness for those with an unhealthy lifestyle or 
those with running the same risk due to adversity (explained to respondents 
as a reduction from 10 to 1 patients in a population of 10,000). When res-
pondents preferred the patients running the risk due to adversity, they were 
asked to indicate how many patients between 1 and 10 would make them 
indifferent between the two groups (and vice versa). The scenarios stated 
there were no other differences between the treatments or patient groups 
than the ones described. 
In all but scenario 2, the post-treatment health status was equal for patient 
groups in both options. However, in scenario 1, patients’ post-treatment 
health status was not measured on a single scale, as in the other scenarios, 
but on a combined QOL and LE scale. In this scenario, the post-treatment 
health status was 18 for both patient groups. This was calculated in option A 
by multiplying 3 months LE by 6 points QOL and in option B by multiplying 6 
months LE by 3 points QOL. Although in scenario 1 respondents’ preferences 
were elicited on a combined QOL and LE scale, respondents who expressed 
a preference for a gain in QOL indicated their point of indifference on a QOL 
scale, while those who expressed a preference for a gain in LE indicated their 
point of indifference on a LE scale. Scenarios 2, 3, and 4 elicited respondents’ 
point of indifference between the options on a single scale, either in terms of 
QOL, LE, or in number of patients.
6.2.4 Statistical analyses and hypotheses
To improve our sample’s representativeness of the general adult population 
in the Netherlands, we weighted the data by applying a combined weigh-
ting factor for age, sex, and education level. For the analyses, respondents 
were divided into a ‘traders’ and a ‘non-traders’ subsample. Respondents who 
expressed WTT in at least one of the four scenarios were classified as ‘trader’ 
and those who did not express WTT were classified as ‘non-trader’. Demo-
graphic and background characteristics of the sample and the two subsamples 
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were calculated in percentages of total and mean (SD). To match respondents 
to one of the views identified by Wouters et al. [17], we applied the following 
procedure. First, respondents’ levels of agreement with the four statements 
were summed for each of the views and, for ease of interpretation, rescaled 
to a 0−10 scale. Next, respondents were matched to the view with the highest 
sum score on the condition that this score was above 5.0, hence indicated 
agreement. When two or three views received an equal highest sum score, 
the levels of agreement with statements 13 and 14 (see Table 6.1) were used 
to untie the scores and, if possible, used to match respondents to one of 
the views. Differences in characteristics between respondents who could and 
could not be matched, between traders and non-traders, and between res-
pondents with different views were examined using independent t-, analysis 
of variance (ANOVA), and Fisher’s exact tests. A Bonferroni correction was 
applied to adjust for the increased risk of a Type 1 error, caused by multiple 
comparisons. 
In each scenario, the WTT of respondents between treatments or patient 
groups was examined by calculating the percentage of traders and non-tra-
ders, and the median (interquartile) range of indifference points of traders 
with a preference for option A or B. Differences in WTT and in median indif-
ference points of traders with different views were examined using Fisher’s 
exact and Kruskal-Wallis tests (Bonferroni corrected). Reasons of non-traders 
for opting out were explored qualitatively. To relate respondents’ preferences 
to background characteristics, including view, logit regression models were 
applied. First, an overall model was composed for the four scenarios. This 
model included the variables age, age squared (to account for non-linearity), 
sex, education level, having children, daily smoking, and view. Having child-
ren and daily smoking were included as these variables were expected to be 
associated with the outcomes of interest in scenario 3 and 4. Subsequently, 
we applied likelihood ratio tests (LRT) to examine if this overall model could 
be improved for specific scenarios by including additional variables that might 
also be associated with the outcomes of interest, such as excessive alcohol 
use and being religious. We used generalised variation inflation factors (VIFs) 
to examine if the coefficient estimates’ standard errors were inflated by 
multicollinearity. 
Based on the description of the views in Wouters et al. [17], three hypotheses 
were formulated for the relationship between respondent’s views and prefe-
rences concerning healthcare priority setting:
Hypothesis 1: Respondents with the view “Equal right to healthcare” have a 
lower WTT in all scenarios than respondents with the views “Limits to health-
care” and “Effective and efficient healthcare”. 
Hypothesis 2: The view “Limits to healthcare” is positively associated with 
respondents’ WTT in all scenarios. In addition, respondents with this view 
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express a preference for health gains in terms of QOL in scenario 1, for health 
maximisation in scenario 2, and for treating those with adversity in scenario 4.
Hypothesis 3: The view “Effective and efficient healthcare” is positively asso-
ciated with respondents’ WTT in all scenarios. In addition, respondents with 
this view express a preference for health maximisation in scenario 2, for trea-
ting children in scenario 3, and for treating those with adversity in scenario 4. 
The analyses were conducted using IBM SPSS Statistics 23.0 (SPSS, Inc, 
Chicago, Ill., USA) and Rstudio 0.99.903 (Rstudio, Inc., Boston, MA, USA). 
6.3 Results
The data were weighted by applying a combined weighting factor for age, 
sex, and education level with a mean (SD) of 1.00 (0.47). Table 6.2 presents 
the descriptive statistics and the distribution of the views in the weighted 
sample (n=261), and in the traders and non-traders subsamples. The majo-
rity of respondents (n=198; 75.9%) expressed WTT in at least one scenario. 
Of the respondents, 90.2% (n=235) could be matched to one of the views 
based on their level of agreement with the 12 statements and 3.9% (n=10) 
could be matched based on their level of agreement with the two additional 
statements. A t-test revealed that respondents who could not be matched to 
one of the views were relatively younger than those who could be matched. 
Mean (SD) age of respondents who could not be matched was 32.3 (13.8) 
years and of those could be matched 47.2 (14.7) years. This difference was 
significant at the 0.01 level (two-tailed, Bonferroni corrected, α/12). In addi-
tion, a Fisher’s exact test revealed that the difference in nationality between 
respondents who could and could not be matched was also significant at the 
0.01 level (two-tailed, Bonferroni corrected, α/12). Respondents with a Dutch 
nationality could more frequently be matched to a view than respondents with 
a different nationality. 
The majority of respondents was matched to the view “Equal right to health-
care” (64.5%), followed by “Limits to healthcare” (22.5%), and “Effective and 
efficient healthcare” (7.1%). A minority of respondents (5.9%) could not be 
matched. A similar distribution of views was observed among traders (60.1%, 
28.8%, 7.6, and 3.5% respectively). However, among non-traders the view 
“Equal right to healthcare” was considerably more prevalent (78.3%), while 
the views “Limits to healthcare” and “Effective and efficient healthcare” were 
less prevalent (2.9% and 5.4%, respectively), and relatively more non-traders 
could not be matched (13.4%). A Fisher’s exact test (two-tailed, Bonferroni 
corrected, α/13) revealed that the difference in views between traders and 
non-traders was significant at the 0.001 level. In addition, a Fisher’s exact 
test (two-tailed, Bonferroni corrected, α/13) revealed that traders were more 
frequently highly educated and less frequently smoked daily (p-value <0.05) 
than non-traders. No differences were revealed between traders and non-tra-
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Sex (Female) 49.4 52.7 44.0 0.312
Nationality (Dutch) 88.9 88.4 90.5 0.008
Education levelb
   Low
   Middle
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   Married/cohabitant











Children (Yes) 60.1 64.3 46.5 0.012
Lifestyle 
   Smoking (Daily)










   Physical
   Mental











Religious (Yes)d 26.8 27.2 25.4 0.871
View on healthcare priority setting
  Equal right to healthcare
  Limits to healthcare
  Effective and efficient healthcare




























VAS, Visual Analogue Scale; a In this table, respondents who expressed willingness to trade-off (WTT) in at 
least one reimbursement scenario are classified as “traders”, respondents who expressed no WTT in all four 
reimbursement scenarios are classified as “non-traders”; b Low = lower vocational and primary school, Middle = 
middle vocational and secondary school, High = higher vocational and academic education; c Applied standard 
for excessive alcohol use for female respondents: consumption of  ≥7 alcohol units per week or of  ≥4 alcohol 
units on one day, for male respondents: consumption of ≥14 alcohol units per week or ≥6 alcohol units on one 
day; d Operationalised by the question “Do you consider yourself to be part of a religious community (yes/no)?”; * 
p<0.05, *** p<0.001 (two-tailed, Bonferroni corrected, α/13).
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ders concerning other characteristics. Between respondents with different 
views, a Fisher’s exact test (two-tailed, Bonferroni corrected, α/12) revealed 
a significant difference at the 0.05 level for education level (not in table). 
Respondents with the view “Equal right to healthcare” were more frequently 
lower educated than respondents with the views “Limits to healthcare” and 
“Effective and efficient healthcare”.
Table 6.3 presents the scenario specifications, the proportion of respondents 
who were willing to trade-off, respondents’ preferences for option A or B, and 
their median (IQR) indifference points for each of the scenarios. Although the 
distribution of indifference points is different between traders with a prefe-
rence for option A or B, an overlap of IQR can be seen in scenario’s 3 and 4. 
Note that for scenario 1 the IQR for option A and B are on a different scale. 
The percentage of respondents who were willing to trade-off ranged between 
42.0% and 50.8% in the four scenarios. The highest WTT percentage was 
expressed in scenario 1, where respondents were asked to prioritise between 
health gains in terms of QOL or LE. The lowest WTT percentage was expressed 
in scenario 2, where respondents were asked to prioritise between maximi-
sing health gains and limiting health inequality between patient groups. Of the 
traders, a large majority expressed a preference for health gains in terms of 
QOL (80.3%) over gains in LE (19.7%), for maximising health gains (91.7%) 
over limiting health inequality (8.3%), for treating children (94.3%) over tre-
ating elderly (5.7%), and reducing risk for those with adversity (89.7%) over 
those with an unhealthy lifestyle (10.3%). In each of the scenarios, 81.0% 
to 84.0% of non-traders consisted of respondents with the view “Equal right 
to healthcare”, who opted out more frequently than respondents with the 
views “Limits to healthcare” and “Effective and efficient healthcare”. Table 6.4 
presents the differences in WTT between respondents with different views 
in each of the scenario. Fisher’s exact tests revealed that these differences 
were significant at the 0.001 level in scenario 1, 3, and 4, and at the 0.01 
level in scenario 2 (two-tailed, Bonferroni corrected, α/4). The difference in 
the median indifference points of respondents with different views was not 
significant.
Between 79.8% and 92.9% of non-traders explained their preference for 
opting out by checking one of the provided answer options, the remainder by 
completing the open text field. In scenario 1, 20.2% (n=26) of the non-traders 
completed the open text field of which 69.2% stated that the choice between 
options A and B was not theirs but only for patients themselves to make. For 
example, because “having a preference for quality of life or life expectancy is 
a personal matter”. Other explanations for opting out included “both options 
are very much alike” or “both patient groups will die regardless of treatment”. 
In scenario 2, 10.9% (n=16) completed the open text field. Explanations for 
opting out included “I do not see a difference between the two options”, “I 
would treat whoever came first”, “the value of a person’s life cannot solely 
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be determined based on the physical condition of that person”, and “quality 
of life is an abstract concept and it provides too little information to form an 
informed opinion”. In scenario 3, 7.1% (n=10) completed the open text field. 
Explanations for opting out included “although I have a preference for treating 
children, the age of patients should not matter”, “my preference in this matter 
depends entirely on the burden of illness of the patients”, and “quality of life 
matters more than life expectancy”. In scenario 4, 8.7% (n=12) completed the 
open text field and stated, for example, “it is nearly impossible to determine 
whether a person is culpable of their own disease”, “two-third of all cancer 
cases are caused by having bad luck”, “having an unhealthy lifestyle may be 
involuntary”, and “having an unhealthy lifestyle is often due to adversity”. The 
explanations for opting out did not seem to differ between respondents with 
different views on healthcare priority setting.
Table 6.5 and 6.6 present the results of the logit regression models examining 
the relationship between background characteristics and the WTT, and the 
most preferred option of respondents in each of the scenarios, with the base-
line set to a preference for opting out. 
The results of the LRTs indicated that the overall model could not be signi-
ficantly improved for any of the scenarios by including additional variables. 
Hence, logit regression models with the same independent variables are pre-
sented for all four scenarios. The VIFs indicated no multicollinearity (VIFs 
<1.90) for all variables except for age and age squared (VIF 40.78−46.60). 
The higher VIFs for age and age squared can be explained by the correlation 
between these two variables. When excluding age or age squared from the 
regression models, the corresponding VIFs were all <1.62. 
Table 6.4 Willingness to trade-off of respondents with different views on healthcare priority setting (n=246)a
View WTT in scenariob No WTT in any 
scenario
1 2 3 4
Equal right to healthcare 74 59 64 58 49
Limits to healthcare 45 36 42 43 2
Effective and efficient healthcare 10 11 11 13 3
n 129 106 117 114 62
WTT, willingness to trade-off (in frequencies); a Respondents who could not be matched to one of the views (n=15) 
are excluded from the table; b In scenario 1, respondents expressed WTT by choosing for a gain in quality of life 
or in life expectancy or expressed no WTT by opting out. In scenario 2, respondents expressed WTT by choosing 
for health maximization or limiting health inequality or expressed no WTT by opting out. In scenario 3, respondents 
expressed WTT by choosing for treating children or elderly or expressed no WTT by opting out. In scenario 4, re-
spondents expressed WTT by choosing for treating those with an unhealthy lifestyle or adversity or expressed no 
WTT by opting out. Respondents who opted out in all four scenarios are included in the table under “no WTT in any 
scenario”. The presented differences in WTT frequencies are significant at the 0.001 level in scenario 1, 3, and 4, 
and at the 0.01 level in scenario 2 (two-tailed, Bonferroni corrected, α/4).
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In terms of background characteristics, having a higher age (OR 0.845−0.877), 
having children (OR 0.261), and daily smoking (OR 0.219−0.312) negatively 
affected, and having a high education level (OR 2.865−3.072) positively affec-
ted the WTT of respondents in different reimbursement scenarios. Having a 
higher age (OR 0.872), having children (OR 0.251), and daily smoking (OR 0.296) 
were negatively associated, and having a high education level (OR 3.122) was 
positively associated with a preference for treating children. Having a higher 
age (OR 0.870) and daily smoking (OR 0.252) were also negatively associated 
with a preference for treating those with adversity. In addition, daily smoking 
(OR 0.261) was negatively associated with a preference for health maximisa-
tion. Having a middle or high education level (OR 2.745−5.309) was positively 
associated with a preference for health gains in terms of QOL. Compared to 
the view “Equal right to healthcare”, the views “Limits to healthcare” (OR 
3.306−5.850) and “Effective and efficient healthcare” (OR 2.608−4.375) were 
positively associated with the WTT of respondents. The view “Limits to health-
care” was also positively associated with a preference for health gains in terms 
of QOL (OR 4.241), maximising health gains (OR 3.443), treating children (OR 
5.354), and those with adversity (OR 6.443). The view “Effective and efficient 
healthcare” was positively associated with a preference for health maximisa-
tion, treating children, and those with adversity (OR 2.640−4.050).
The WTT of respondents with different views on healthcare priority setting 
differed significantly in each of the scenarios and the majority of non-traders 
in each of the scenarios consisted of respondents with the view “Equal right 
to healthcare”. These findings provide evidence in support of hypothesis 1. 
The logit regression analyses discussed above provide additional evidence 
in support of hypothesis 1 by indicating that, compared to having the view 
“Equal right to healthcare”, the views “Limits to healthcare” and “Effective 
and efficient healthcare” are positively associated with WTT and the most 
preferred option in all scenarios. The logit regression analyses also provide 
evidence in support of hypotheses 2 and 3. Having the view “Limits to health-
care” was positively associated with WTT in all scenarios as well as with a 
preference for health gains in terms of QOL, health maximisation, and trea-
ting those with adversity. Having the view “Effective and efficient healthcare” 
was also positively associated with WTT in all scenarios. In addition, having 
this view was positively associated with a preference for health maximisation, 
treating children, and those with adversity. The lower significance levels that 
accompany these latter associations may be explained by the relatively small 
number of respondents having the view “Effective and efficient healthcare” 
(n=18).






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Societal views and preferences concerning healthcare priority setting | 143











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































144 | Chapter 6
6.4 Discussion
This study was performed against the background of the ongoing debate about 
societal concerns for an equitable and fair allocation of healthcare resources. 
The aim of this study was twofold. The first aim was to examine the distribu-
tion of three societal views on healthcare priority setting, i.e. “Equal right to 
healthcare”, “Limits to healthcare”, and “Effective and efficient healthcare” 
[17], in the general adult population in the Netherlands. The second aim was 
to examine the relationship between the views and preferences concerning 
healthcare priority setting, by examining respondents’ WTT between treat-
ments or patient groups in four different reimbursement scenarios as well as 
by relating respondents’ preferences to background characteristics, including 
their view. 
The results of our study suggest that “Equal right to healthcare” is the most 
prevalent view on healthcare priority setting in Dutch society. Based on our 
analyses, we found evidence in support of the hypothesis that respondents 
with this view had a lower WTT in the different reimbursement scenarios than 
respondents with the views “Limits to healthcare” and “Effective and efficient 
healthcare”. In addition, we found evidence in support of hypotheses 2 and 3. 
The view “Limits to healthcare” is positively associated with WTT and with a 
preference for health gains in terms of QOL, health maximisation, and treating 
those with adversity. The view “Effective and efficient healthcare” is positively 
associated with WTT and with a preference for health maximisation, treating 
children, and reducing the risk of a life threatening disease for people with 
adversity. It should be noted, however, that the significance levels of these 
associations were higher for having the view “Limits to healthcare” than for 
having the view “Effective and efficient healthcare”. Although, on average, the 
WTT differed between respondents with different views, our results suggest 
that the indifference points of those who are willing to trade-off did not differ, 
hence did not depend on their view. Our results also suggest that those who 
are willing to trade-off in different reimbursement scenarios generally prefer 
gains in QOL over LE, maximising health gains over limiting health inequality, 
treating children over the elderly, and treating those with adversity over those 
with an unhealthy lifestyle.
The finding that the majority of the general adult population in the Nether-
lands is willing to trade-off between competing health technologies or patient 
populations in at least one reimbursement scenario is in line with other empi-
rical studies that suggest that the majority of the public is willing to prioritise 
in healthcare [4,23,24]. Although a large majority was willing to trade-off in at 
least one scenario, the proportions were close to 50% in each of the scenarios 
separately. Hence, respondents’ characteristics and their view on healthcare 
priority setting influenced their WTT and preferences differently in different 
reimbursement scenarios. As preferences of the public are heterogeneous 
and may conflict, aligning reimbursement decisions with these preferences 
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is challenging and any allocation decision made by health policymakers may 
receive opposition from some group in society. 
Empirical evidence about the heterogeneity of societal preferences or the 
relationship between underlying rationales and preferences for priority 
setting is limited [17,18,25–27], and research relating views on healthcare 
priority setting to such preferences may indeed be considered innovative. 
Using the same methodology as Wouters et al. [17], Baker et al. [25,30] iden-
tified three views on healthcare priority setting in the United Kingdom (UK) 
and examined the distribution of these views in British society. McHugh et al. 
[26] identified three views on the relative value of end-of-life treatments and, 
in a more recent study; Mason et al. [27] examined the distribution of these 
views in British society. Although in both studies, two of the identified views 
share similarities with the views “Equal right to healthcare” and “Effective 
and efficient healthcare” of Wouters et al. [17], none of the views appeared 
to be as dominant in the UK [25,27] as the view “Equal right to healthcare” 
in the Netherlands. Van Exel et al. [18] identified five views on healthcare 
priority setting in ten European countries, among which the Netherlands and 
the UK. Mason et al. [31] examined the distribution of these views in a subset 
of nine countries. The results of this study support our finding that an ega-
litarian view on healthcare priority setting is the most prevalent view in the 
Netherlands. In addition, the results of this study suggest that an egalitarian 
view on healthcare priority setting in the most prevalent view in the UK as 
well as in the other European countries. Further comparative research will be 
necessary to investigate the difference in views and their distribution between 
countries, and the relationship between the views and societal preferences for 
priority setting in these countries. The results of our study generally align with 
the results of other studies indicating that the social value of the QALY does 
not exist [14] as societal concerns for an efficient and equitable allocation of 
health and healthcare are heterogeneous. Our findings support those of other 
studies indicating, for example, that priority should be given to younger over 
older people [32–36] and to those with adversity over those with an unhealthy 
lifestyle [37–39]. 
Some limitations of this study need to be mentioned. A first limitation con-
cerns the four relatively simple WTT exercises. Because our primary aim was 
to explore the relationship between the three societal views and preferences in 
a number of reimbursement scenarios based on distinguishing characteristics 
of those views, we chose for fairly straightforward WTT exercises. In addition, 
we expected that respondents might find the WTT exercises rather difficult 
and, therefore, kept the WTT exercises clear and concise. A second limitation 
concerns the initial lack of representativeness of our sample, resulting from 
suboptimal recruitment of respondents. To improve our sample’s representa-
tiveness, we weighted the data by applying a combined weighting factor for 
age, sex, and education level. Although this method is often associated with 
an increased level of uncertainty concerning the results, a comparison of the 
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results pre and post weighting indicated no major changes in the size or direc-
tion of estimates. A third limitation concerns the non-randomised order in 
which the reimbursement scenarios were presented to respondents. However, 
as respondents were presented with only four scenarios that differed in terms 
of treatment and patient characteristics, we expect the possible risk of order 
bias to be limited. A fourth limitation is concerned with the possibility for 
respondents to avoid prioritisation and opt out in each of the four scenarios. 
Although we provided an opt-out to examine respondents’ WTT and to explore 
non-traders’ reasons for opting out in each of the scenarios, in decision-making 
practice opting out is not possible for health policymakers. It is unclear, how 
not providing an opt-out would have influenced the results of our study. A fifth 
limitation concerns the exclusion of respondents that could not be matched 
from the logit regression analyses. These respondents significantly differed in 
age and nationality from respondents who could be matched and, excluding 
these respondents resulted in a loss of information concerning our sample’s 
preferences in the different reimbursement scenarios. However, excluding 
these respondents did not affect our primary aim of conducting the regres-
sion analyses, i.e. to explore the relationship between the three views and 
respondents’ preferences in different reimbursement scenarios. In addition, 
as the excluded group of respondents was relatively small (n=15) and could 
not be matched to one of the views, we considered the loss of information to 
be limited. A final limitation concerns the lack of a normative discussion of the 
views and preferences concerning healthcare priority setting. Our aim was to 
examine the distribution of the three views and the relationship between the 
views and preferences and, therefore, a normative discussion was outside the 
scope of this paper. We refer the interested reader to e.g. Schwappach [4], 
Olsen et al. [15], Ottersen [40], and Bognar [41,42] for normative discussions 
about societal preferences concerning healthcare priority setting. In addition 
to these limitations, we would like to address that we consider it a strength 
of our study that we combined different methods to examine the relationship 
between societal views on healthcare priority setting and preferences in dif-
ferent healthcare reimbursement scenarios. This type of study is regarded as 
methodologically challenging [30] and is infrequently conducted. 
Our results indicate that societal preferences concerning healthcare priority 
setting are heterogeneous and complex as people’s view on healthcare priority 
setting and background characteristics influence their preferences differently 
in different reimbursement scenarios. Hence, when aiming to align allocation 
decisions with societal preferences for equity and efficiency, the use of a mix 
of equity concerns in decision-making practice is recommended. As we exa-
mined the relationship between societal views and preferences in the context 
of only four reimbursement scenarios, we recommend extending our research 
to scenarios that include other potential sources that contribute to the social 
value of the QALY [4,14]. For example, patients’ prior healthcare consumption, 
the duration of health benefits, and the burden of illness that is associated 
with a disease. As heterogeneous preferences may sometimes be conflic-
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ting, aligning allocation decisions with societal preferences is challenging 
and decisions will almost inevitably receive opposition from some group or 
another in society. Given the available evidence, this is unlikely to be a strictly 
Dutch phenomenon. Hence, knowledge about the (distribution of the) socie-
tal views and related preferences concerning healthcare priority setting may 
help health policymakers to be considerate of these views and preferences 
when allocating resources in healthcare. This knowledge, for example about 
the high prevalence of the egalitarian view on healthcare priority setting, may 
also help health policymakers in communicating and explaining (inevitable) 
allocation decisions to the public.
6.5 Conclusions
The results of this study suggest that “Equal right to healthcare” is the most 
prevalent view on healthcare priority setting in the Netherlands. Although 
we expected this egalitarian view to be negatively associated with WTT, our 
results indicate that the majority of people is still willing to prioritise between 
competing health technologies or patient groups regardless of their view on 
healthcare priority setting. People’s characteristics and views on healthcare 
priority setting influence preferences differently in different reimbursement 
scenarios. As societal views and preferences are heterogeneous and may 
conflict, aligning allocation decisions with societal preferences remains chal-
lenging and any decision may be expected to receive opposition from some 
group in society. When aiming to align allocation decisions with societal pre-
ferences concerning healthcare priority setting, accounting for the variety in 
societal views and preferences is recommended.
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Appendix 6.1: Example of reimbursement scenario
General introduction: 
Healthcare resources are scarce and, therefore, health policymakers have 
to decide which treatments can be reimbursement from the public health 
insurance package, and which cannot. These decisions are often difficult, as 
reimbursing treatment for one patient group implies not being able to reim-
burse (the best possible) treatment for another. 
Presented below are some of these difficult decisions. Which decision would 
you advise health policymakers to make in these scenarios? Which choice 
do you consider best in order to allocate healthcare resources as optimal as 
possible? 
Scenario 1:
Introduction. There are two possible treatments for patients with a specific 
type of cancer. Only one of these treatments can be reimbursed. Without tre-
atment, the patients have a life expectancy of 3 months and their quality of 
life is 3 on a scale from 0 to 10. The ‘0’ represents the worst health possible 
and ‘10’ represents the best health possible. 
Question 1: 
Which treatment would you advise health policymakers to choose?
 Treatment A improves patients’ quality of life with 3 points (from 3 to 6), but 
does not influence their life expectancy. 
 Treatment B improves patients’ life expectancy with 3 months (from 3 to 6), but 
does not influence their quality of life.
 I do not have a preference for treatment A or treatment B. 
Question 2: 
When choosing treatment A: 
Suppose that the improvement in quality of life by treatment A is unsatisfac-
tory and less than 3 points. According to you, at which point will treatment A 
(improvement in quality of life) be equally good as treatment B (improvement 
in life expectancy of 3 months)?
 An improvement in quality of life of 2.5 points is equally good as an improvement 
in life expectancy of 3 months.
 An improvement in quality of life of 2.0 points is equally good as an improvement 
in life expectancy of 3 months.
 An improvement in quality of life of 1.5 point is equally good as an improvement 
in life expectancy of 3 months.
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 An improvement in quality of life of 1.0 point is equally good as an improvement 
in life expectancy of 3 months.
 An improvement in quality of life of 0.5 point is equally good as an improvement 
in life expectancy of 3 months.
 An improvement in quality of life of 0 points is equally good as an improvement 
in life expectancy of 3 months.
When choosing treatment B:
Suppose that the improvement in life expectancy by treatment B is unsatisfac-
tory and less than 3 months. According to you, at which point will treatment B 
(improvement in life expectancy) be equally good as treatment A ((improve-
ment in quality of life of 3 points)?
 An improvement in life expectancy of 2.5 months is equally good as an improve-
ment in quality of life of 3 points. 
 An improvement in life expectancy of 2.0 months is equally good as an improve-
ment in quality of life of 3 points.
 An improvement in life expectancy of 1.5 month is equally good as an improve-
ment in quality of life of 3 points.
 An improvement in life expectancy of 1.0 month is equally good as an improve-
ment in quality of life of 3 points.
 An improvement in life expectancy of 0.5 month is equally good as an improve-
ment in quality of life of 3 points.
 An improvement in life expectancy of 0 months is equally good as an improve-
ment in quality of life of 3 points.
When choosing the opt-out:
Why do you not have a preference for treatment A or treatment B? 
 Both treatments are equally effective for these patient groups.
 Both treatments are equally ineffective for these patients groups.
 Other: …
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Chapter 7 
How does participating in 
a deliberative citizens panel 
on healthcare priority set-
ting influence the views of  
participants?
Based on: Reckers-Droog VT, Jansen M, Bijlmakers L, Baltussen R, Brouwer 
WBF, van Exel NJA. How does participating in a deliberative citizens panel on 
healthcare priority setting influence the views of participants? Health Policy. 
2020;124(2):143-151.
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Abstract
A deliberative citizens panel was held to obtain insight into criteria considered 
relevant for healthcare priority setting in the Netherlands. Our aim was to 
examine whether and how panel participation influenced participants’ views 
on this topic. Participants (n=24) deliberated on eight reimbursement cases in 
September and October, 2017. Using Q methodology, we identified three dis-
tinct viewpoints before (T0) and after (T1) panel participation. At T0, viewpoint 
1 emphasised that access to healthcare is a right and that prioritisation should 
be based solely on patients’ needs. Viewpoint 2 acknowledged scarcity of 
resources and emphasised the importance of treatment-related health gains. 
Viewpoint 3 focused on helping those in need, favouring younger patients, 
patients with a family, and treating diseases that heavily burden the families 
of patients. At T1, viewpoint 1 had become less opposed to prioritisation and 
more considerate of costs. Viewpoint 2 supported out-of-pocket payments 
more strongly. A new viewpoint 3 emerged that emphasised the importance of 
cost-effectiveness and that prioritisation should consider patient characteris-
tics, such as their age. Participants’ views partly remained stable, specifically 
regarding equal access and prioritisation based on need and health gains. 
Notable changes concerned increased support for prioritisation, consideration 
of costs, and cost-effectiveness. Further research into the effects of delibera-
tive methods is required to better understand how they may contribute to the 
legitimacy of and public support for allocation decisions in healthcare.
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7.1 Introduction
Priority setting in the allocation of healthcare resources is inevitable due to the 
increasing demand for healthcare and resulting pressure on limited budgets. 
Different principles have been proposed for informing allocation decisions, 
including the principles of maximising health and prioritising those who are 
worse off in terms of health [1,2]. The proposed principles to some extent all 
reflect a shared understanding of distributive justice; however, none addres-
ses completely the complex and value-laden problems that arise from the 
need to set priorities [1,3–5]. For example, some have argued that these 
principles insufficiently reflect public views and preferences concerning the 
allocation of scarce resources [6–9]. A considerable part of the public even 
opposes priority setting altogether and considers access to healthcare a right 
to which patients are entitled without exception or restriction [10–12]. Those 
who do support priority setting hold different, sometimes conflicting views 
about the criteria that should be taken into account when setting priorities 
[6–9]. This heterogeneity of public views may partly explain why the outco-
mes of allocation decisions at times lead to public debate and controversy 
[12].
In a time when the public demands greater transparency and accountability 
from their governments and increasingly seeks opportunities to actively par-
ticipate in shaping the policies that affect their lives [13], it has been argued 
that allocation decisions in healthcare could be improved by considering pre-
ferences from the public that are evidence-informed and elicited by means of 
rational democratic deliberations [3,13–15]. Such deliberative methods aim to 
meet the demand for a fair, legitimate, and publicly transparent way of deci-
sion making and may increase support for the outcomes of such decisions as 
they are more informed [3,15–17]. Examples of deliberative methods include 
deliberative focus groups, citizens juries, and citizens panels [17–20] that all 
share the following characteristics: (i) the formation of a small group of citi-
zens who represent a larger population based on predefined characteristics, 
(ii) one or more meetings about the issue of interest, (iii) the preparation 
and dissemination of background information concerning the issue of inte-
rest, (iv) the involvement of experts to either inform the citizens or answer 
their questions about the issue of interest, and (v) the formulation of a set of 
recommendations or proposals based on the participants’ deliberations [17]. 
Deliberative methods are increasingly applied to inform allocation decisions in 
healthcare, even though they are generally more time-consuming, labour-in-
tensive, and expensive than non-deliberative methods (e.g. preference 
elicitation by means of surveys) [21], and very little is known about their 
effect. For example, empirical evidence concerning their effect on allocation 
decisions and the views and preferences of participants is scarce [17–22]. 
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In the autumn of 2017, a deliberative citizens panel was held to obtain insight 
into participants’ views and preferences concerning healthcare priority setting 
and identify the criteria they considered relevant for decisions concerning the 
composition of the basic benefits package of the health-insurance system in 
the Netherlands [23,24]. Health insurance is mandatory for all inhabitants 
of the Netherlands and the basic benefits package covers a broad range of 
curative and preventive treatments to protect citizens against catastrophic 
healthcare spending. Although in some countries deliberative citizens panels 
are more frequently applied, e.g. the citizens council applied by the National 
Institute for Health and Care Excellence (NICE) in the United Kingdom (UK) 
[25], this panel was the first to be applied in the Netherlands in the context of 
healthcare priority setting. A detailed description of the applied deliberative 
approach and results of the panel can be found in Bijlmakers et al. [24]. The 
aim of the current study was to examine whether and how panel participation 
influenced participants’ views on healthcare priority setting. To meet this aim, 
we used Q methodology to investigate the views among participants before 
and after they participated in the panel. This methodology is increasingly 
applied in health services research [7,26] and to identify and describe public 
views on healthcare priority setting [e.g. 17,52,169,170]. In the current study, 
we extended previous applications of this methodology to examine changes 
in participants’ views over time. The application of Q methodology enabled us 
to combine aspects of quantitative and qualitative methods to systematically 
examine whether and how views changed at the group level as well as the 
extent to which individual participants still identified with their initial view-
points after the panel. With this study, we aim to contribute to the existing 
literature on the effect of applying deliberative methods for informing alloca-
tion decisions in healthcare. The approach and results of this study may be 
of interest to public authorities and organisations in the healthcare sector as 
well as in other sectors that apply, or consider applying, deliberative methods 
in the context of policy development and evaluation. Furthermore, the results 
of this study provide insight into the possible additional value of applying deli-
berative methods in the context of healthcare priority setting.
7.2 Methods
7.2.1 Citizens panel
Twenty-four citizens were recruited for panel participation by Motivaction; 
an independent research and consultancy agency in the Netherlands. The 
sampling was aimed at composing a varied, yet balanced, panel regarding 
age, sex, geographical spread, and eight mentality groups (see Table 7.1). 
Each of these groups represents a different set of shared values regarding 
work, leisure, and politics and has a distinct lifestyle and consumption pattern 
[24,27]. For more information on the recruitment of participants and a des-
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cription of the mentality groups, we refer the interested reader to Bijlmakers 
et al. [24] and Motivaction [27].
The panel met during three full weekends between 16 September and 29 
October 29 2017. Two experienced moderators, who were employed by Moti-
vaction, lead the panel’s deliberations on eight reimbursement cases: dental 
(orthodontic) braces for children, medicines and informal care for patients 
with Alzheimer’s disease, for patients with heartburn (pyrosis), and for child-
ren with Attention Deficit Hyperactivity Disorder, the orphan drug eculizumab 
for patients with atypical Hemolytic Uremic Syndrome (aHUS), a total body 
scan, bariatric surgery and secondary prevention for patients with obesity, 
and a hip replacement for elderly patients [24]. These cases concern a broad 
range of health technologies and patient populations, and were selected to 
represent the variety of criteria, arguments, dilemmas, and societal values 
that the panel could deem relevant for setting priorities [23,24]. The first 
four cases were discussed during the first weekend and the latter four during 
the second weekend. Each case was introduced with a short video in which 
information was provided about the prevalence, symptoms, and course of 
the disease as well as the available treatment options. After watching the 
video, participants read written case descriptions individually and deliberated 
on them in small groups, followed by plenary deliberations. During the third 
weekend, participants were asked to prioritise the eight cases for reimbur-
sement and discuss the trade-off between the criteria they deemed relevant 
for setting these priorities. In three separate plenary sessions that were held 
during the second and third weekend, participants were given the opportunity 
to discuss their questions about medical, ethical, and economic aspects of 
healthcare priority setting with three experts on these topics who also had 
expertise on the reimbursement process in the Netherlands. These experts 
were instructed to answer participants’ questions based on their professional 
knowledge and experience, but not divulge their personal views on this topic. 
More information on the selection of the reimbursement cases and a detailed 
overview of the programme of the panel can be found in Bijlmakers et al. [24]. 
On 4 September, i.e. two weeks before the panel commenced, an information 
meeting was held during which the participants received general information 
Table 7.1 Panel characteristics (n=24)a
 n (%) Mean (SD) Min Max
Age (Years) 44.5 (17.4) 20.0 72.0
Sex (Female) 12 (50.0)
Education levelb
   Middle 
   High
9 (37.5)
15 (62.5)
a Participants were distributed equally across the eight mentality groups and, therefore, this characteristic is omitted 
from the table; b Middle = middle vocational and secondary school, High = higher vocational and academic edu-
cation. 
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about the topic, objective, and procedure of the panel. The provided informa-
tion was kept sparse to avoid influencing the participants before the start of 
the panel [24]. After the first weekend, the participants received a brochure 
with information about increasing healthcare expenditures, the organisation 
and financial structure of the Dutch healthcare system, and how healthcare 
priorities are currently set in the Netherlands. This information was provided 
to facilitate more in-depth deliberations during the second and third weekend 
of the panel [24].
7.2.2 Approach
Our study was conducted in three consecutive steps common to Q metho-
dology studies [26]. First, we developed a comprehensive set of statements 
relating to the topic of healthcare priority setting in the Netherlands. Second, 
we collected data by administering the same statement-ranking exercise 
twice: before the participants received the information package during the 
information meeting and directly after the final panel meeting. Third, we ana-
lysed the collected data to examine possible changes in participants’ views 
during the course of the panel. We describe the steps in more detail below.
7.2.3 Statement set
We developed a structured statement set that was broadly representative 
of our topic of interest, and hence aimed to cover all issues that participants 
could deem relevant for healthcare priority setting in the Netherlands. For 
this, we adopted the conceptual framework of the most recently conducted 
Q methodology study on healthcare priority setting in the Netherlands [9]. 
This study focused specifically on prioritising end-of-life care in the Nether-
lands and its framework distinguished 20 characteristics that are categorised 
into six domains: characteristics of the patient, characteristics of the illness, 
characteristics of the treatment, health effects of treatment, broader effects 
of treatment, and moral principles. To better align this framework with our—
more general—topic of interest, we additionally inspected the framework of 
a Q methodology study that focused more generally on healthcare priority 
setting in ten European countries, among which the Netherlands [7]. After 
considering the relevance of the characteristics included in these two frame-
works for the current study, we removed statements concerning ‘prior health 
consumption/previous health profile’, ‘distribution of fixed health gains/thres-
hold effect’, and ‘capacity to benefit’ from the first framework [9] and included 
statements concerning ‘rarity of the disease’, ‘costs/budget impact of the tre-
atment’, and ‘supplier-induced demand’ from the second framework [7]. We 
then selected 25 statements from the first framework [9] and one statement 
from the second framework [7], and supplemented these with two statements 
from related Q methodology studies that were conducted in the UK [6,8]. In 
order to achieve a balanced statement set that covered all issues of interest 
to this study, we formulated seven additional statements based on criteria and 
 Does participating in a citizens panel influence participants’ views? | 161
  7 
considerations that policy makers in the Netherlands deem relevant in alloca-
tion decisions that were not yet reflected in the statement set [23,24,28,29]. 
Finally, we translated the statements into the Dutch language. Because the 
set was based on four previous carefully designed and piloted studies, no pilot 
test was conducted.
Table 7.3 in the results section includes the final set of 35 statements and their 
origin. The 20 characteristics in six domains and the associated statement 
numbers are presented in Appendix 7.1.
7.2.4 Data collection
All 24 participants in the citizens panel also participated in this study. This 
sample size was sufficient for the purpose of this analysis [26,30]. The par-
ticipants completed the first statement-ranking exercise directly after the 
information meeting on September 4, 2017 (T0) and the second during the 
final panel meeting on October 29, 2017 (T1). Before performing the exercise, 
participants received an oral group instruction on how to perform the exercise 
from one of the researchers (MJ). They received a copy of these instructions 
on paper (see Appendix 7.2), for reference. This researcher remained present 
during the exercise in case participants had any questions about the proce-
dure. Subsequently, participants received a set of the 35 statements printed 
on cards, a sorting grid (see Appendix 7.3), and a response sheet. Participants 
first read all statements and divided them into three piles (‘agree’, ‘disagree’, 
and ‘neutral’). Then, they re-read the statements in the ‘agree’ pile, selected 
the two they agreed with most, and placed them in column 9 of the sorting 
grid, followed by placing the next three statements they then agreed with 
most in column 8 and so on until they finished this pile. Next, they followed 
the same procedure for the ‘disagree’ pile, starting with column 1, and finally 
placed the statements in the ‘neutral’ pile in the remaining open spots in the 
middle of the grid. After finishing the exercise, participants used the response 
sheet to explain in writing their motivation for placing the statements in the 
extreme positions of the grid, i.e. columns 1 and 9. The columns were presen-
ted to participants as being from 1 to 9 on the sorting grid to avoid imposing 
connotations of negative, neutral or positive to columns of the grid; however, 
we recoded the columns to -4 to +4 for the analysis of the data and interpre-
tation of the viewpoints.
7.2.5 Data analysis
We conducted a principal component analysis followed by oblimin rotation 
to identify groups of participants with highly (Pearson) correlated statement 
rankings at both time points separately. This type of oblique rotation method 
is typically used to allow for a non-orthogonal rotation. We selected the best 
number of factors from all possible factor solutions that were supported 
by the data by applying the criteria: (i) eigenvalues of factors >1 and (ii) a 
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minimum of two non-confounded ‘exemplars’ per factor. Exemplars are those 
participants with (i) a factor loading above the significance threshold of 0.33 
(p<0.05; calculated as 1.96/√35, where 35 is the number of statements) and 
(ii) for whom the square of the loading for a factor is larger than the sum of 
the square loadings for all other factors [30,31]. Based on inspections of the 
correlations between factors and the interpretation of the factors in each 
factor solution, we selected the factor solution that lead to the most intelligi-
ble reduction of the data. Subsequently, we computed factor arrays for each 
factor. These arrays represent how a participant with a correlation of 1 with a 
factor would have ranked the statements. We used the factor arrays, including 
the characterising and distinguishing statements, for interpreting the factors 
as viewpoints. Characterising statements are those that hold the positions -4, 
-3, +3, and +4 in the factor arrays, and as such represent the statements that 
participants with a specific viewpoint least and most agreed with. Distinguis-
hing statements are those with a statistically significantly different position 
in a factor array from their position in the array of at least one other factor 
(p<0.05; calculated based on the absolute difference in z-scores of state-
ments between the factor arrays). We used the verbatim quotes of exemplars 
that we obtained from the response sheets to help describe the viewpoints in 
the wording of the participants. 
We examined changes in viewpoints in multiple ways. At the level of the view-
points, we examined the correlations and the main similarities and differences 
between the viewpoints at T0 and T1. At the level of the participants, we 
examined the extent to which participants associated themselves with the 
initial viewpoints, i.e. the viewpoints identified at T0, after they participated in 
the panel (at T1). For this, we combined the data of T1 with the factor arrays 
of T0 and calculated the mean (SD) difference in correlation with the initial 
viewpoints between T0 and T1. Furthermore, we examined the transitions 
between viewpoints made by exemplars over time and the extent to which the 
views of participants converged after the panel. We did this by examining the 
mean (SD) correlations of the statement rankings between participants at T0 
and T1 and applying an F-test for small sample sizes to examine the difference 
in the associated variances.
We used Cohen’s classification system for interpreting the obtained corre-
lation coefficients [32]. In line with this system, we interpreted correlations 
below 0.30 as low, between 0.30 and 0.50 as moderate, and above 0.50 as 
high. 
We used the qmethod package in Rstudio 1.0.143 (Rstudio, Inc., Boston, MA, 
USA) for conducting the analyses [31].
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7.2.6 Ethics
The Committee on Research Involving Human Subjects of the Radboud Uni-
versity Medical Center reviewed and waived ethical approval for this study 
(reference 2017-3444). 
7.3 Results
Table 7.2 presents the participants’ factor loadings with the viewpoints at T0 
and T1, respectively. 
Table 7.2 Factor loadings at T0 and T1 (n=24)
Views at T0 Views at T1
id 1 2 3 1 2 3
1 0.74* 0.02 -0.28 0.85* -0.17 0.10
2 0.72* 0.00 0.19 0.32 0.37 -0.33
3 0.50 0.55* -0.06 0.16 0.67* -0.35
4 0.58* 0.46 0.25 0.80* 0.14 0.27
5 0.94* -0.20 -0.01 0.66* 0.14 -0.39
6 0.37 0.28 0.28 0.03 0.69* -0.23
7 0.77* 0.21 -0.15 0.42 0.47 0.25
8 0.31 0.28 -0.52* 0.21 0.49* 0.10
9 -0.13 0.03 0.71* 0.12 0.14 0.54*
10 -0.01 -0.01 0.82* 0.14 -0.13 -0.22
11 -0.16 0.89* 0.10 0.13 0.73* 0.02
12 -0.09 0.79* -0.18 -0.38 0.85* 0.01
13 0.81* -0.04 0.21 0.62* -0.03 -0.37
14 0.62* -0.31 0.39 0.30 0.11 -0.73*
15 0.20 0.76* 0.02 0.59* 0.42 0.13
16 0.91* -0.01 -0.17 0.60* 0.36 -0.01
17 0.75* -0.13 0.04 0.40 0.05 0.63*
18 0.84* 0.06 0.00 0.86* -0.08 -0.22
19 0.47 0.63* 0.07 0.18 0.83* -0.03
20 0.25 0.48* 0.11 -0.02 0.78* -0.03
21 -0.28 0.78* -0.25 -0.13 0.73* 0.38
22 0.78* -0.01 -0.14 0.85* -0.05 0.03
23 0.05 0.68* 0.01 0.15 0.54 0.53
24 0.72* 0.22 0.13 0.47 0.26 -0.42
Explained variance (%) 33.6 19.2 8.8 22.6 22.5 11.1
Exemplarsa (n) 12 8 3 8 8 3
a The factor loadings of exemplars are indicated with an asterisk (*). These loadings meet the following two criteria: 
(i) the loading is above the significance threshold of 0.33 (p<0.05, calculated as 1.96/√35, where 35 is the number 
of statements) and (ii) the square of the loading for a factor is larger than the sum of the square loadings for all 
other factors [26,30].
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Table 7.3 on the previous pages presents the factor arrays, including the 
characterising and distinguishing statements. Below, we describe the view-
points before and after the panel and discuss the changes in viewpoints. We 
present the numbers of the most relevant statements within parenthesis with 
a hashtag (#), followed by their position in a factor array, e.g. (#1,+4). Distin-
guishing statements are presented with an additional asterisk, e.g. (#1,+4*). 
Verbatim quotes of exemplars are presented within quotation marks, followed 
by their identification number, e.g. (id2).
7.3.1 Viewpoints before the panel
At T0, we identified three factors that together explained 61.6% of the vari-
ance in the statement rankings. The correlations between the factors were 
low to moderate (ρ=0.14 for 1 vs. 2, ρ=-0.01 for 1 vs. 3, ρ=-0.30 for 2 vs. 3). 
The factors had 12, eight, and three exemplars, respectively. Factor 3 had two 
positive exemplars (id9 and id10) and one negative exemplar (id8) and was, 
therefore, interpreted as being bipolar. One participant (id6) was statistically 
significantly associated with factor 1; however, did not meet the second crite-
rion for being identified as an exemplar.
Viewpoint 1
People with viewpoint 1 considered access to healthcare as a right and belie-
ved that everyone should have equal access to healthcare. According to 
people with this view access should solely be based on patients’ need for 
care and not on their personal characteristics, such as their gender, age, 
ethnicity (#16,+3; #18,-3), lifestyle (#19,-4*; #28,-4*), or socio-economic 
status (#13,-3). “Everyone has a right to healthcare [and] personal characte-
ristics are not important at all” (id7). As prioritisation in healthcare should be 
based on patients’ need for care, “there should be no discrimination [between 
patients]” (id24). People with this view believed that healthcare costs should 
play no role in priority setting as “you cannot regard a life in an economic 
way” (id4). If there is a way of helping patients, it is morally wrong to deny 
them this treatment (#14,+3*). People holding this view did not believe that 
a treatment should receive less priority if the total costs of treating a disease 
(for all patients) are high (#31,-3). Rather, if a treatment is costly in relation 
to its benefits, but is the only treatment available, it should still be provided 
(#21,+3*). People with this view also believed that patients’ choice for treat-
ment should be supported, even if it is very costly in relation to its benefits 
(#11,+2*). “Everyone has a right to healthcare; even when there is no or little 
treatment benefit you cannot deny treatment [to patients]!” (id 13). They 
emphasised that you cannot put a price on life (#17,+4) and if it is possible 
to save a life, every effort should be made to do so (#29,+4). “Regardless of 
money, if it is possible, a life has to be saved” (id18). 
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Viewpoint 2
People with viewpoint 2 believed that everyone has a right to healthcare, but 
that this does not mean that everything can always be reimbursed (#25,+3*). 
“Everyone is insured and has […] a right to healthcare, but not everything 
can always be covered by the [public health] insurance” (id15). As “health-
care costs keep rising, there should be restricting measures” (id21). People 
with this view emphasised the importance of the effectiveness of treatments. 
The health system should be about getting the greatest benefit overall for 
society (#27,+3*) and there is no point in providing treatments that do not 
generate considerable health benefits (#23,+3*). Accordingly, they support 
prioritisation based on treatment characteristics, such as the type and size of 
health gains from treatment, but like viewpoint 1, they oppose prioritisation 
based on patient characteristics, such as their age (#18,-4). They further 
emphasised that, at the end of life, it is more important to provide a death 
with dignity than treatments that may extend life only for a short period of 
time (#26,+4*). They neither believed that, if it is possible to save a life, every 
effort should be made to do so (#29,-3*) nor that it is important to respect 
the wishes of patients who feel they should take every opportunity to extend 
their life (#12,-3*). They do believe that priority should be given to preventive 
healthcare (#7,+4*), because “this can save a lot of money” (id12).
Viewpoint 3
People with viewpoint 3 were positively oriented towards prioritisation based 
on patient characteristics, such as their age. They believed that children 
should be given priority over adults (#2,+4), because they may benefit from 
treatment longer (#18,+2*). “Children hold the future and, if […] a choice has 
to be made, the child is the first one entitled to receiving care” (id9). However, 
they opposed prioritisation based on lifestyle (#3,-4*). People holding this 
view also found that broader treatment effects should be taken into consi-
deration. They believed that treatment of illnesses that put a high burden on 
families of patients should receive priority (#24,+3*), because treating these 
patients benefits them as well as others (#8,+3*). Consequently, treatments 
that are beneficial for both the patient and society should be allowed to cost 
more (#32,+2*). Although being positively oriented towards prioritisation in 
healthcare, they emphasised that you cannot put a price on life (#17,+4) and 
that, if it is possible to save a life, every effort should be made to do so 
(#29,+3). They believed there is a sense in saving lives, even if the quality of 
those lives will be really bad (#22,-3*), and in providing treatments that do 
not generate considerable health gains (#23,-2*). 
In contrast, people who opposed this viewpoint were in favour of priority 
setting based on lifestyle (#3,-4*). They also believed that priority should be 
given to those treatments that generate the most health #5,-2*) and that the 
health system should restrict itself to treatments that have proven to bring 
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about health gains (#10,-4*). “If there is evidence that a treatment is effec-
tive, it should always be reimbursed” (id8).
7.3.2 Viewpoints after the panel
At T1, we identified three factors that together explained 56.3% of the variance. 
The correlations between viewpoints were again low to moderate (ρ=0.30 for 
1 vs. 2, ρ=-0.18 for 1 vs. 3, ρ=0.06 for 2 vs. 3). The factors had eight, eight, 
and three exemplars, respectively. Factor 3 had two positive exemplars (id9 
and id17) and one negative exemplar (id14) and was, therefore, interpreted as 
being bipolar. Four participants (id2, id7, id23, and id24) were ‘mixed loaders’ 
as they were statistically significantly associated with more than one factor. 
They did not meet the second criterion for being identified as exemplars. One 
participant (id10) was a ‘null loader’ as s/he was not statistically significantly 
associated with any of the factors. 
Factors 1 and 2 at T1 strongly resembled factors 1 and 2 at T0, with ρ=0.84 
and ρ=0.78, and hence can be regarded as slightly different manifestations 
of their corresponding viewpoints at T0. Therefore, we describe only the main 
similarities and differences between these viewpoints at T0 and T1. The cor-
relation between factors 3 at T0 and T1 was ρ=0.32 and, therefore, we regard 
and describe factor 3 at T1 as a newly emerged viewpoint.
Viewpoint 1
Before the panel, people with viewpoint 1 emphasised equal access to care 
and that all treatments should be available for patients. Like people with this 
view before the panel, people with viewpoint 1 at T1 believed that it is morally 
wrong to deny patients treatment, if there is a way of helping them (#14,+4*) 
or if a treatment is the only one available (#35,+3*). They also believed that 
access to care should be based on need and not on patient characteristics, 
such as their gender, age, ethnicity (#16,+4), or or socio-economic status 
(#13,-4*). However, people with this view less were strongly opposed to 
prioritisation based on lifestyle than those with viewpoint 1 at T0 (#19,-1*; 
#28,-2) and more strongly opposed to prioritisation based on characteristics 
of the illness, such as its rarity (#33,-3). They were notably more considerate 
of treatment costs. They believed less strongly that you cannot put a price 
on life (#17,+2*) and that treatment should always be supported, even if it is 
very costly in relation to its health benefits (#11,0*). They also believed less 
strongly that a treatment may cost more if it is not only beneficial for a patient 
but also for society (#32,-3).
Viewpoint 2
Before the panel, people with viewpoint 2 believed that everyone has an equal 
right to healthcare and emphasised the importance of treatment effectiveness 
and efficiency. Like people with this view before the panel, people with vie-
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wpoint 2 at T1 believed that everyone has a right to healthcare, but that this 
does not mean that everything can always be reimbursed (#25,+3*). “There 
simply is a limited budget [and] choices have to be made” (id19). People with 
this view believed that access to care should be based on need for care and 
not on patient characteristics, such as their gender, age, ethnicity (#16,+3; 
+18,-3), or socio-economic status (#13,-4*). However, people with this view 
were less strongly opposed to prioritisation based on lifestyle (#3,-2). They 
believed more strongly than those with viewpoint 2 at T0 that inexpensive tre-
atments can be paid out of pocket (#30,+4) as “it is relatively cheap” (id6) and 
“does not really affect patients’ disposable income” (id12). They also believed 
more strongly that medical tests for the early detection of diseases that often 
lead to unnecessary treatments, should not be reimbursed (#34,+2*) and that 
if you choose to spend a lot of money on a specific patient group, you have 
to realise there will be less money left for other groups (#15,+3). For people 
with this viewpoint, it was “more important that patients can die with dignity” 
(id20) than to extend life for a short period of time (#26,+4*). 
Viewpoint 3
People with viewpoint 3 at T1 believed that prioritisation should be based on 
the health effect of treatment and patient characteristics such as their gender, 
age, and ethnicity (#1,+2*; #2,+2*; #13,-1*; #16,-3*; #18,+2*), and lifestyle 
(#3,-2; #19,+1; #28,-1). “People do have control over their lives, they cannot 
live recklessly and still benefit” (id9). According to people with this view, the 
health system should restrict itself to treatments that have proven to bring 
about health gains (#10,+3*). They considered treatments that generate the 
most health to be the most important (#5,+3*) and believed there is neither 
a point in providing treatments that do not generate significant health gains 
(#23,+4*), nor in saving lives if the quality of those lives will be really bad 
(#22,+4*). People with this view did not agree with the statements that you 
cannot put a price on life (#17,-4*) and that it is morally wrong to deny patients 
treatment (#14,-3). They believed that treatments that are very costly in rela-
tion to their health gain should not be reimbursed (#9,+3*). Nonetheless, they 
disagreed that medical tests for the early detection of diseases, that often 
lead to unnecessary treatments, should not be reimbursed (#34,-4*).
In contrast, people who opposed this viewpoint believed that “costs are not 
the only thing that matters” (id14). If a treatment is the only available treat-
ment for a disease it should be reimbursed and if it is not only beneficial for 
the patient but also for society it may cost more (#32,-3; #35,-2*). “If costs 
need to be taken into account, people can pay for inexpensive treatments 
themselves in order to reimburse expensive treatments [from public funding]” 
(id14).
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7.3.3 Association with initial viewpoints
The mean (SD) correlation between participants’ statement rankings at T0 
and T1 was 0.57 (0.17), ranging from 0.19 to 0.78 (see Appendix 7.4). For 18 
participants the correlation between T0 and T1 was strong, for three mode-
rate, and for another three low. Although none of the participants ranked the 
statements in exactly the same way, these relatively high correlations indicate 
that the views of most participants were largely similar before and after the 
panel. 
Table 7.4 presents the extent to which participants associated themselves 
with the initial viewpoints, i.e. the viewpoints from before the panel (at T0), 
after they participated in the panel (at T1). These results show that most 
participants (n=19) correlated less strongly with the initial viewpoint 1 at T1, 
with a mean (SD) decrease in correlation of 0.08 (0.21). Of the participants, 
17 correlated more strongly with the initial viewpoint 2 at T1 with a mean 
(SD) increase in correlation of 0.07 (0.21) and 18 correlated less strongly with 
the initial viewpoint 3 at T1, with a mean (SD) decrease in correlation of 0.15 
(0.22).
Table 7.5 presents the transitions between viewpoints made by exemplars 
over time. These results show that of the 12 exemplars with viewpoint 1 at 
T0, seven made no transition and still adhered to this viewpoint, two changed 
their view to viewpoint 3, and three were no longer associated with one of 
the viewpoints at T1. Of the eight exemplars with viewpoint 2, six made no 
transition and still adhered to this viewpoint, one changed his/her view to vie-
wpoint 1, and one was no longer associated with one of the viewpoints at T1. 
Of the three exemplars with viewpoint 3, none still adhered to this viewpoint 
at T1. One exemplar changed his/her view to viewpoint 2, one changed his/
her view to the new viewpoint 3, and one was no longer associated with one 
of the viewpoints at T1.
Table 7.5 Transition matrix of exemplars’ views
 Views at T1
1 2 3 No distinct viewpoint Total
Views at T0
1 7 NA 2 3 12
2 1 6 NA 1 8
3 NA 1 1 1 3
No distinct viewpoint NA 1 NA NA 1
Total 8 8 3 5 24
NA, Not Applicable.
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7.3.4 Convergence between views
At T0, the mean (SD) correlation between participants’ statement rankings 
was 0.32 (0.28), ranging from -0.43 to 0.79. At T1, this was 0.32 (0.25), 
ranging from -0.26 to 0.73. See Appendices 7.5 and 7.6 for the correlation 
matrices of participants’ rankings at T0 and T1. The difference in variance 
decreased marginally between the rankings at both time points (p<0.001), 
indicating some modest convergence between the views of participants over 
time. 
7.4 Discussion
In this study, we examined whether and how participation in a deliberative 
panel influenced the views of participants on healthcare priority setting. 
Our main finding is that participants’ views before and after the panel partly 
remained stable. There was a strong resemblance between two of the three 
views identified before and after the panel, while the third view was distinctly 
different at both time points and 18 participants showed high correlation 
between their views at T0 and T1. Equal access to healthcare, prioritisation 
based on patients’ needs, and the relevance of the size and type of treatment 
benefits remained important during the course of the panel. We observed 
two notable changes. Firstly, support for prioritisation in healthcare gene-
rally seems to have increased after panel participation. Secondly, participants 
became more considerate of healthcare costs and of cost-effectiveness as a 
relevant criterion for setting priorities in healthcare. 
To our knowledge, this study is one of the few to examine changes in views 
on healthcare priority setting through deliberation and the first to do so in 
the Netherlands. This limits us in our ability to compare our results with those 
of other studies. However, we can compare our results to two other studies 
that examined the effect of deliberation on views in the context of healthcare 
priority setting and two Q methodology studies that examined views on this 
topic in the Netherlands. Dolan et al. [21] examined the effect of deliberation 
on views in a sample of 60 patients in the UK. They observed a trend towards 
treating different patient groups more equally and participants who were 
initially unwilling to prioritise between patient groups remained so after deli-
beration. Abelson et al. [17] examined the effect of deliberation in a sample 
of 46 participants in Canada, by using a controlled design. They found that 
participants’ views became more susceptible to change when more delibera-
tion was introduced. Participants who changed their view did so in a similar 
direction, indicating that deliberation may lead to increased consensus among 
participants. Like in these studies, we found views opposing priority setting 
that remained relatively stable and that deliberation can lead to changes in 
viewpoints as well as to convergence between them. Van Exel et al. [7] and 
Wouters et al. [9] applied Q methodology to examine views on healthcare pri-
ority setting in the Netherlands. Like in these studies, we found that members 
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of the public—before deliberation—generally hold a view on priority setting 
that emphasises the importance of equal access and disregards costs, while 
some recognise the scarcity of healthcare resources and are willing to accept 
certain criteria for setting priorities.
Before discussing the main strengths and limitations of our study, we would 
like to reflect on the bipolar nature of viewpoints 3 at T0 and T1. Previous lite-
rature shows that there are different ways to deal with the computation and 
interpretation of bipolar factors. Some have argued that negative exemplars 
should be excluded from the computation of the factor array as this leads to 
a clearer, or purer, interpretation of the positive pole of the viewpoint [e.g. 
199]. Others have argued that negative exemplars should be included in the 
computation of the factor array. Excluding them would lead to an unbalan-
ced interpretation of the factor, as it no longer fully represents the views of 
the participants who define the factor (albeit on different sides of the pole) 
[26]. Here, we followed the latter argument and chose to retain the negative 
exemplars in the computation of the factor arrays and the interpretation of 
the bipolar factors 3 at T0 and T1. In order to explore the implications of this 
choice, we also inspected a solution excluding the negative exemplars. At 
T0, the correlation between factors 3 with and without negative exemplars 
was 0.97, and hence these factors seem to portray the same view. At T1, the 
correlation between factors 3 with and without negative exemplars was 0.65 
and the positioning of some statements changed considerably. More speci-
fically, compared to the interpretation presented in the Results section, the 
viewpoint would agree less strongly that personal characteristics should be 
taken into account in healthcare priority setting (#1,+1*; #2,+1*; #13,-4*; 
#16,-1*; #18,+1*), and more strongly that individual responsibility is relevant 
(#3,-3*) and inexpensive treatments can be paid out of pocket (#30,+4). Alt-
hough excluding the negative exemplar leads to a slightly different viewpoint 
3 at T1, it remains a new view as compared to viewpoint 3 at T0 (excluding 
the negative exemplar; ρ = -0.03), and, therefore, does not affect the main 
finding of our study.
The main strength of our study lies in the repeated use of Q methodology to 
examine in depth whether and how deliberation influences views on healthcare 
priority setting. To our knowledge, this approach has not been applied before, 
neither in nor outside the field of healthcare. Despite this strength, some limi-
tations need to be discussed. Firstly, although we speak of the ‘influence’ of 
deliberation on views, no causal conclusions can be drawn in the absence of a 
control group. Secondly, the reimbursement cases may have primed the need 
for setting priorities and the relative importance of certain characteristics 
after the panel. We do note that the cases were carefully selected to repre-
sent all issues participants may have deemed relevant for setting priorities in 
a broad range of health technologies and patient populations. In that sense, 
they were aligned with the broad considerations represented in the statement 
set. Therefore, insofar the cases influenced the statement rankings after the 
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panel we think this influence is relevant in the context of this study. Finally, 
lower-educated people are not represented in the panel. However, this is only 
problematic if they differ from higher-educated people with respect to their 
susceptibility for deliberation. This we do not know and would be a relevant 
topic for further research.
Our study contributes to the limited literature on the effect of deliberative 
methods by giving insight into whether and how deliberation influences views 
on healthcare priority setting. Based on our results, some questions can be 
raised regarding the application of deliberative methods in the context of 
healthcare priority setting. For example, if the purpose is to inform allocation 
decisions, questions can be raised about the extent to which participants’ 
views over time still represent the actual views of the public. If the latter is 
desired in a panel, one could argue that the time anyone participates in such 
a panel should be restricted and that panel participants should regularly be 
replaced by other members of the public. However, if changes in views, as 
observed here, are interpreted as the effect of learning and the purpose is 
that better informed and more considered views are represented in a panel, 
it can also be argued that panel members should participate in a panel for a 
longer period of time. In this case, one could also argue against the application 
of a deliberative citizens panel and in favour of better information provision 
to the public and more public debate, through which a similar learning effect 
perhaps can be achieved in members of the public at large. Notwithstanding, 
it is important to note that it is unlikely that any one of these approaches will 
lead to public consensus about allocation decisions. The recurrent finding in 
the literature that views on priority setting in healthcare differ and can con-
flict, together with the current finding that views remain diverse and only 
moderately converge after deliberation, suggests that any allocation decision 
will probably still be met with opposition from some group in society. Still, 
insight into the diversity of views is important to be able to understand the 
opposition that allocation decisions can bring about and how the outcomes of 
decisions, if so desired, can be better aligned with societal preferences.
We appreciate that, based on the design and results of the current study 
it remains unclear why exactly participants’ views changed and the extent 
to which their views changed under the influence of, for example, the other 
participants, information provided, and experts consulted. If changes do not 
result from the deliberations, but rather from external influences (e.g. from 
stakeholders, such as experts, patients, and industry), a deliberate panel may 
have limited additional value as these views usually are already represented 
in allocation decisions. The crucial question in this context is the purpose of 
applying deliberative panels. Is it for policy makers to consult citizens or give 
them a vote in allocation decisions, strengthen the appraisal of available evi-
dence, increase the legitimacy of decisions, or rather to predict or increase 
public support for the outcomes of such decisions? Regardless of the purpose, 
it is important that citizens contribute in a way that is complementary to 
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other stakeholders. Although answering these questions lies outside the 
scope of this paper, they are related to the issue that panel participants may 
experience (moderate) changes in their viewpoints over time. Moreover, they 
emphasise that further research is indispensable for applying these methods 
in a way that contributes to the legitimacy of and public support for allocation 
decisions in healthcare.
7.5 Conclusions
Our study showed that participants’ views partly remained stable over the 
course of the panel, specifically regarding equal access to healthcare, priori-
tisation based on patients’ needs, and the importance of the size and type of 
treatment benefits. Notable changes after deliberation concerned the incre-
ased support for prioritisation, consideration of costs, and relevance of a 
cost-effectiveness criterion in allocation decisions. Considering the increasing 
interest in deliberative methods among policy makers in healthcare and the 
limited empirical evidence concerning the effect of deliberative methods on 
participants’ views and preferences, further research is required to better 
understand how deliberative methods can contribute to the legitimacy of and 
public support for the outcomes of allocation decisions in healthcare.
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Appendix 7.1: Domains and characteristics of the statements 
Table 7.1.1 Statements according to their domains and characteristics
Domain Characteristic Statement #
A. Characteristics of the patient 1. Age(ism)/fair innings 1, 18, 2
B. Characteristics of the illness 2. Severity 20
3. Rarity 33, 35
4. Rule of rescue 29
5. Probable cause/culpability 19, 28, 3
C. Characteristics of the treatment 6. Availability 21, 10
7. Costs/budget impact 30, 31
8. Efficiency 9
D. Health effects of treatment 9. Size of the effect 5, 27, 4, 23
10. Length vs. quality of life 22
11. Start-point before/end-point after treatment 6
12. Direction of the effect: health gain/loss avoidance 7
13. Supply induced demand 34
E. Broader effects of treatment 14. Being dependent/caregiving effect 24
15. Having dependents/family effect/productivity 8, 32
16. Dignified end of life 26
F. Moral principles 17. Patient choice 11, 12
18. Values 17, 14, 25
19. Income/contribution 13
20. Equality 16, 15
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Appendix 7.2: Instruction for participants
These instructions will guide you through the study in a step-by-step manner. 
Before you start, please read every step in its entirety. 
1. The healthcare budget is limited and hence choices have to be made 
about which treatments can and which cannot be reimbursed from the 
basic health-insurance package. Shortly, you will read 35 statements 
about how to allocate the available healthcare resources in an optimal 
way. We will ask you to what extent you agree with these statements. 
As this study focuses on your personal view, there will be no right or 
wrong answers. 
2. Please read the statements carefully and divide them into three piles: 
one pile for statements with which you agree, one pile for statements 
with which you disagree, and one pile for statements with which you do 
not explicitly agree or disagree, which are unclear, or which you regard 
as irrelevant. The numbers on the cards (from 1 to 35) have no other 
meaning than to help you complete the exercise.
3. Take the pile with statements with which you “AGREE”. Read these sta-
tements again and select the two statements with which you “AGREE 
MOST”. Place these two statements in the two rightmost boxes on the 
large sorting grid, below the “9”. It does not matter which of the two 
statements you place at the top or at the bottom. Next, select from the 
remaining pile of statements with which you “AGREE” the three state-
ments with which you agree most and place them in the three boxes 
below the “8”. Continue with this until all statements with which you 
“AGREE” have been placed on the sorting grid. 
4. Take the pile with statements with which you “DISAGREE”. Read these 
statements again and, like in the previous step, select the two state-
ments with which you “DISAGREE MOST”. Place these two statements 
in the two leftmost boxes on the sorting grid, below the “1”. It does 
not matter which of the two statements you place at the top or at the 
bottom. Like in the previous step, continue with this until all statements 
with which you “DISAGREE” have been placed on the sorting grid. 
5. Now take the remaining pile with statements. Read these statements 
again and place them in the remaining open spaces in the middle of the 
sorting grid, in the way you think they should be placed. 
6. You have now placed all the statements on the sorting grid. Read them 
all again carefully and change the placement of statements if you feel 
the need to do so. 
7. Finally, complete the questions on both pages of the response sheet. 
Please leave the sorting grid and the statements as they are, we will 
document this for you. 
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8.1 Introduction
The increasing demand for healthcare and the resulting pressure on limited 
budgets renders priority setting in the allocation of healthcare resour-
ces inevitable. It has been argued that an optimal allocation of healthcare 
resources involves setting priorities that contribute to meeting efficiency as 
well as equity objectives of publicly financed healthcare systems. Whilst an 
increasing number of countries integrates societal concerns for equity with 
concerns for efficiency into the decision-making framework, important ques-
tions remain about what and how equity considerations should be integrated 
and what (relative) weight these considerations should receive in resource-al-
location decisions. This thesis addressed these questions with the objective 
to contribute to the improvement of the decision-making framework by provi-
ding further insight into societal concerns for equity, in particular for priority 
setting based on disease severity and the age of patients.
This final chapter discusses the main findings of this thesis in relation to the 
research questions outlined in Chapter 1. Furthermore, this chapter discusses 
the strengths and limitations of this thesis and highlights several of its impli-
cations for policy and future research.
8.2 Main findings
Chapter 2 examined the normative justification and empirical support for 
equity weighting based on proportional shortfall in the Netherlands (rese-
arch question 1). The results of this chapter indicated that the decision model 
in which severity-based equity weights are applied in economic evaluations 
is generally supported and increasingly used for healthcare priority setting 
in the Netherlands. However, the results also indicated that theoretical and 
empirical support for defining disease severity in terms of proportional short-
fall may be limited. Proportional shortfall combines aspects of the renowned 
severity and fair innings approaches and may, therefore, insufficiently reflect 
societal preferences for either of these two approaches in resource-allocation 
decisions. Proportional shortfall may further insufficiently reflect age-related 
preferences in society, in particular for prioritisation of younger patients in 
resource-allocation decisions. Empirical evidence on the relationship between 
societal preferences for priority setting based on disease severity (e.g. defined 
in terms of proportional shortfall) and the age of patients is scarce. Therefore, 
we conducted a series of empirical studies to obtain further insight into the 
relative strength of these preferences. Chapters 3 to 5 described the results 
of these studies. 
Chapter 3 examined how much weight members of the public the Netherlands 
attach to disease severity and the age of patients in resource-allocation deci-
sions (research question 2). We applied the person trade-off approach in an 
innovative manner to estimate separate and combined weights for priority 
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setting based on disease severity and age. When estimating these weights 
separately, we found that respondents, on average, attached a higher weight 
to allocating resources towards more severely ill patients and towards younger 
patients. When estimating these weights jointly, we found that respondents, 
on average, attached a higher weight to allocating towards younger patients, 
even when they were less severely ill than older patients. We further found 
that the implied equity weights were dependent on the type of difference (i.e. 
in terms of disease severity and/or age) and size of the difference between the 
patient groups. Chapters 4 and 5 examined what members of the public the 
Netherlands are willing to pay for health gains in patients with different ages 
and levels of disease severity (research question 3), the latter also operatio-
nalised in an end-of-life context (research question 4). In accordance with the 
results of the previous chapter, we found that respondents, on average, had 
a higher willingness to pay for health gains in younger patients and in more 
severely ill patients, though at a decreasing marginal rate. We found that the 
willingness to pay for health gains in patients of different ages was dependent 
on their disease severity and the size of the health gain. We further found that 
the willingness to pay was higher for health gains in patients who fully recove-
red than for similar health gains in patients who died one year after falling ill. 
In addition, we found some evidence that willingness to pay for health gains 
in end-of-life patients was dependent on the type of health gain as willingness 
to pay was, on average, higher for gains in health-related quality of life than 
for gains in life expectancy. A consistent finding in Chapters 3 to 5 was that 
respondents, on average, least preferred to allocate resources towards health 
gains in the oldest patient group (i.e. patients aged 70). Another consistent 
finding was that there is considerable preference heterogeneity amongst 
members of the public, both in the strength and (to a lesser extent) direction 
of their preferences. 
Chapter 6 examined how different viewpoints on healthcare priority setting 
relate to concerns for equity and efficiency in resource-allocation decisions 
(research question 5). We found that the vast majority of respondents belie-
ved that access to healthcare is a basic human right to which patients are 
entitled without restriction. Respondents who held this view opposed priority 
setting based on characteristics of the patients, disease, and health tech-
nology and believed that priority setting should solely be based on patients’ 
need for care. We found that a minority of respondents appreciated that 
healthcare resources are scarce and priority setting is necessary. Of those 
who held this latter view, most believed that priority setting should be based 
on the type and size of health gains that health technologies generate and 
that resources should primarily be allocated towards health technologies that 
increase patients’ quality of life. Only a few respondents believed that priority 
setting should be based on patient characteristics and the cost-effective-
ness of health technologies. The findings of Chapter 6 further indicated that 
members of the public who oppose priority setting based on anything other 
than patients’ need for care are less likely to prioritise between competing 
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health technologies and patient populations than others. However, this was 
dependent of the specific context of the resource-allocation decision. Indeed, 
most respondents were willing to prioritise one patient group over another at 
least once, irrespective of their view on healthcare priority setting. 
Finally, in Chapter 7 we applied Q methodology in an innovative manner to 
examine whether and how participating in a deliberative citizens panel influen-
ced participants’ viewpoints on healthcare priority setting (research question 
6). The results of this chapter indicated that participants’ initial viewpoints 
partly remained stable over the course of the panel. In particular, participants’ 
belief that access to healthcare is a basic human right and that priority setting 
should be based on patients’ need for care and the type and size of health 
gains remained important. Notable changes in participants’ viewpoints con-
cerned their increased support for healthcare priority setting, consideration of 
healthcare costs, and appreciation of cost-effectiveness as a relevant decision 
criterion after participating in the panel. Despite these changes, we found 
that the viewpoints of participants only moderately converged and remained 
diverse after the panel. 
The findings of this thesis provide further insight into societal concerns for 
equity, in particular for priority setting based on disease severity and the 
age of patients. The findings indicate that applying equity weights based on 
proportional shortfall in economic evaluations is largely consistent with socie-
tal preferences for prioritising more severely ill patients; however, may be 
insufficiently consistent with societal preferences for prioritisation of younger 
patients in resource-allocation decisions. The insights provided by this thesis, 
for example into the rather complex relationship between societal preferences 
for prioritising more severely ill and younger patients, can be used to inform 
decisions on improving (different key aspects of) the current decision-ma-
king framework in the Netherlands. Furthermore, the insights can be used to 
inform decisions on how to involve the public in the decision-making process, 
be it on the level of communication, consultation, or participation.
8.3 Strengths and limitations
The main strength of this thesis lies in the application of different methods for 
obtaining insight into societal concerns for equity in healthcare priority setting. 
Firstly, we applied different methods in order to elicit different (i.e. non-mone-
tary and monetary) types of societal preferences. Hence, the findings of this 
thesis can be used to improve different key aspects of the decision-making 
framework in the Netherlands. Secondly, we applied different methods—
whilst standardising certain design aspects to improve comparability between 
findings—in order to examine the robustness of societal concerns for equity 
across preference-elicitation and statistical methods. Although each chapter 
of this thesis provides some new insights into societal concerns for equity, the 
chapters also confirm the main findings that in general, members of the public 
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in the Netherlands, seem to prefer allocating healthcare resources towards 
more severely ill and younger patients. Therefore, the empirical evidence pre-
sented in this thesis may be considered compelling. Finally, we applied the 
person trade-off method and Q methodology in innovative manners in order 
to examine to what extent societal preferences for priority setting relate to 
disease severity and the age of patients (Chapter 3) and how viewpoints on 
healthcare priority setting are influenced by participating in a deliberative 
citizens panel on this topic (Chapter 7). As such, this thesis contributes to the 
further development and wider application of these two methods in, and pos-
sibly beyond, the context of healthcare priority setting. Despite this strength, 
some general limitations need to be taken into account when interpreting the 
findings and considering the policy and research implications of this thesis. 
A first limitation concerns an important premise that underlies the studies 
presented in this thesis, specifically that the decision-making framework 
should (to some extent or entirely) be aligned with societal preferences for 
healthcare priority setting. It should be noted that whether and, if so, to what 
extent resource-allocation decisions in publicly financed healthcare systems 
should be aligned with the preferences of members of the general public are 
in themselves normative questions that cannot be answered with empirical 
research. Normative research is warranted to examine if this alignment is 
indeed desirable or if resource-allocation decisions should, for example, (also) 
be aligned with the preferences of other stakeholders, such as patients and 
decision makers. Irrespective of the outcome of such research, the impor-
tance of understanding and (in some way) accounting for societal preferences 
in resource-allocation decisions may be evident from the public debate and 
controversy that often follow (in particular, negative) decisions. This may 
further be evident from the increased interest amongst decision makers in the 
participation of members of the public in resource-allocation decisions. The 
empirical studies presented in this thesis may, therefore, aid decision makers 
in at least two ways. Firstly, the findings may aid them in better aligning the 
outcomes and process of resource-allocation decisions with societal preferen-
ces. Secondly, the findings may aid them in identifying potential controversies 
and communicating decisions on the allocation of resources or on adjustments 
to the decision-making framework to the public. 
A second limitation concerns the focus of this thesis on the examination of 
societal preferences for priority setting based on, specifically, disease seve-
rity and the age of patients (Chapters 2 to 5). This focus was intentional and 
enabled us to provide detailed insight into the complex relationship between 
these societal preferences. Nonetheless, this focus inevitably resulted in 
largely disregarding other (potentially relevant) societal preferences for pri-
ority setting. For example, societal preferences for priority setting based on 
the prevalence of a disease (i.e. whether it is common or rare) or based on the 
socioeconomic status, productivity, individual responsibility (e.g. illness due 
to unhealthy lifestyle choices), or social role of patients have not been exa-
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mined in this thesis. Further research is warranted to examine (the strength 
of) such other societal preferences for priority setting, also in relation to 
disease severity and the age of patients. 
A third limitation, related to the narrow focus discussed above, concerns the 
elicitation of societal preferences for priority setting based on disease seve-
rity and the age of patients under the assumption that the health gains and 
costs of health technologies were the same for all patients (Chapters 3 to 5). 
Ideally, we would have examined these preferences in relation to differences 
in costs and benefits, and hence to differences in the level of cost-effec-
tiveness of health technologies. This would have resulted in more realistic 
scenarios, albeit potentially to the detriment of our ability to disentangle res-
pondents’ reasons for preferring one health technology or patient group over 
another. Further research is warranted to examine societal preferences for 
priority setting, based on not only disease severity and the age of patients, 
but also based on other characteristics of the patients, diseases, and health 
technologies, including their level of cost-effectiveness.
A fourth limitation concerns the collection of data at single points in time for 
obtaining insight into societal preferences for priority setting (Chapters 3 to 
6). The applied designs facilitated a thorough examination of societal prefe-
rences based on cross-sectional as well as panel data structures. However, 
the designs did not facilitate the examination of consistencies or of possible 
changes in societal preferences over time. Just like viewpoints on healthcare 
priority setting may change over time, for example, under the influence of 
participating in a citizens panel on this topic (Chapter 7), societal preferences 
for priority setting may also change. The collection of data at multiple points 
in time may aid in obtaining insight into potential changes in societal preferen-
ces as well as into the underlying causal mechanisms. Under the assumption 
that decision makers (at least to some extent) aim to align the outcomes and 
process of resource-allocation decisions with societal preferences, regular 
assessment of societal preferences may help decision makers in communica-
ting decisions to the public and in adjusting the decision-making framework in 
accordance with changing preferences. Note that such adjustments need to 
be weighed against preferences for consistency in decision making over time.
A final limitation concerns the external validity of the empirical studies pre-
sented in this thesis. Firstly, we elicited societal preferences in samples drawn 
from (online) research panels. As such, the generalisability of our findings 
need to be considered in light of the inevitable risk of selection and non-res-
ponse bias that comes with the use of such panels. Secondly, we elicited 
societal preferences in quota samples that were representative of the general 
public in terms of age (i.e. 18+), sex, and education level (in Chapters 3 to 
6) and, in addition, of the diversity in values, lifestyles, and consumption 
patterns (in Chapter 7) in the Netherlands. Evidently, the generalisation of 
our findings to populations outside of the Netherlands warrants caution, for 
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example, because of socioeconomic and cultural differences between coun-
tries. Multi-country data may be used to obtain insight into the impact of such 
differences and the generalisability of our findings to resource-allocation deci-
sions in other countries as well as to decisions taken at a supranational level. 
Note that members of the public in the Netherlands may, on average, be more 
accustomed to more explicit public debates about sensitive and controversial 
issues, such as healthcare priority setting, than in some other countries. Con-
sequently, they may also be more willing to and comfortable with completing 
preference-elicitation tasks in which their preferences are elicited in a fairly 
direct manner (e.g. person trade-off and contingent-valuation tasks). Rese-
archers should be aware that the elicitation of societal preferences in other 
cultural contexts may require different methods than those applied in this 
thesis. Finally, we elicited societal preferences under certainty in relatively 
simple hypothetical resource-allocation scenarios. This may have increased 
the internal validity of our research, for example, by improving the feasibility 
of the preference-elicitation tasks for respondents. However, this inevitably 
came to the detriment of the generalisability of our findings to the complex 
resource-allocation decisions with which decision makers are typically con-
fronted in real life.
8.4 Implications for policy and future research
This thesis provided further insight into societal concerns for equity with the 
objective to improve priority setting in healthcare. The findings of this thesis 
have several implications for policy and future research. 
Several countries have incorporated societal preferences for priority setting 
based on disease severity into the decision-making framework. In the Nether-
lands, disease severity is defined in terms of proportional shortfall and divided 
into four severity classes with the successive proportional-shortfall levels 
of less than 10%, between 10 and 40%, between 41 and 70% and more 
than 71%. Resources are, in principle, not allocated towards health techno-
logies indicated for patients who fall into the lowest class (i.e. suggesting a 
monetary threshold of €0 in economic evaluations). The incremental cost-ef-
fectiveness ratios of health technologies indicated for patients who fall into the 
three higher classes are evaluated against monetary thresholds of €20,000, 
€50,000, and €80,000, respectively. The findings of this thesis indicate that 
the principles underlying this framework may not be fully aligned with societal 
preferences. For example, they indicate that the public may indeed attach 
a higher weight to health gains in more severely ill patients; however, the 
differences between the monetary thresholds applied for the different seve-
rity classes may be smaller (at least in relative terms) than in the current 
decision-making framework. It needs emphasis that the empirical studies pre-
sented in this thesis examined societal preferences in such relative terms, and 
hence their findings cannot fully inform decisions on the absolute height of 
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the monetary threshold. Further empirical research is warranted to examine 
appropriate monetary thresholds in absolute terms. Further methodological 
research is also warranted to examine what approach would be most suitable 
for examining this.
In addition to societal preferences for priority setting based on disease severity, 
decision makers may consider incorporating societal preferences for priority 
setting based on the age of patients into the decision-making framework for 
two main reasons. Firstly, accumulating evidence shows that the public con-
siders age to be an important equity-relevant characteristic, perhaps even 
more important than disease severity. It could be argued that these societal 
preferences should be taken into account in decisions that concern the allo-
cation of public healthcare resources, at least in communicating (the reasons 
that underlie) such decisions to the public. Secondly, definitions of disease 
severity that are derived from the severity and fair innings approaches are not 
independent from age. Indeed, some age groups may implicitly be prioritised 
over other age groups, even when decision makers do not (wish to) explicitly 
account for age in resource-allocation decisions. As such, the paradox in the 
Netherlands is that proportional shortfall may need to be corrected for socie-
tal preferences for prioritisation of younger patients, even when the ultimate 
objective is to avoid discrimination on the basis of age between patients. 
The findings of this thesis clearly indicate that the public has a preference 
for allocating healthcare resources towards younger patients. Considering 
that we elicited societal preferences in relative terms, we want to stress that 
the findings should be interpreted with care. Decision makers should, for 
example, be aware that an age preference as detected in this thesis should 
not be equated with an absolute preference for allocating healthcare resour-
ces towards children. Moreover, the findings also do not allow the conclusion 
that the public has no preference for allocating resources towards older (e.g. 
70-year-old) patients. Decision makers should also be aware that the empiri-
cal studies presented in this thesis reveal considerable preference uncertainty 
and heterogeneity. Hence, aligning the outcomes of resource-allocation deci-
sions with societal preferences will likely remain challenging. Indeed, even 
when decision makers account for the relatively strong societal preferences 
for prioritisation of younger patients in resource-allocation decisions, these 
decisions will likely still be met with opposition from some groups in society 
and be followed by public debate.
Aligning the outcomes of resource-allocation decisions with societal prefe-
rences will likely also remain challenging in consideration of the diversity of 
societal concerns for equity and their interdependency and dependency on 
contextual and personal factors. Further research is warranted to examine 
how the eclectic mix of societal concerns for equity can best be combined 
and integrated into the decision-making framework, whilst retaining its ability 
to facilitate transparent and consistent decision making. Irrespective of the 
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outcome of this research, decision makers may also consider (better) aligning 
the process of resource-allocation decisions with societal preferences in order 
to increase the legitimacy of and public support for resource-allocation decisi-
ons. Further research is warranted to examine on what level members of the 
public would want and would be able to be involved in the decision-making 
process, whether and how this can be operationalised, and what the (e.g. poli-
tical and societal) impact of this involvement will be.
8.5 Final remarks
The increasing demand for healthcare and the resulting pressure on limited 
budgets renders healthcare priority setting inevitable. In order to allocate the 
available resources in an optimal way for society, countries aim to integrate 
societal concerns for equity and efficiency into the decision-making frame-
work. This thesis contributed to meeting this aim by providing further insight 
into societal concerns for equity in this context. It showed that members 
of the public consider priority setting based on disease severity and on the 
age of patients important in resource-allocation decisions in healthcare. The 
findings of this thesis suggest that the current decision-making framework 
(in the Netherlands as well as in other countries) could be adjusted to better 
reflect age-related preferences in society, not only because these preferen-
ces are relatively strong but also because the age of patients is inextricably 
related to definitions of disease severity. The findings further suggest that, 
in addition to adjusting the decision-making framework to (better) align the 
outcomes of decisions with societal preferences, the framework can (also) be 
adjusted to align the process of decision making with societal preferences. 
For example, by implementing citizens panels that inform or take on a more 
prominent role in resource-allocation decisions. 
The findings of this thesis moreover suggest that societal concerns for equity 
are diverse, interdependent, and dependent on contextual and personal 
factors. Therefore, (better) aligning the outcomes and process of resource-al-
location decisions, and hence increasing the legitimacy and public support for 
these decisions, will likely continue to be a challenge for decision makers. My 
hope is that this thesis contributes to facing this challenge and ultimately to 
allocating the available healthcare resources in a more efficient and equitable 
manner. 
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The demand for healthcare is rapidly increasing for reasons that include 
ageing populations, the availability of increasingly advanced and expensive 
new health technologies, and higher standards of living that raise the expec-
tations of health and healthcare. As healthcare resources are limited, the 
resulting pressure on available budgets renders priority setting in the alloca-
tion of healthcare resources inevitable. 
Two important objectives of publicly financed healthcare systems are to gen-
erate as much (health) value as possible from the healthcare budget and 
to distribute health and healthcare fairly. To set priorities that contribute to 
meeting both objectives, an increasing number of countries—among which 
the Netherlands—integrates efficiency and equity considerations into their 
decision-making frameworks. For example, by applying equity weights in eco-
nomic evaluations of new health technologies. Important questions remain, 
however, about which equity considerations should be considered, what (rel-
ative) weight these considerations should receive, and how they should be 
incorporated in resource-allocation decisions. This thesis addressed these 
questions with the objective to contribute to the improvement of deci-
sion-making frameworks by providing further insight into societal concerns 
for equity, in particular for priority setting based on disease severity and the 
age of patients.
Chapter 2 examined the normative justification and empirical support for equity 
weighting based on proportional shortfall in the Netherlands. Proportional 
shortfall is derived from the renowned severity and fair innings approaches 
and used to define and quantify disease severity in resource-allocation deci-
sions. The results of this chapter indicated that the decision model in which 
severity-based equity weights are applied in economic evaluations is generally 
supported and increasingly used for healthcare priority setting in the Neth-
erlands. However, the results also indicated that theoretical and empirical 
support for defining and quantifying disease severity in terms of proportional 
shortfall is limited. Proportional shortfall, for example, insufficiently reflected 
age-related preferences in society, in particular for prioritisation of younger 
patients in resource-allocation decisions.
Chapters 3 to 5 built on the results of Chapter 2 and examined societal pref-
erences for healthcare priority setting based on disease severity and the age 
of patients. Chapter 3 presents the results of an experiment in which we esti-
mated separate and combined weights for priority setting based on disease 
severity and age. The results indicated that respondents, on average, attached 
a higher weight to allocating resources towards more severely ill and towards 
younger patients. The results also indicated that preferences for prioritisation 
of younger patients were relatively strong as respondents attached a higher 
weight to younger patients, even when they were less severely ill than older 
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patients. Chapters 4 and 5 present the results of an experiment in which we 
examined the willingness to pay of respondents for health gains in patients 
with different ages and levels of disease severity, the latter also operation-
alised in an end-of-life context. The results of these two chapters indicated 
that willingness to pay was, on average, higher for health gains in younger and 
in more severely ill patients, though at a decreasing marginal rate. The results 
furthermore indicated that willingness to pay for health gains in patients of 
different ages was dependent on their level of disease severity, the size (and 
to a lesser extent the type) of the health gain, and the outcome of the disease. 
We found that willingness to pay was, on average, lower for gains in end-of-life 
patients than for similar gains in patients who fully recovered. 
Chapter 6 examined how different viewpoints on healthcare priority setting 
related to societal concerns for equity and efficiency in resource-allocation 
decisions. The results of this chapter indicated that the majority of respon-
dents held a view that opposed priority setting based on characteristics of 
the patients, disease, and health technology and believed that priority setting 
should solely be based on patients’ need for care. A minority of respondents 
appreciated the scarcity of healthcare resources and necessity of healthcare 
priority setting. However, only a few respondents believed that priority setting 
should be based on patient characteristics and the cost-effectiveness of health 
technologies. The results indicated that respondents who opposed priority 
setting were less likely to prioritise between competing health technologies 
and patient populations than respondents with another view. Nonetheless, 
the results showed that this was dependent on the specific decision-making 
context. Indeed, most respondents were willing to prioritise one technology or 
patient group over another at least once, irrespective of their view on health-
care priority setting. 
Chapter 7 examined how participating in a deliberative citizens panel influen-
ced participants’ viewpoints on healthcare priority setting. The results of this 
chapter indicated that participants’ initial viewpoints partly remained stable 
over the course of the panel. In particular, participants’ belief that access to 
healthcare is a basic human right and that priority setting should be based 
on patients’ need for care and on the size and type of health gains remained 
important. Notable changes in participants’ viewpoints concerned their incre-
ased support for healthcare priority setting, consideration of healthcare costs, 
and appreciation of cost-effectiveness of health technologies as a relevant 
decision criterion after participating in the panel. 
This thesis contributes to the improvement of the decision-making framework 
by providing further insight into societal concerns for equity in healthcare 
priority setting, in particular for priority setting based on disease severity 
and the age of patients. The results of this thesis indicated that members 
of the public consider disease severity and the age of patients important 
in resource-allocation decisions in healthcare. This suggests that currently 
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applied decision-making frameworks (in the Netherlands as well as in other 
countries) may need to be adjusted in order to better reflect age-related pre-
ferences in society. Not only because these societal preferences are relatively 
strong but also because the age of patients is inextricably related to definiti-
ons of disease severity, like proportional shortfall. Moreover, the results of this 
thesis indicate that, in addition to adjusting the decision-making framework 
to (better) align the outcomes of decisions with societal preferences, decision 
makers could also consider to (better) align the process of resource-allocation 
decisions with societal preferences in order to increase the legitimacy of and 
public support for decisions. For example, by implementing citizens panels 





De vraag naar gezondheidszorg neemt snel toe, onder andere door de ver-
grijzing van de bevolking, de beschikbaarheid van steeds geavanceerdere en 
duurdere nieuwe behandelingen, en een hogere levensstandaard die de ver-
wachtingen ten aanzien van gezondheid en gezondheidszorg doet toenemen. 
Omdat de middelen voor gezondheidszorg beperkt zijn, maakt de daaruit 
voortvloeiende druk op beschikbare budgetten  prioritering in de gezond-
heidszorg onvermijdelijk. 
Twee belangrijke doelstellingen van publiek gefinancierde zorgstelsels zijn 
het genereren van zoveel mogelijk (gezondheids) baten gegeven het zorg-
budget en het nastreven van een eerlijke verdeling van gezondheid en 
gezondheidszorg. Om prioriteiten te stellen die bijdragen aan het bereiken 
van deze doelstellingen, integreert een toenemend aantal landen—waaron-
der Nederland—doelmatigheids- en rechtvaardigheidsoverwegingen in het 
besluitvormingskader. Bijvoorbeeld door rechtvaardigheidsoverwegingen 
mee te nemen in economische evaluaties van nieuwe behandelingen. Er zijn 
echter nog altijd belangrijke vragen over welke rechtvaardigheidsoverwegin-
gen in aanmerking moeten komen, welk (relatief) gewicht deze overwegingen 
moeten krijgen, en hoe zij moeten worden meegenomen in vergoedingsbe-
sluiten. In dit proefschrift zijn deze vragen aan de orde gesteld met als doel 
bij te dragen aan de verbetering van het besluitvormingskader door meer 
inzicht te verschaffen in maatschappelijke voorkeuren voor een rechtvaardige 
verdeling van de beschikbare middelen, in het bijzonder voor prioritering op 
basis van ziektelast en de leeftijd van de patiënten.
Hoofdstuk 2 onderzocht de normatieve rechtvaardiging en empirische onder-
steuning voor de operationalisatie van rechtvaardigheidsoverwegingen in 
termen van proportional shortfall in Nederland. Proportional shortfall is afge-
leid van de gerenommeerde severity  en fair innings benaderingen en wordt 
gebruikt om ziektelast te definiëren en kwantificeren in vergoedingsbesluiten. 
De resultaten van dit hoofdstuk lieten zien dat het beslismodel, waarin op 
ziektelast gebaseerde rechtvaardigheidsoverwegingen worden meegenomen 
in economische evaluaties, breed wordt ondersteund en in toenemende mate 
wordt gebruikt voor het maken van vergoedingsbesluiten in Nederland. De 
resultaten lieten echter ook zien dat de theoretische en empirische ondersteu-
ning voor het definiëren van ziektelast in termen van proportional shortfall 
beperkt is. Proportional shortfall houdt bijvoorbeeld onvoldoende rekening 
met leeftijdsgebonden voorkeuren in de samenleving, met name voor priori-
tering van jongere patiënten in vergoedingsbesluiten.
In de hoofdstukken 3 tot en met 5 is voortgebouwd op de resultaten van 
hoofdstuk 2 en zijn maatschappelijke voorkeuren voor prioritering in de 
gezondheidszorg op basis van ziektelast en de leeftijd van patiënten onder-
zocht. In hoofdstuk 3 worden de resultaten van een experiment gepresenteerd 
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waarin wij afzonderlijke en gecombineerde gewichten voor prioritering op 
basis van ziektelast en de leeftijd van patiënten hebben geschat. De resul-
taten lieten zien dat respondenten, gemiddeld genomen, een hoger gewicht 
gaven aan het vergoeden van behandelingen voor patiënten met een hogere 
ziektelast en voor jongere patiënten. De resultaten lieten verder zien dat de 
voorkeur voor prioritering van jongere patiënten relatief sterk was, omdat 
respondenten een hoger gewicht gaven aan jongere patiënten, zelfs wanneer 
zij een lagere ziektelast hadden dan oudere patiënten. In de hoofdstukken 
4 en 5 zijn de resultaten gepresenteerd van een experiment waarin wij de 
betalingsbereidheid van respondenten voor gezondheidswinst in patiënten 
met verschillende leeftijden en niveaus van ziektelast hebben onderzocht, het 
laatste ook geoperationaliseerd in de context van terminale ziekte. De resulta-
ten van deze hoofdstukken lieten zien dat de betalingsbereidheid, gemiddeld 
genomen, hoger was voor gezondheidswinst in jongere patiënten en in patiën-
ten met een hogere ziektelast, zij het in een afnemende mate. De resultaten 
lieten verder zien dat de betalingsbereidheid voor gezondheidswinst in patiën-
ten van verschillende leeftijden afhankelijk was van de ziektelast, de grootte 
van (en in mindere mate het type) gezondheidswinst, en de gevolgen van de 
ziekte. De betalingsbereidheid was, gemiddeld genomen, lager voor gezond-
heidswinst in terminaal zieke patiënten dan voor een vergelijkbare winst in 
patiënten die volledig van hun ziekte herstelden.
Hoofdstuk 6 onderzocht hoe verschillende visies op prioritering in de 
gezondheidszorg samenhingen met maatschappelijke doelmatigheids- en 
rechtvaardigheidsoverwegingen in vergoedingsbesluiten. De resultaten van 
dit hoofdstuk lieten zien dat de meerderheid van de respondenten tegen prio-
ritering op basis van kenmerken van de patiënten, ziekte en behandeling was 
en dat deze groep van mening was dat prioritering uitsluitend gebaseerd zou 
moeten zijn op de zorgbehoefte van patiënten. Een minderheid van de res-
pondenten zag in dat de beschikbare middelen schaars zijn en dat prioritering 
in de gezondheidszorg noodzakelijk is. Echter, slechts een klein aantal respon-
denten vond dat prioritering gebaseerd zou moeten zijn op kenmerken van 
de patiënten en de kosteneffectiviteit van behandelingen. De resultaten lieten 
zien dat respondenten die tegen prioritering waren minder geneigd waren om 
te prioriteren tussen concurrerende behandelingen en patiëntengroepen dan 
respondenten met een andere visie. Desalnietemin gaven de resultaten aan 
dat dit afhankelijk was van de specifieke besluitvormingscontext. De meeste 
respondenten waren inderdaad bereid om ten minste één keer de ene behan-
deling of patiëntengroep boven de andere te verkiezen, ongeacht hun visie op 
prioritering in de gezondheidszorg.
Hoofdstuk 7 onderzocht hoe deelname aan een deliberatief burgerforum van 
invloed was op de visie van de deelnemers op prioritering in de gezondheids-
zorg. De resultaten van dit hoofdstuk lieten zien dat de aanvankelijke visies 
van de deelnemers in de loop van het forum gedeeltelijk stabiel bleven. Met 
name de overtuiging van deelnemers dat toegang tot gezondheidszorg een 
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fundamenteel mensenrecht is en dat prioritering gebaseerd zou moeten zijn 
op de zorgbehoefte van patiënten en op de grootte en het type gezondheids-
winst bleef belangrijk. Relevante veranderingen in de visies van de deelnemers 
hadden betrekking op de grotere steun voor prioritering in de gezondheids-
zorg, het in acht nemen van de kosten van zorg, en het besef van de relevantie 
van kosteneffectiviteit als beslis criterium na deelname aan het forum. 
Dit proefschrift draagt bij aan de verbetering van het besluitvormingska-
der door meer inzicht te verschaffen in de rechtvaardigheidsoverwegingen 
die maatschappelijk relevant worden geacht in de prioritering van gezond-
heidszorg, in het bijzonder voor prioritering op basis van ziektelast en de 
de leeftijd van patiënten. De resultaten van dit proefschrift suggereren dat 
de bevolking bij prioritering zowel ziektelast als de leeftijd van de patiënten 
belangrijk vindt. Dit suggereert dat de momenteel gebruikte besluitvormings-
kaders (zowel in Nederland als in andere landen) mogelijk aangepast moeten 
worden om beter rekening te houden met leeftijdsgebonden voorkeuren in 
de samenleving. Niet alleen omdat deze maatschappelijke voorkeuren relatief 
sterk zijn, maar ook omdat de leeftijd van patiënten onlosmakelijk verbon-
den is met definities van ziektelast, zoals proportional shortfall. Bovendien 
wijzen de resultaten van dit proefschrift erop dat, naast het aanpassen van 
het besluitvormingskader om de uitkomsten van vergoedingsbesluiten (beter) 
af te stemmen op maatschappelijke voorkeuren, beleidsmakers ook kunnen 
overwegen om het besluitvormingsproces rond vergoedingsbesluiten (beter) 
af te stemmen op maatschappelijke voorkeuren om de legitimiteit van en 
publieke steun voor besluiten te vergroten. Bijvoorbeeld door het implemen-
teren van burgerforums die besluiten informeren of zelfs een prominentere 
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voor het bijwonen van
de openbare verdediging
van het proefschrift
Giving Weight to Equity:




op vrijdag 21 mei 2021
om 10:30 uur 
Wegens de COVID-19  
pandemie is er beperkte  
mogelijkheid om de  
verdediging bij te wonen in 
de Senaatszaal van de  
Erasmus Universiteit  
Rotterdam.
Informatie over het digitaal 
bijwonen van de  
verdediging is vanaf 14 mei 
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